Information
-
Patent Application
-
20030220272
-
Publication Number
20030220272
-
Date Filed
November 21, 200221 years ago
-
Date Published
November 27, 200320 years ago
-
CPC
-
US Classifications
-
International Classifications
- A61K031/7048
- A61K031/7052
- C07H017/08
Abstract
6-O-Acyl ketolide antibacterials of the formula:
1
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. §119(e) of provisional applications Serial No. 60/392,513, filed Jun. 28, 2002, and No. 60/338,566, filed Dec. 5, 2001, both of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of macrolide compounds having antibacterial activity, pharmaceutical compositions containing the compounds, and methods of treating bacterial infections with the compounds.
BACKGROUND OF THE INVENTION
[0003] Erythromycins are well-known antibacterial agents widely used to treat and prevent bacterial infection caused by Gram-positive and Gram-negative bacteria. However, due to their low stability in acidic environment, they often carry side effects such as poor and erratic oral absorption. As with other antibacterial agents, bacterial strains having resistance or insufficient susceptibility to erythromycin have developed over time and are identified in patients suffering from such ailments as community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections. Particularly problematic pathogens include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and penicillin- and macrolide-resistant Streptococcus pneumoniae. Therefore, continuing efforts are called for to identify new erythromycin derivative compounds with improved antibacterial activity, and/or unanticipated selectivity against various target microorganisms, particularly erythromycin-resistant strains.
[0004] The following references relate to various erythromycin derivatives disclosed as having antibacterial activity:
[0005] EP 216,169 and U.S. Pat. No. 4,826,820 to Brain et al. disclose antibacterially active 6-carbamate erythromycin derivatives stated to “have antibacterial properties, in particular against Gram-positive bacteria but also against some Gram-negative bacteria.”
[0006] U.S. Pat. Nos. 5,444,051, 5,561,118, and 5,770,579, all to Agouridas et al., disclose erythromycin compounds such as those of the formulae
2
[0007] wherein substituents are as described in the respective references, which are all stated to be useful as antibiotics.
[0008] U.S. Pat. No. 5,866,549 to Or et al. and WO 98/09978 (Or et al.) disclose 6-O-substituted ketolides stated to have increased acid stability relative to erythromycin A and 6-O-methyl erythromycin A and enhanced activity toward gram negative bacteria and macrolide resistant gram positive bacteria.
[0009] WO 97/17356 (Or et al.) discloses tricyclic erythromycin derivatives stated to be useful in the treatment and prevention of bacterial infections.
[0010] WO 99/21871 (Phan et al.) discloses 2-halo-6-O-substituted ketolide derivatives of the formula
3
[0011] wherein substituents are as described in the respective reference, which are stated to possess antibacterial activity.
[0012] WO 99/21864 (Or et al.) discloses 6,11-bridged erythromycin derivatives having antibacterial activity.
[0013] WO 00/75156 (Phan et al.) discloses 6-O-carbamate ketolide derivatives that are useful as antibacterial agents for the treatment and prevention of infection in a mammal.
[0014] EP1146051 to Kaneko et al. discloses macrolide compounds of the following formula that are useful as antibacterial and antiprotozoal agents in mammals,
4
[0015] wherein substituents are as described in the reference.
[0016] EP1114826 to Kaneko and McMillen discloses novel erythromycin derivatives useful as antibacterial, antiprotozoal and/or prokinetic agents.
[0017] WO 00/71557 to Dirlam et al. discloses 13-methyl-erythromycin derivatives that are useful as antibacterial and antiprotozoal agents in mammals (including humans), fish and birds.
[0018] U.S. Pat. No. 6,355,620 to Ma et al. discloses C-2 modified erythromycin derivatives that are useful in treating bacterial infections.
[0019] WO 02/032918 to Hlasta et al. discloses a series of erythromycin ketolides that possess anti-infective activity and are useful for the treatment of bacterial and protozoal infections.
[0020] WO 00/062783 to Hlasta et al. discloses erythromycin analogs useful in the treatment of bacterial and protozoal infections and in the treatment of other conditions involving gastric motility.
[0021] U.S. Pat. No. 5,922,683 to Or et al. discloses multicyclic erythromycin compounds having antibacterial activity.
[0022] U.S. Pat. No. 6,034,069 to Or et al. discloses 3′-N-modified 6-O-substituted erythromycin ketolide compounds having antibacterial activity.
SUMMARY OF THE INVENTION
[0023] The invention provides compounds of Formula 1:
5
[0024] wherein
[0025] R1 is selected from the group consisting of hydrogen, halogen, and hydroxy;
[0026] Z is selected from the group consisting of —NH—(CH2)n—, —(CH2)n—, —O—(CH2)n—, —NH—C1-C6alkenyl-, —C1-C6alkenyl-, —O—C1-C6alkenyl-, NHC1-C6alkynyl-, —C1-C6alkynyl-, and —O—C1-C6alkynyl-, wherein n is an integer from 0 to 5;
[0027] R2 is selected from the group consisting of hydrogen, aryl, and heteroaryl;
[0028] R3 is selected from the group consisting of hydrogen, C1-C10alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl, heterocyclo, aryl(C1-C10)alkyl, aryl(C2-C10)alkenyl, aryl(C2-C10)alkynyl, heterocyclo(C1-C10)alkyl, heterocyclo(C2-C10)alkenyl, and heterocyclo(C2-C10)alkynyl, C3-C6-cycloalkyl, C5-C8-cycloalkenyl, alkoxyalkyl containing 1-6 carbon atoms in each alkyl or alkoxy group, and alkylthioalkyl containing 1-6 carbon atoms in each alkyl or thioalkyl group;
[0029] R4 is hydrogen or a hydroxy protecting group;
[0030] W is selected from the group consisting of
[0031] (1) a substituted pyrrole of the formula
6
[0032] wherein
[0033] R5 and R6 are independently selected from the group consisting of hydrogen, CN, —C(NH)CHR10R11, nitro, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO2R7, C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, wherein
[0034] R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclo, aralkyl, heteroaralkyl, and heterocycloalkyl; and
[0035] R10 and R11 are independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, or R10 and R11, taken together with the atoms to which they are attached, form an optionally substituted 4-8 membered carbocyclic ring wherein the substituents are selected from the group consisting of C0-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl;
[0036] (2)—OR9, wherein
[0037] R9 is independently selected from the group consisting of C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, and C5-C8-cycloalkenyl;
[0038] (3) —NR10OR11, wherein
[0039] R10 and R11 are independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, or R10 and R11, taken together with the atoms to which they are attached, form an optionally substituted 5-8 membered heterocyclic ring wherein the substituents are selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl;
[0040] (4) —NR12NR13R14, wherein
[0041] R12, R13, and R14 are independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl,
[0042] or R12 and R13, taken together with the nitrogens to which they are attached, form an optionally substituted 5-8 membered heterocyclic ring, wherein the substituents are selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl;
[0043] or R13 and R14, taken together with the nitrogen to which they are attached, form an optionally substituted 3-8 membered heterocyclic ring or an optionally substituted 5-10 membered heteroaryl ring, wherein the substituents are selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl;
[0044] (5) —NR5N═CHR13a, wherein
[0045] R15 is independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl; and
[0046] R13a is independently selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl;
[0047] (6) —NR10NR11C(O)R16, wherein
[0048] R16 is independently selected from the group consisting of hydrogen, C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl;
[0049] (7) —NR10NR11C(O)OR17, wherein
[0050] R17 is independently selected from the group consisting of C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl;
[0051] (8) —NR10NR11C(O)NR18R19, wherein
[0052] R18 and R19 are independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, or R18 and R19, taken together with the nitrogen to which they are attached, form an optionally substituted 3-8 membered heterocyclic ring or an optionally substituted 5-10 membered heteroaryl ring, wherein the substituents are selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl;
[0053] (9) —NR10NR21SO2R20, wherein
[0054] R20 is independently selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl; and
[0055] R21 is independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, C2-C6 acyl, aryl, and heteroaryl;
[0056] (10) —SR9, wherein
[0057] R9 is independently selected from the group consisting of C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, and C5-C8-cycloalkenyl;
[0058] (11) —CHR10R11, wherein
[0059] R10 and R11 are independently selected from the group consisting of hydrogen, C1-C8-alkyl, C3-C8-alkenyl, C3-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, or R10 and R11, taken together with the atoms to which they are attached, form an optionally substituted 4-8 membered carbocyclic ring wherein the substituents are selected from the group consisting of C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, aryl, and heteroaryl; and
[0060] (12) a substituted pyrazole of the formula
7
[0061] wherein
[0062] R22 and R23 are independently selected from the group consisting of hydrogen, —C(O)OR7, —C(O)NR7R8, C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, and heteroaryl, wherein
[0063] R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclo, aralkyl, heteroaralkyl, and heterocycloalkyl;
[0064] X and X′, together with the carbon atom to which they are attached, form C═O, C═NRc, or C═NORc, wherein Rc is independently selected from hydrogen, alkyl, alkenyl and alkynyl; and
[0065] Y and Y′, together with the carbon atom to which they are attached, form C═O, —CHOH, C═NRc, or C═NORc, wherein Rc is independently selected from hydrogen, alkyl, alkenyl and alkynyl;
[0066] or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, or a pharmaceutically acceptable salt, esters or pro-drugs thereof.
[0067] Compounds of the above formula are useful as antibacterial agents for the treatment of bacterial infections in a subject such as human and animal.
[0068] The present invention is also directed to a method of treating a subject having a condition caused by or contributed to by bacterial infection, which comprises administering to said subject a therapeutically effective amount of the compound of Formula 1.
[0069] The present invention is further directed to a method of preventing a subject from suffering from a condition caused by or contributed to by bacterial infection, which comprises administering to the subject a prophylactically effective amount of the compound of Formula 1.
[0070] Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing specification.
DETAILED DESCRIPTION
[0071] Relative to the above description, certain definitions apply as follows.
[0072] Unless otherwise noted, under standard nomenclature used throughout this disclosure the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment.
[0073] Unless specified otherwise, the terms “alkyl”, “alkenyl”, and “alkynyl,” whether used alone or as part of a substituent group, include straight and branched chains having 1 to 8 carbon atoms, or any number within this range. The term “alkyl” refers to straight or branched chain hydrocarbons. “Alkenyl” refers to a straight or branched chain hydrocarbon with at least one carbon-carbon double bond. “Alkynyl” refers to a straight or branched chain hydrocarbon with at least one carbon-carbon triple bound. For example, alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl. “Alkoxy” radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. “Cycloalkyl” groups contain 3 to 8 ring carbons and preferably 5 to 7 ring carbons. “Cycloalkenyl” groups contain 5 to 8 ring carbons and at least one carbon-carbon double bond. The alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and alkoxy group may be independently substituted with one or more members of the group including, but not limited to, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, oxo, aryl, heteroaryl, heterocyclo, CN, nitro, —OCORa, —ORa, —SRa, —SORa, —SO2Ra, —COORa, —NRaRb, —CONRaRb, —OCONRaRb, —NHCORa, —NHCOORa, and —NHCONRaRb, wherein Ra and Rb are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclo, aralkyl, heteroaralkyl, and heterocycloalkyl. “Aralkyl,” “heteroaralkyl,” and “heterocycloalkyl” are alkyl groups substituted with aryl, heteroaryl, and heterocyclo, respectively. “Arylalkenyl,” “heteroarylalkenyl,” and “heterocycloalkenyl” are alkenyl groups substituted with aryl, heteroaryl, and heterocyclo, respectively. “Arylalkynyl,” “heteroarylalkynyl,” and “heterocycloalkynyl” are alkynyl groups substituted with aryl, heteroaryl, and heterocyclo, respectively.
[0074] The term “acyl” as used herein, whether used alone or as part of a substituent group, means an organic radical having 2 to 6 carbon atoms (branched or straight chain) derived from an organic acid by removal of the hydroxyl group. The term “Ac” as used herein, whether used alone or as part of a substituent group, means acetyl.
[0075] The term “halo” or “halogen” means fluoro, chloro, bromo and iodo. (Mono-, di-, tri-, and per-)halo-alkyl is an alkyl radical substituted by independent replacement of the hydrogen atoms thereon with halogen.
[0076] “Aryl” or “Ar,” whether used alone or as part of a substituent group, is a carbocyclic aromatic radical including, but not limited to, phenyl, 1- or 2-naphthyl and the like. The carbocyclic aromatic radical may be substituted by independent replacement of 1 to 3 of the hydrogen atoms thereon with halogen, OH, CN, mercapto, nitro, amino, C1-C8-alkyl, aryl, heteroaryl, heterocyclo, C1-C8-alkoxyl, C1-C8-alkylthio, C1-C8-alkyl-amino, di(C1-C8-alkyl)amino, (mono-, di-, tri-, and per-) halo-alkyl, formyl, carboxy, alkoxycarbonyl, C1-C8-alkyl-CO—O—, C1-C8-alkyl-CO—NH—, or carboxamide. Illustrative aryl radicals include, for example, phenyl, naphthyl, biphenyl, fluorophenyl, difluorophenyl, benzyl, benzoyloxyphenyl, carboethoxyphenyl, acetylphenyl, ethoxyphenyl, phenoxyphenyl, hydroxyphenyl, carboxyphenyl, trifluoromethylphenyl, methoxyethylphenyl, acetamidophenyl, tolyl, xylyl, dimethylcarbamylphenyl and the like. “Ph” or “PH” denotes phenyl.
[0077] Whether used alone or as part of a substituent group, “heteroaryl” refers to a cyclic, fully unsaturated radical having from five to ten ring atoms of which one ring atom is selected from S, O, and N; 0-3 ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon. The radical may be joined to the rest of the molecule via any of the ring atoms. Exemplary heteroaryl groups include, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrroyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, triazolyl, triazinyl, oxadiazolyl, thienyl, furanyl, quinolinyl, isoquinolinyl, indolyl, isothiazolyl, N-oxo-pyridyl, 1,1-dioxothienyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl-N-oxide, benzimidazolyl, benzopyranyl, benzisothiazolyl, benzisoxazolyl, benzodiazinyl, benzofurazanyl, indazolyl, indolizinyl, benzofuryl, cinnolinyl, quinoxalinyl, pyrrolopyridinyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl, or furo[2,3-b]pyridinyl), imidazopyridinyl (such as imidazo[4,5-b]pyridinyl or imidazo[4,5-c]pyridinyl), naphthyridinyl, phthalazinyl, purinyl, pyridopyridyl, quinazolinyl, thienofuryl, thienopyridyl, and thienothienyl. The heteroaryl group may be substituted by independent replacement of 1 to 3 of the hydrogen atoms thereon with halogen, OH, CN, mercapto, nitro, amino, C1-C8-alkyl, aryl, heteroaryl, heterocyclo, C0-C8-alkoxyl, C1-C8-alkylthio, C1-C8-alkyl-amino, di(C1-C8-alkyl)amino, (mono-, di-, tri-, and per-) halo-alkyl, formyl, carboxy, alkoxycarbonyl, C1-C8-alkyl-CO—O—, C1-C8-alkyl-CO—NH—, or carboxamide. Heteroaryl may be substituted with a mono-oxo to give for example a 4-oxo-1H-quinoline.
[0078] The terms “heterocycle,” “heterocyclic,” and “heterocyclo” refer to an optionally substituted, fully saturated, partially saturated, or non-aromatic cyclic group which is, for example, a 3- to 7-membered monocyclic, 7- to 11-membered bicyclic, or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, or 3 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized. The nitrogen atoms may optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom.
[0079] Exemplary monocyclic heterocyclic groups include pyrrolidinyl; oxetanyl; pyrazolinyl; imidazolinyl; imidazolidinyl; oxazolinyl; oxazolidinyl; isoxazolinyl; thiazolidinyl; isothiazolidinyl; tetrahydrofuryl; piperidinyl; piperazinyl; 2-oxopiperazinyl; 2-oxopiperidinyl; 2-oxopyrrolidinyl; 4-piperidonyl; tetrahydropyranyl; tetrahydrothiopyranyl; tetrahydrothiopyranyl sulfone; morpholinyl; thiomorpholinyl; thiomorpholinyl sulfoxide; thiomorpholinyl sulfone; 1,3-dioxolane; dioxanyl; thietanyl; thiiranyl; 2-oxazepinyl; azepinyl; and the like. Exemplary bicyclic heterocyclic groups include quinuclidinyl; tetrahydroisoquinolinyl; dihydroisoindolyl; dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl); dihydrobenzofuryl; dihydrobenzothienyl; benzothiopyranyl; dihydrobenzothiopyranyl; dihydrobenzothiopyranyl sulfone; benzopyranyl; dihydrobenzopyranyl; indolinyl; chromonyl; coumarinyl; isochromanyl; isoindolinyl; piperonyl; tetrahydroquinolinyl; and the like. The heterocyclic group may be substituted by independent replacement of 1 to 3 of the hydrogen atoms thereon with OH, CN, mercapto, nitro, amino, C1-C8-alkyl, aryl, heteroaryl, heterocyclo, C1-C8-alkoxyl, C1-C8-alkylthio, C1-C8-alkyl-amino, di(C1-C8-alkyl)amino, (mono-, di-, tri-, and per-) halo-alkyl, formyl, carboxy, alkoxycarbonyl, C1-C8-alkyl-CO—O—, C1-C8-alkyl-CO—NH—, or carboxamide.
[0080] Designated numbers of carbon atoms (e.g., C1-8) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
[0081] Unless specified otherwise, it is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.
[0082] The term “hydroxy protecting group” refers to groups known in the art for such purpose. Commonly used hydroxy protecting groups are disclosed, for example, in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991), which is incorporated herein by reference. Illustrative hydroxyl protecting groups include but are not limited to tetrahydropyranyl; benzyl; methylthiomethyl; ethythiomethyl; phenylsulfonyl; triphenylmethyl; trisubstituted silyl such as trimethyl silyl, triethylsilyl, tributylsilyl, tri-isopropylsilyl, t-butyldimethylsilyl, tri-t-butylsilyl, methyldiphenylsilyl, ethyldiphenylsilyl, t-butyldiphenylsilyl; acyl and aroyl such as acetyl, pivaloyl, benzoyl, 4-methoxybenzoyl, and 4-nitrobenzoyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, and benzyloxycarbonyl.
[0083] Where the compounds according to this invention have at least one stereogenic center, they may accordingly exist as enantiomers. Where the compounds possess two or more stereogenic centers, they may additionally exist as diastereomers. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
[0084] Some of the compounds of the present invention may have trans and cis isomers. In addition, where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared as a single stereoisomer or in racemic form as a mixture of some possible stereoisomers. The non-racemic forms may be obtained by either synthesis or resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation. The compounds may also be resolved by covalent linkage to a chiral auxiliary, followed by chromatographic separation and/or crystallographic separation, and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using chiral chromatography.
[0085] The phrase “a pharmaceutically acceptable salt” denotes one or more salts of the free base which possess the desired pharmacological activity of the free base and which are neither biologically nor otherwise undesirable. These salts may be derived from inorganic or organic acids. Examples of inorganic acids are hydrochloric acid, nitric acid, hydrobromic acid, sulfuric acid, or phosphoric acid. Examples of organic acids are acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like. Suitable salts are furthermore those of inorganic or organic bases, such as KOH, NaOH, Ca(OH)2, Al(OH)3, piperidine, morpholine, ethylamine, triethylamine and the like.
[0086] Included within the scope of the invention are the hydrated forms of the compounds which contain various amounts of water, for instance, the hydrate, hemihydrate, and sesquihydrate forms. The present invention also includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
[0087] The term “subject” includes, without limitation, any animal or artificially modified animal. As a particular embodiment, the subject is a human.
[0088] The term “drug-resistant” or “drug-resistance” refers to the characteristics of a microbe to survive in presence of a currently available antimicrobial agent such as an antibiotic at its routine, effective concentration.
[0089] The compounds described in the present invention possess antibacterial activity due to their novel structure, and are useful as antibacterial agents for the treatment of bacterial infections in humans and animals.
[0090] Compounds of Formula 1 wherein R2 is hydrogen and Z is —(CH2)n— wherein n is 0 are preferred embodiments of the present invention.
[0091] Compounds of Formula 1 wherein W is selected from groups (1), (2), (3), or (4) as described above are other preferred embodiments of the present invention.
[0092] Compounds of Formula 1 wherein R3 is ethyl are still other preferred embodiments of the present invention.
[0093] Compounds of Formula 1 wherein R4 is hydrogen are yet other embodiments of this invention. R4 may also be selected from acyl and aroyl.
[0094] Compounds of Formula 1 wherein R is hydrogen and Z is —(CH2)n— wherein n is 0, W is selected from groups (1), (2), (3), or (4) as described above, R3 is ethyl, and R4 is hydrogen, are still other preferred embodiments of the present invention.
[0095] Especially preferred embodiments of compounds of Formula 1 are those compounds having Formula 1′:
8
[0096] wherein, R1, R3, R4 and W are as described above.
[0097] Compounds of Formula 1′ whrerin R1 is selected from the group consisting of H and F are preferred embodiments of the invention.
[0098] Compound of Formula 1′ wherein R3 is ethyl are also preferred embodiments of the invention.
[0099] Compound of Formula 1′ wherein R4 is selected from the group consisting of H and acyl are still other preferred embodiments of the invention.
[0100] Compounds of Formula 1′ wherein W is selected from the group consisting of groups (1), (2), (3), (4), (10), (11) and (12) as defined above are also preferred embodiments of the invention.
[0101] Compounds of Formula 1′ wherein R1 is H and R3 is ethyl are still other preferred embodiments of the invention.
[0102] Compounds of Formula 1′ wherein R1 is F and R3 is ethyl are still other preferred embodiments of the invention.
[0103] Compounds of Formula 1′ wherein R1 is H, R3 is ethyl and R4 is H are also preferred embodiments of the invention.
[0104] Compounds of Formulal 1′ wherein W is selected from group consisting of groups (1) and (2) as defined above are still other preferred embodiements of the invention.
[0105] This invention also provides processes for preparing the instant compounds.
[0106] The compounds of Formula 1 may be prepared from readily available starting materials such as erythromycin and erythromycin derivatives well known in the art. Outlined in Schemes 1 through 13 are representative procedures to prepare the compounds of the instant invention.
910
[0107] Scheme 1 illustrates the method of synthesis of the 2′,4″-diacetyl-6-carbamyl-11,12-dideoxy-11,12-iminocarbonyloxyerythromycin A (VI) and the 2′-acetyl-6-carbamyl-11,12-dideoxy-3-O-descladinosyl-11,12-iminocarbonyloxyerythromycin A (VII) precursors to the compounds of the invention.
[0108] Erythromycin A is treated with acetic anhydride in the presence of a tertiary amine base, such as triethylamine, diisopropylethylamine, or pyridine, and an acylation catalyst, such as 4-(dimethylamino)pyridine (DMAP), in a suitable solvent such as methylene chloride, chloroform or tetrahydrofuran (THF) at a temperature ranging from −20° C. to 37° C. for 2 to 48 hours to afford 2′,4″,11-triacetylerythromycin A (I). The 10,11-anhydro derivative (II) can be readily obtained by treatment of I with a base in an inert solvent such as THF, dioxane, 1,2-dimethoxyethane (DME), or dimethylformamide (DMF) at a temperature ranging from −78° C. to 80° C. for 1-24 hours. Suitable bases to effect the elimination reaction include, but are not limited to, sodium hexamethyldisilazide, potassium hexamethyldisilazide, lithium diisopropylamide (LDA), lithium tetramethylpiperidide, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and tetramethylguanidine. It will be apparent to one skilled in the art that alternative methods for synthesis of 2′,4″-diacetyl-10,11-anhydroerythromycin A are available, including conversion of erythromycin A to the 11,12-cyclic carbonate derivative with ethylene carbonate, followed by elimination with tetramethylguanidine, as described in Hauske, J. R. and Kostek, G., J. Org. Chem. 1982, 47,1595. Selective protection of the 2′ and 4″-hydroxyl groups can then be readily accomplished with acetic anhydride in the presence of a tertiary amine base. Likewise, alternative protecting group strategies may be employed. For example, erythromycin A may be treated with benzoic anhydride, propionic anhydride, or formic acetic anhydride under similar conditions as described above to obtain the 2′,4″,11-triacylated erythromycin A derivative followed by elimination to afford the corresponding 10,11-anhydro compound.
[0109] Once the suitably protected 10,11-anhydro derivative is obtained, derivatization of both tertiary hydroxyl groups can be carried out by treatment with trichloroacetylisocyanate in an inert solvent, such as methylene chloride, chloroform, or THF at a temperature ranging from −20° C. to 37° C. for 1-24 hours to yield the di-(N-trichloroacetyl)carbamate derivative (III). The N-trichloroacetylcarbamate functionalities can be hydrolyzed to the corresponding primary carbamates by treatment with a suitable base, such as triethylamine, in an aqueous solvent mixture, such as methanol/water for 1-24 hours at a temperature ranging from 20° C. to 80° C. Alternative bases may likewise be used to effect this conversion, such as sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate. Under the reaction conditions, the primary carbamate formed at the 12-position undergoes spontaneous Michael addition to the electrophilic 11-position of the α,β-unsaturated ketone and the 2′-acetoxy group is hydrolyzed to the corresponding hydroxyl to afford the cyclic carbamate derivative (IV). Compound IV is generally isolated as a mixture of methyl epimers at the C10-position, which can be readily converted to the desired C10-β-methyl epimer (V) by treatment with an equilibrating base, such as potassium t-butoxide, tetramethylguanidine, or DBU in a suitable solvent, such as THF, dioxane, DME, DMF or t-butanol at a temperature ranging from −78° C. to 80° C. for 1 to 24 hours. Reprotection of the 2′-hydroxyl group to give VI can be carried out by treatment with acetic anhydride in the presence of a tertiary amine base, such as triethylamine, diisopropylethylamine, or pyridine, and optionally an acylation catalyst, such as DMAP, in a suitable solvent such as methylene chloride, chloroform or THF at a temperature ranging from −20° C. to 37° C. for 2 to 48 hours. It is understood that an orthogonal protection strategy of the sugar hydroxyls may also be employed by treatment of V with alternate reagents such as benzoic anhydride, benzyl chloroformate, hexamethyldisilazane, or a trialkylsilyl chloride. Finally, selective removal of the cladinose sugar can be accomplished by reaction of VI with an acid, such as hydrochloric, sulfuric, chloroacetic, and trifluoroacetic, in the presence of alcohol and water to afford VII. Reaction time is typically 0.5-24 hours at a temperature ranging from −10° C. to 37° C.
11
[0110] Scheme 2 depicts the synthesis of compounds of formulae VIII and IX and compounds of the instant invention of formula Ia. Oxidation of the 3-hydroxy group of VII to yield compound VIII can be effected with dimethylsulfoxide (DMSO) and a carbodiimide, such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), in the presence of pyridinium trifluoroacetate in a suitable solvent, such as methylene chloride, for 1 to 24 hours at a temperature ranging from −20° C. to 37° C. Alternative methods of oxidation include N-chlorosuccinimide and dimethylsulfide complex followed by treatment with a tertiary amine base, Dess-Martin periodinane, or oxalyl chloride/DMSO followed by treatment with a tertiary amine base. Removal of the 2′-acetyl group of compound VIII is readily accomplished by transesterification with methanol for 2-48 hours at a temperature ranging from 15-20° C. to 60° C. to yield compound IX. Alternative methods for deprotection of the 2′-acetyl group include hydrolysis in the presence of an alkali metal hydroxide or alkali metal carbonate, such as sodium hydroxide or potassium carbonate, or ammonolysis with ammonia in methanol. Compounds of formula 1a can be obtained by reaction of IX with a suitably substituted 1,4-dialdehyde or its equivalent in the presence of an acid. Equivalents of 1,4-dialdehydes include 2,5-dialkoxytetrahydrofurans, 1,4-dialdehyde monoacetals, and 1,4-dialdehyde diacetals. A preferred acid for effecting this transformation is trifluoroacetic acid in a suitable solvent, like acetonitrile, methylene chloride, or toluene at −20° C. to 100° C. Typically, the reaction is conducted for from 2-96 hours. Preferred 1,4-dialdehydes or their equivalents include 2-formyl-4,4-dimethoxybutanenitrile, tetrahydro-2,5-dimethoxy-3-furancarboxaldehyde, tetrahydro-2,5-dimethoxy-3-furancarboxylic acid methyl ester, and tetrahydro-2,5-dimethoxy-3-furancarboxylic acid ethyl ester.
12
[0111] Compounds of formula 1a can be converted to other compounds of the instant invention by displacement of the pyrrole with hydrazines, hydroxylamines, and alcohols. Preferred substrates for this conversion are those in which the pyrrole is substituted with electron-withdrawing groups including, but not limited to, cyano, formyl, and alkoxycarbonyl. A particularly preferred substrate is compound 1a, where R5=CN and R6=H. Scheme 3 illustrates the conversion of compound 1a to compounds of formula 1b, 1c, and 1d, wherein R9, R10, R11, R12, R13, and R14 are as defined previously. Compounds of formula 1b can be prepared by reaction of 1a with hydrazine or a suitably substituted hydrazine in a suitable solvent, such as acetonitrile, dimethylformamide, dimethyl sulfoxide, or tetrahydrofuran, at a temperature ranging from −20° C. to 120° C. for 0.5 to 72 hours. Compounds of formula 1c can be prepared by reaction of 1a with hydroxylamine or a suitably substituted hydroxylamine in a suitable solvent, such as acetonitrile, dimethylformamide, dimethyl sulfoxide, or tetrahydrofuran, at a temperature ranging from −20° C. to 120° C. for 0.5 to 72 hours. The hydrazines and hydroxylamines used in the preparation of compounds of formulae 1b and 1c may be in the form of acid addition salts, in which case the reaction is preferably conducted in the presence of a base such as pyridine, triethylamine, or an alkali metal carbonate. Compounds of formula 1d can be prepared by reaction of 1a with a suitably substituted alcohol in the presence of a suitable base such as DBU, DBN, tert-butyltetramethylguanidine, sodium hydride, potassium hydride, or an alkyllithium, in a suitable solvent, such as acetonitrile, dimethylformamide, dimethyl sulfoxide, or tetrahydrofuran, at a temperature ranging from −20° C. to 120° C. for 0.5 to 72 hours. Preformed alkali or alkaline earth metal alkoxides are also suitable reagents for the preparation of compounds of formula 1d.
13
[0112] The compound of formula 1e, obtained by reaction of compound 1a with hydrazine as described in Scheme 3, can be further converted to other compounds of the instant invention as shown, for example, in Scheme 4. Compound 1e can be converted to compounds of formula 1f by reaction with a suitably substituted aldehyde, R13aCHO, in a suitable solvent, including but not limited to methanol, ethanol, acetonitrile, THF, or dichloromethane, at a temperature ranging from −20° C. to 120° C. for 0.5 to 72 hours, and preferably in the presence of an acid catalyst, such as acetic acid, trifluoroacetic acid, or hydrochloric acid. Furthermore, reaction of 1e with a 1,3-dialdehyde or a 1,3-dialdehyde equivalent, such as a 2,5-dialkoxytetrahydrofuran, under similar conditions as above produces an optionally substituted pyrrole. Compound 1f can be converted to compounds of formula 1g by treatment with a variety of reducing agents including sodium cyanoborohydride in the presence of an acid catalyst such as acetic acid, triethylsilane in trifluoroacetic acid, and hydrogen in the presence of a noble metal catalyst such as palladium on carbon. The conversion of compound 1e to compounds of formula 1g can also be carried out without isolation of the intermediate compound of formula 1f. A preferred method for the conversion of compound 1e to compounds of formula 1g consists of treatment with a suitably substituted aldehyde in the, presence of acetic acid in methanol as solvent for 0.5 to 24 hours, and subsequently adding sodium cyanoborohydride and, if necessary, additional acetic acid to produce the compound of formula 1g after a period of from 0.5 to 72 hours. In the direct conversion of compound 1e to compounds of formula 1g, it is also possible to isolate compounds of formula 1h in which R13a and R14a are the same, which are also compounds of the instant invention, depending on the reactivity of the aldehyde and the number of equivalents of aldehyde employed. Additionally, compounds of formula 1h in which R13a and R14a are not necessarily the same may be prepared, for example, by reaction of compounds of formula 1g with an aldehyde, R14aCHO, in the presence of acetic acid and sodium cyanoborohydride in methanol. The conversion of compound 1e to compounds of formula 1h can also be carried out without isolation of the intermediate compound of formula 1g. For example, compound 1e may be treated with a suitably substituted aldehyde, R13aCHO, in the presence of acetic acid in methanol as solvent for from 0.5 to 24 hours, followed by addition of sodium cyanoborohydride and, if necessary, additional acetic acid. Following reaction for from 0.5 to 72 hours, a second suitably substituted aldehyde, R14aCHO, is added, optionally in the presence of additional acetic acid and additional sodium cyanoborohydride, to produce the compound of formula 1h after a period of from 0.5 to 72 hours. Additionally, if a dialdehyde is used, compounds of formula 1h in which R13a and R14a are connected to form a ring may be prepared. For example, reaction of compound 1e with a 1,5-dialdehyde or a 1,5-dialdehyde equivalent such as a 3,4-dihydro-2-alkoxy-2H-pyran in the presence of triethylsilane and trifluoroacetic acid produces a compound of formula 1h in which R13a and R14a are connected to form a piperidine ring.
14
[0113] In the case where R14a contains a functionality that can be converted to a leaving group, intramolecular reaction with the alpha-nitrogen atom to form a heterocycle can occur under appropriate conditions. This is illustrated in Scheme 5. For example, the compound of formula 1j′, in which n is an integer from 1-3, can be obtained by reaction of compound 1k′ with a dialdehyde in the presence of a suitable reducing agent, such as sodium cyanoborohydride, and an acid catalyst, such as acetic acid at temperatures ranging from 0° C. to 60° C. for from 1 to 24 hours. Suitable dialdehydes to effect this conversion include, for example, glutaraldehyde, butanedial, and malondialdehyde. Alternatively, a suitable dialdehyde equivalent, such as 3,4-dihydro-2-methoxy-2H-pyran, 2,5-dimethoxytetrahydrofuran or 1,1,3,3-tetramethoxypropane may be employed. Conversion of compounds of formula 1j′ to heterocycles of formula 1k′ can be accomplished by reaction with a suitable sulfonyl chloride, such as p-toluenesulfonyl chloride or methanesulfonyl chloride, in an inert solvent in the presence of a base at temperatures ranging from −20° C. to 60° C. for from 1 to 120 hours. Suitable bases to effect this conversion include for example, triethylamine, diisopropylethylamine, or pyridine. Suitable solvents include, but are not limited to, methylene chloride, chloroform or tetrahydrofuran.
15
[0114] Scheme 6 shows methods for the conversion of compounds of formula 1i, prepared by the methods described above, into additional compounds of the invention of the formulae 1k, 1l, 1m, and 1n. For some of these conversions, derivatization of the 2′-hydroxyl may occur concurrently with the desired transformation. In suitable cases, as detailed below, the 2′-derivatized compound may be converted into the corresponding 2′-hydroxy compound.
[0115] Compounds of formula 1i may be converted into compounds of formula 1k by reaction with an excess of an acylating agent in the presence of a tertiary amine, followed by de-acylation of the 2′-hydroxyl by the methods described above, such as transesterification with methanol for 2-48 hours at a temperature ranging from −20° C. to 60° C. to yield compounds of formula 1k. Alternatively, compounds of formula 1k may be prepared directly from compounds of formula 1i by reaction with an acylating agent (1-4 equivalents, depending on the reactivity of the acylating agent), optionally in the presence of an amine base, such as pyridine, in an inert solvent such as dichloromethane, tetrahydrofuran or toluene at temperatures ranging from −20° C. to 60° C. for from 1-48 hours. Acylating agents include acid halides, acid anhydrides, and acids in the presence of an activating agent such as dicyclohexylcarbodiimide, EDCI, BOP-CI, BOP, PyBOP, and the like. Compounds of formula 1i may be converted into compounds of formula 1l by reaction with an excess of a carbonylating agent in the presence of a tertiary amine, followed by de-acylation of the 2′-hydroxyl by the methods described above, such as transesterification with methanol for 2-48 hours at a temperature ranging from −20° C. to 60° C. to yield compounds of formula 1l. Alternatively, compounds of formula 1l may be prepared directly from compounds of formula 1i by reaction with a carbonylating agent (1-1.5 equivalents, depending on the reactivity of the carbonylating agent), optionally in the presence of an amine base, such as pyridine, in an inert solvent such as dichloromethane, tetrahydrofuran or toluene at temperatures ranging from −20° C. to 60° C. for from 1-48 hours. Carbonylating agents include chloroformates, fluoroformates, azidoformates, and pyrocarbonates. Compounds of formula 1i may be converted into compounds of formula 1m by reaction with a carbamoyl chloride in the presence of a tertiary amine or with an isocyanate (1-1.5 equivalents, depending on the reactivity of the carbamoyl chloride or isocyanate), optionally in the presence of an amine base, such as pyridine, in an inert solvent such as dichloromethane, tetrahydrofuran or toluene at temperatures ranging from −20° C. to 60° C. for from 1-120 hours. Compounds of formula 1i may be converted into compounds of formula 1n by reaction with a sulfonyl chloride or sulfonic anhydride (1-1.5 equivalents, depending on the reactivity of the sulfonyl chloride or sulfonic anhydride), optionally in the presence of anamine base, such as pyridine, in an inert solvent such as dichloromethane, tetrahydrofuran or toluene at temperatures ranging from −20° C. to 60° C. for from 1-48 hours.
16
[0116] Compounds of formula 1m′, in which R21′ is C2-C6 acyl, may be prepared from compounds of formula 1l′ in a two-step process involving reaction with an excess of an acylating agent in the presence of an amine base, such as pyridine, followed by de-acylation of the 2′-hydroxyl by the methods described above, such as transesterification with methanol for 2-48 hours at a temperature ranging from −20° C. to 60° C. (Scheme 7).
17
[0117] Scheme 8 illustrates an alternative method of synthesis of N-alkoxycarbamate compounds of formula 1o′, wherein Ar is aryl or heteroaryl. The compound of formula 1n′ (prepared as depicted in Scheme 3 by reaction of compounds of formula 1a with O-allylhydroxylamine) may be converted to compounds of formula 1o′ under Heck reaction conditions, employing a aryl or heteroaryl halide or triflate (ArX) in the presence of a Pd(0) or Pd(II) catalyst, a phosphine ligand, and an amine or inorganic base, for from 2 to 72 hours at a temperature ranging from 20° C. to 120° C. Suitable palladium catalysts to effect this conversion include, for example, palladium(II)acetate, tetrakis(triphenylphosphine)palladium(0), and the like. Suitable phosphine ligands include, for example, triphenylphosphine, tri-o-tolylphosphine, and the like. Suitable bases include tertiary amines, such as triethylamine, sodium or potassium acetate, and sodium bicarbonate. Suitable solvents include, but are not limited to, N,N-dimethylformamide, acetonitrile and dimethylsulfoxide.
18
[0118] Scheme 9 illustrates a method for synthesis of N-alkoxycarbamate compounds of formula 1c, in which R10 is C1-C8-alkyl, C3-C8-alkenyl and C3-C8-alkynyl and R11 is as previously defined. The compound of formula 1p′ (prepared by reaction of compounds of formula 1a with a suitably substituted hydroxylamine) may be converted to compounds of formula 1c by reaction with a suitably substituted aldehyde in the presence of a reducing agent and an acid catalyst, in a suitable solvent, such as acetonitrile, methylene chloride, or toluene, for from 2 to 72 hours at a temperature ranging from 0° C. to 100° C. A preferred reducing agent to effect this conversion is triethylsilane. A preferred acid catalyst is trifluoroacetic acid.
1920
[0119] It will be clear to one skilled in the art that the order of the steps in the synthetic sequence leading to compounds of the invention can be altered, provided that the functionality present in the molecule is compatible with the desired selective transformations. This is illustrated in Scheme 10 wherein W′ is W other than
21
[0120] For example, compound VII can be converted to compound 1o under similar conditions as described above for the conversion of compound IX to compound 1a (Scheme 2). Removal of the 2′-acetyl group of compound 10 as described for the conversion of compound VIII to compound IX (Scheme 2) provides compound 1p. Compound 1p may then be converted to compounds of formula 1q by methods analogous to those described above in Schemes 3-9. Alternatively, oxidation of the 3-hydroxyl of compound 1o to the ketone of compound 1r can be conducted as described for the analogous transformation of VII to VIII in Scheme 2. Deprotection of the 2′-acetyl group of 1r is readily effected as described for the conversion of compound VIII to compound IX (Scheme 2) to provide the compounds of formula 1a. Compound 1a may then be converted to compounds of formula 1s as described above in Schemes 3-9.
22
[0121] Scheme 11 illustrates an alternate route for the preparation of the compounds of the invention (1a). Reaction of compound VI with a suitably substituted 1,4-dialdehyde or its equivalent in the presence of an acid, such as trifluoroacetic acid, in a suitable solvent, such as acetonitrile, methylene chloride, or toluene, at a temperature ranging from −20° C. to 100° C. for 2-96 hours leads to the simultaneous removal of the cladinose sugar and the formation of the pyrrole to afford compound 1o. Equivalents of 1,4-dialdehydes include 2,5-dialkoxytetrahydrofurans, 1,4-dialdehyde monoacetals, and 1,4-dialdehyde diacetals. Conversion of compound 1o to compound 1a then follows the procedure described above (Scheme 10).
23
[0122] Scheme 12, wherein R1a is halogen, illustrates the procedures by which compounds of formula VIII can be converted to compounds of formula 1v.
[0123] Fluorination of compound VIII can be accomplished with any one of a number of fluorinating reagents, including N-fluorobenzenesulfonimide in the presence of base, 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis[tetrafluoroborate] (SELECTFLUOR™) in the presence of base, 10% F2 in formic acid, 3,5-dichloro-1-fluoropyridinium tetrafluoroborate, 3,5-dichloro-1-fluoropyridinium triflate, (CF3SO2)2NF, N-fluoro-N-methyl-p-toluenesulfonamide in the presence of base, N-fluoropyridinium triflate, and N-fluoroperfluoropiperidine in the presence of base to give X wherein R1a is F. Chlorination of VIII can be effected with hexachloroethane in the presence of base, sulfuryl chloride, thionyl chloride, trifluoromethanesulfonyl chloride in the presence of base, chlorine, or sodium hypochlorite in the presence of acetic acid to give X wherein R1a is Cl. Suitable brominating agents would include pyridinium hydrobromide perbromide, bromine in acetic acid, N-bromosuccinimide in the presence of base, 1,2-dibromoethane in the presence of base, or carbon tetrabromide in the presence of base to give X wherein R1a is Br. Suitable iodinating agents include N-iodosuccinimide in the presence of base or iodine to give X wherein R1a is I.
[0124] Transformation of the halogenated derivatives X to the corresponding compounds of formula 1v can be accomplished through analogous synthetic routes as above for the non-halogenated compounds. For example, reaction of compounds of formula X with a suitably substituted 1,4-dialdehyde or its equivalent in the presence of an acid, such as trifluoroacetic acid, in a suitable solvent, such as acetonitrile, methylene chloride, or toluene, at a temperature ranging from −20° C. to 100° C. for 2-96 hours provides compounds of formula 1t. Equivalents of 1,4-dialdehydes include 2,5-dialkoxytetrahydrofurans, 1,4-dialdehyde monoacetals, and 1,4-dialdehyde diacetals. Deprotection of the 2′-acetyl group of compounds of formula 1t is readily effected as described for the conversion of compound VIII to compound IX (Scheme 2) to provide the compounds of formula 1u. Compounds of formula 1u may then be converted to compounds of formula 1v by procedures analogous to those described above in Schemes 3-9.
24
[0125] Once again, it will be apparent to one skilled in the art that by changing the order of steps compounds of formula 1t′ may be obtained by reaction of suitably protected precursors with a suitable fluorinating agent, followed by deprotection. This is illustrated in Scheme 13 wherein W″ is W other than
25
[0126] or —NR12NR13R14, wherein R13 or R14 are hydrogen. For example, compounds of formula 1q′ may be converted to compounds of formula 1r′ by reaction with acetic anhydride in the presence of a tertiary amine base, such as triethylamine, diisopropylethylamine, or pyridine, and optionally an acylation catalyst, such as DMAP, in a suitable solvent such as methylene chloride, chloroform or THF at a temperature ranging from −20° C. to 37° C. for 2 to 48 hours. Fluorination of compounds of formula 1r′, as described for the conversion of compounds of formula VIII to compounds of formula X, wherein R1a is fluoro (Scheme 12), provides compounds of formula 1s′. Finally, de-acylation of the 2′-hydroxyl by the methods described above, such as transesterification with methanol for 2-48 hours at a temperature ranging from −20° C. to 60° C., provides compounds of formula 1t′.
2627
[0127] Schemes 14A and 14B illustrate the procedures by which compound VIII can be converted to 2α- and 2β-fluoro derivatives of formulae XI and XII. Fluorination of compound VIII can be accomplished as described herein above. Reagent combinations for the conversion of compound VIII to the 2α-fluoro derivative XI include SELECTFLUOR and sodium hexamethyldisilazide in DMF and N-fluorobenzenesulfonimide and potassium t-butoxide in THF. Typically, the reaction is conducted at −78° C. to −60° C. for 5 minutes to 24 hours. Reagent combinations for the conversion of compound VIII to the 2β-fluoro derivative XII include N-fluorobenzenesulfonimide and sodium hydride in DMF. Typically, this reaction is conducted at 0° C. to 20° C. for 1 to 24 hours.
[0128] Transformation of the fluorinated derivatives XI and XII to the corresponding compounds of the invention 1y and 1b′, respectively, can be accomplished through analogous synthetic routes as above. For example, reaction of compounds of formula XI or XII with a suitably substituted 1,4-dialdehyde or its equivalent in the presence of an acid, such as trifluoroacetic acid, in a suitable solvent, such as acetonitrile, methylene chloride, or toluene, at a temperature ranging from −20° C. to 100° C. for 2-96 hours provides compounds of formula 1w or 1z, respectively. Equivalents of 1,4-dialdehydes include 2,5-dialkoxytetrahydrofurans, 1,4-dialdehyde monoacetals, and 1,4-dialdehyde diacetals. Deprotection of the 2′-acetyl group of compounds of formula 1w or 1z is readily effected as described for the conversion of compound VIII to compound IX (Scheme 2) to provide the compounds of formula 1x or 1a′, respectively. Compounds of formula 1×or 1a′ may then be converted to compounds of formula 1y or 1b′, respectively, by procedures analogous to those described above in Schemes 3-9.
[0129] It will be understood by one skilled in the art of organic synthesis that the halogenation reaction can also be conducted at a later stage in the synthetic sequence. For example, halogenation of compound 1r (Scheme 10) affords the corresponding 2-halo derivative 1t, which likewise can be converted to compounds of the invention as shown in Scheme 12.
28
[0130] Compounds which contain an alkenyl or alkynyl function may be converted to the corresponding saturated compounds. For example, as illustrated in Scheme 15, a substituted O-propenylcarbonate derivative such as 1c′ may be converted to the corresponding substituted O-propylcarbonate compound (1d′). Typically, this transformation is conducted via catalytic transfer hydrogenation, in which the olefin is reacted with ammonium formate in the presence of a suitable catalyst, such as palladium on carbon, in a suitable solvent, such as methanol or ethanol, at a temperature ranging from 20° C. to 60° C. for 15 minutes to 24 hours. Other methods for reduction of the double bond could also be applicable, for example treatment with hydrogen in the presence of a noble metal catalyst, such as palladium or platinum, or reaction with diimide. It will be obvious to one skilled in the art that the analogous O-propynylcarbonate may likewise be reduced to the corresponding O-propenylcarbonate or O-propylcarbonate under similar conditions.
29
[0131] Scheme 16 illustrates a method for the preparation of certain arylacetaldehydes and heteroarylacetaldehydes (XV) used in the preparation of some of the compounds of the invention. In this method, an aryl or heteroaryl aldehyde XIII is allowed to react with (methoxymethylene)triphenylphosphorane in a suitable solvent to form the corresponding enol ether XIV. The (methoxymethylene)triphenylphosphorane reagent is generally generated in situ by reaction of the corresponding phosphonium salt with a strong base such as an alkyllithium, an alkali metal hydride, or an alkali metal amide. A preferred base for this transformation is sodium hexamethyldisilazide. The enol ether is then hydrolyzed to the desired aldehyde XV by treatment with aqueous acid. The hydrolysis step may be conducted on the isolated enol ether or, alternatively, the reaction solution containing the enol ether may be directly treated with aqueous acid to effect the hydrolysis.
30
[0132] Scheme 17 illustrates a method for the preparation of certain alcohols (XVII) used in the preparation of some of the compounds of the invention. In this method, an aldehyde XVI is reduced to the alcohol XVII. A preferred reducing agent is sodium borohydride in an alcoholic solvent such as methanol or ethanol. Another preferred reducing agent is diisobutylaluminum hydride in an inert solvent such as dichloromethane, toluene, or tetrahydrofuran. It will be obvious to one skilled in the art that numerous methods for reducing an aldehyde to an alcohol are known, and any of these may be suitable provided that the method is compatible with other functional groups that may be present in the molecule.
[0133] Certain alcohols used in the preparation of compounds of the invention contain an alkene. Such alkenyl alcohols, including compounds in which the alkene is trisubstituted, may be made by methods known in the art. Methods are also known in the art for the preparation of alkenyl alcohols when one of the alkene substituents is a halogen and in particular when the alkene substituent is fluorine. Additionally, methods are known in the art for the preparation of trisubstituted, including fluorinated, alkenyl acids, esters, and aldehydes, such compounds being easily converted to the desired alcohols by reduction with typical hydride reducing agents such as sodium or lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, and many others well known in the art. References which provide examples of the art known for the preparation of fluorinated alkenes relevant to the present invention include but are not limited to Synleff 1998, 777; J. Chem. Soc. Chem. Comm. 1989,1493; and J. Chem. Soc. Chem. Comm. 1985,961. In addition several examples of the preparation of alkenyl alcohols, including fluorinated alkenyl alcohols, are included as reference examples.
31
[0134] Scheme 18 illustrates a method for the preparation of certain hydroxylamines (XX) used in the preparation of some of the compounds of the invention. In this method, an alcohol XVIII is first converted to the phthalimide derivative XIX. A preferred method for this transformation involves treatment of the alcohol with N-hydroxyphthalimide in the presence of triphenylphosphine and diethyl azodicarboxylate. The phthalimide compound XIX is then converted to the hydroxylamine XX by reaction with hydrazine. The method is more fully described, for example, in J. Med. Chem. 1997, 40, 2363.
32
[0135] Scheme 19 illustrates a method for the preparation of certain thiols (XXIII) used in the preparation of some of the compounds in this invention. In this method, an alkyl halide XXI is first converted to the thiolacetate derivative XXII. A preferred method for this transformation involves reaction of the alkyl bromide with potassium thiolacetate in a suitable solvent, such as N,N-dimethyl acetamide (DMA), for from 1 to 24 hours at a temperature ranging from 0° C. to 100° C. The thiolacetate XXII is then converted to the corresponding thiol XXIII by treatment with aqueous base in a suitable solvent, such as methanol, for from 1 to 24 hours at a temperature ranging from 0° C. to 60° C. It will be obvious to one skilled in the art that numerous methods for reducing a thiolacetate to a thiol are known, and any of these may be suitable provided that the method is compatible with other functional groups that may be present in the molecule.
33
[0136] Scheme 20 illustrates the preparation of thiocarbonate compounds of formula 1e′, wherein R9 is as defined previously, by reaction of 1′a with a suitably substituted thiol in the presence of a suitable base such as DBU, DBN, tert-butyltetramethylguanidine, sodium hydride, potassium hydride, or an alkyllithium. This reaction is conducted in a suitable solvent, such as acetonitrile, dimethylformamide, or tetrahydrofuran at a temperature ranging from −20° C. to 120° C. for 0.5 to 72 hours. Preferred substrates for this conversion are those in which the pyrrole of 1a is substituted with electron-withdrawing groups including, but not limited to, cyano, formyl, and alkoxycarbonyl. A particularly preferred substrate is compound 1a, where R5=CN and R6=H. Preformed alkali or alkaline earth metal thiolates are also suitable reagents for the preparation of compounds of formula 1e′.
34
[0137] Scheme 21 depicts the synthesis of compounds of the instant invention of formulae 1f′ and 1g′. Compounds of formula 1f′ can be obtained by reaction of 1e with a suitably substituted β-dicarbonyl compound or its equivalent, optionally in the presence of an acid. Equivalents of β-dicarbonyl compounds include for example monoketals or monoacetals of a β-dicarbonyl compound, diketals or diacetals of a β-dicarbonyl compound, β-alkoxy or β-amino-α,β-unsaturated carbonyl compounds and α,β-acetylenic carbonyl compounds. A preferred acid for effecting this transformation is trifluoroacetic acid in a suitable solvent, like acetonitrile, methylene chloride, or toluene at −20° C. to 100° C. The reaction mixture may optionally contain an adsorbent such as molecular sieves to remove alcohol or water that may be generated during the reaction. Typically, the reaction is conducted for from 15 minutes to 24 hours. Preferred 1,3-dicarbonyl compounds or their equivalents include 1,3-malondialdehyde, 1,1,3,3-tetramethoxypropane and 3,3-dimethoxypropanal.
[0138] Compounds of formula 1f′ can be converted to esters of formula 1g′ by displacement of the pyrazole with carbon nucleophiles, such as Grignard reagents, organolithium species, or organocuprates. A preferred class of carbon nucleophiles are the Grignard reagents. A preferred substrate for this conversion is the derivative of 1f′ in which the pyrazole ring is unsubstituted, that is where R21 and R22=H. Typically this reaction is conducted in an inert solvent such as THF, ether, dioxane or toluene at temperatures ranging from −78° C. to 65° C. for from 5 minutes to 24 hours.
35
[0139] Scheme 22 illustrates the synthesis of compounds of the instant invention 1i′, wherein R5 is hydrogen, —C(O)NR7R8, —SO2R7, C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, or heteroaryl, by reaction of compounds of the instant invention 1h′, wherein R5 is hydrogen, —C(O)NR7R8, —SO2R7, C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-C8-cycloalkyl, C5-C8-cycloalkenyl, aryl, or heteroaryl, with a suitably substituted organometallic reagent, such as a Grignard reagent or an organolithium species. A preferred class of organometallic reagents for this conversion are the Grignard reagents. Typically, this transformation is conducted in an inert solvent, such as THF, ether, dioxane, or toluene at temperatures ranging from −78° C. to 25° C. for from 5 minutes to 24 hours.
[0140] Compounds of the invention wherein R4 is a hydroxy protecting group other than acyl may be prepared by methods analogous to those shown in the above schemes with appropriate reagents that are either commercially available or may be made by known methods.
[0141] Compounds of the invention wherein R3 is a group other than ethyl may be prepared beginning with modified erythromycin derivatives as starting materials as described in various publications including, but not limited to, WO99/35157, WO00/62783, WO00/63224, and WO00/63225, which are all incorporated by reference herein.
[0142] Compounds of the invention wherein R2-Z is a group other than hydrogen may be prepared beginning with starting materials prepared as described in WO 00/75156 and EP1146051, which are both incorporated by reference herein.
[0143] These compounds have antimicrobial activity against susceptible and drug resistant Gram positive and Gram negative bacteria. In particular, they are useful as broad spectrum antibacterial agents for the treatment of bacterial infections in humans and animals. These compounds are particularly active against S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, Enterococci, Moraxella catarrhalis and H. influenzae. These compounds are particularly useful in the treatment of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections.
[0144] Minimal inhibitory concentration (MIC) has been an indicator of in vitro antibacterial activity widely used in the art. The in vitro antimicrobial activity of the compounds was determined by the microdilution broth method following the test method from the National Committee for Clinical Laboratory Standards (NCCLS). This method is described in the NCCLS Document M7-A4, Vol.17, No.2, “Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically—Fourth Edition”, which is incorporated herein by reference.
[0145] In this method two-fold serial dilutions of drug in cation adjusted Mueller-Hinton broth are added to wells in microdilution trays. The test organisms are prepared by adjusting the turbidity of actively growing broth cultures so that the final concentration of test organism after it is added to the wells is approximately 5×104 CFU/well.
[0146] Following inoculation of the microdilution trays, the trays are incubated at 35° C. for 16-20 hours and then read. The MIC is the lowest concentration of test compound that completely inhibits growth of the test organism. The amount of growth in the wells containing the test compound is compared with the amount of growth in the growth-control wells (no test compound) used in each tray. As set forth in Table 1, compounds of the present invention were tested against a variety of Gram positive and Gram negative pathogenic bacteria resulting in a range of activities depending on the organism tested.
[0147] Table 1 below sets forth the biological activity (MIC, μg/mL) of some compounds of the present invention.
1TABLE 1
|
|
MIC Values (μg/mL) of Some Compounds of Formula I
(A: E. coli OC2605; B: S. aureus ATCC29213;
C: E. faecalis ATCC29212;
D: S. pneumoniae ATCC49619; E: H. influenzae ATCC49247)
MIC (μg/mL)
No.ABCDE
|
2>16>1680.5>16
3>16>1641>16
4>16>1641>16
5>161640.58
6 160.120.120.031
7 80.120.060.032
15NDa0.120.060.030.5
19NDa0.120.06≦0.015NDa
20 80.120.060.032
21NDa0.120.06≦0.015NDa
22NDa0.250.06≦0.0150.5
24NDa0.120.06≦0.0151
26NDa0.250.120.032
30NDa0.120.06≦0.0151
31NDa0.120.060.031
33NDa0.250.120.061
34NDa0.250.120.031
35NDa0.250.120.031
37NDa0.120.06≦0.0150.5
40NDa0.120.060.06NDa
44NDa0.120.06≦0.015NDa
47NDa0.120.06≦0.0150.5
48NDa0.120.120.031
49NDa0.120.120.031
50NDa10.50.062
52NDa0.120.06≦0.0151
55NDa0.250.120.031
56NDa0.50.250.062
58NDa0.50.50.064
61NDa0.120.120.031
63NDa0.250.120.061
64NDa0.120.060.031
65NDa0.250.120.031
72NDa0.250.060.032
73NDa210.2516
76NDa0.250.120.031
77 80.120.060.032
80 160.250.120.032
86 80.120.060.032
87 80.120.060.031
122NDa0.120.06≦0.0151
137NDa0.250.120.034
139NDa0.120.060.12ND
159NDa0.250.120.031
160NDa0.120.060.031
168NDa0.120.06≦0.0150.5
224NDa0.120.06≦0.0152
286NDa0.250.250.064
288NDa0.250.120.06ND
570>1610.250.034
571>160.50.120.034
578NDa0.50.250.12NDa
599 160.50.250.062
601NDa0.250.120.032
602NDa0.250.120.03NDa
603NDa0.250.120.032
605 160.250.250.064
606NDa0.250.120.06NDa
607NDa0.250.250.03NDa
608>160.50.50.064
611>1620.50.128
612>1610.250.064
615NDa10.250.06NDa
616NDa0.50.250.06NDa
617NDa0.250.120.03NDa
618NDa0.250.060.031
619NDa0.250.120.03NDa
620NDa0.50.120.03NDa
621NDa10.250.12NDa
622NDa0.250.250.034
623NDa0.250.120.034
624>1640.50.124
625>1620.250.034
626>160.250.120.034
661>160.50.120.032
675 160.50.120.062
676 80.250.120.034
744>160.250.250.038
774>1620.250.064
803>160.250.120.034
804>160.50.120.038
805 160.250.250.062
806>16210.1216
807>16210.124
809NDa10.50.032
810NDa20.50.064
811NDa20.50.064
812NDa>1642>16
813NDa1610.2516
814NDa80.50.128
815NDa410.2516
816NDa1610.516
817NDa20.250.068
818NDa40.250.068
819NDa1610.25>16
820NDa10.250.068
821NDa20.50.1216
822NDa410.128
823NDa810.12>16
824NDa210.1216
825NDa40.50.1216
826NDa820.258
827NDa110.128
828NDa0.50.250.062
829NDa10.50.062
830NDa10.50.124
831NDa20.250.068
832NDa40.50.258
833NDa0.50.250.0616
834NDa0.50.12<0.0158
835NDa0.50.120.034
836NDa0.250.120.031
837NDa20.250.128
838NDa0.250.120.061
839NDa10.120.062
840NDa0.50.120.062
841NDa0.50.120.032
843NDa820.516
844NDa0.50.120.034
845NDa>16>164>16
846NDa810.252
|
aNot determined
[0148] This invention further provides a method of treating bacterial infections, or enhancing or potentiating the activity of other antibacterial agents, in warm-blooded animals, which comprises administering to the animals a compound of the invention alone or in admixture with another antibacterial agent in the form of a medicament according to the invention.
[0149] When the compounds are employed for the above utility, they may be combined with one or more pharmaceutically acceptable carriers, e.g., solvents, diluents, and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing for example, from about 0.5% to 5% of suspending agent, syrups containing, for example, from about 10% to 50% of sugar, and elixirs containing, for example, from about 20% to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.5% to 5% suspending agent in an isotonic medium. These pharmaceutical preparations may contain, for example, from about 0.5% up to about 90% of the active ingredient in combination with the carrier, more usually between 5% and 60% by weight.
[0150] Compositions for topical application may take the form of liquids, creams or gels, containing a therapeutically effective concentration of a compound of the invention admixed with a dermatologically acceptable carrier.
[0151] In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
[0152] The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred. These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacological acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
[0153] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
[0154] The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg/kg to about 400 mg/kg of animal body weight, which may be given in divided doses two to four times a day, or in sustained release form. For most large mammals the total daily dosage is from about 0.07 g to 7.0 g, preferably from about 100 mg to 2000 mg. Dosage forms suitable for internal use comprise from about 100 mg to 1200 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
[0155] The production of the above-mentioned pharmaceutical compositions and medicaments is carried out by any method known in the art, for example, by mixing the active ingredients(s) with the diluent(s) to form a pharmaceutical composition (e.g. a granulate) and then forming the composition into the medicament (e.g. tablets).
[0156] The following examples describe in detail the chemical synthesis of representative compounds of the present invention. The procedures are illustrations, and the invention should not be construed as being limited by chemical reactions and conditions they express. No attempt has been made to optimize the yields obtained in these reactions, and it would be obvious to one skilled in the art that variations in reaction times, temperatures, solvents, and/or reagents could increase the yields.
Compound IX
[0157] Step A
[0158] Triethylamine (42.0 mL, 301 mmol), DMAP (0.6 g, 4.9 mmol), and acetic anhydride (28.5 mL, 302 mmol) were added to a 0° C. suspension of erythromycin (36.7 g, 50 mmol) in dichloromethane (250 mL). The mixture was allowed to warm to room temperature and stir for 18 h. Methanol (10 mL) was added and stirring was continued for 5 min. The mixture was diluted with ether (750 mL), washed with sat. aq. NaHCO3, water, and brine (500 mL each), dried (MgSO4), and concentrated to provide the title compound as a colorless foam. The material was used in the next step without further purification. MS 860 (M+H)+.
[0159] Step B
[0160] Sodium hexamethyldisilazide (1.0M in THF, 60.0 mL, 60.00 mmol) was added over 25 min to a 0° C. solution of the compound from step A (50.0 mmol) in THF (500 mL). After 2 h at 0° C., the mixture was diluted with water (250 mL) and brine (250 mL) and extracted with ethyl acetate (3×250 mL). The combined organic layers were dried (MgSO4) and concentrated. The material was used in the next step without further purification. If desired, pure material could be obtained by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH). MS 800 (M+H)+.
[0161] Step C
[0162] Trichloroacetylisocyanate (18.0 mL, 151 mmol) was added over 20 min to a 0° C. solution of the compound from step B (50 mmol) in dichloromethane (350 mL). After 3 h at 0° C., the reaction was quenched by the addition of methanol (30 mL) and concentrated. The residue was dissolved in a mixture of methanol (450 mL), water (45 mL), and triethylamine (18 mL), heated to reflux for 2 h, and concentrated. The residue was dissolved in ethyl acetate (500 mL), washed with sat. aq. NaHCO3 (250 mL) and brine (250 mL), dried (MgSO4), and concentrated. The resulting mixture of C-10 epimers was dissolved in THF (500 mL) at 0° C. and potassium t-butoxide (1.0 M in THF, 60.0 mL, 60.0 mmol) was added over 15 min. The resulting mixture was stirred at 0° C. to 15° C. for 6 h. Sat. aq. NaHCO3 (250 mL) was added, the bulk of the THF was removed in vacuo, and the resulting solution was extracted with ethyl acetate (3×250 mL). The combined organic extracts were washed with brine (250 mL), dried (MgSO4), and concentrated. The material was used in the next step without further purification. If desired, pure material could be obtained by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH). MS 844 (M+H)+.
[0163] Step D
[0164] A solution of the compound from step C (50 mmol), triethylamine (13.0 mL, 93.3 mmol), and acetic anhydride (8.8 mL, 93.3 mmol) in dichloromethane (250 mL) was stirred at room temperature for 20 h. The solution was washed with sat. aq. NaHCO3 (2×250 mL) and brine (250 mL), dried (MgSO4), and concentrated. The material was used in the next step without further purification. MS 886 (M+H)+.
[0165] Step E
[0166] The compound from step D (50 mmol) was dissolved in 1.2 N HCl (400 mL) and ethanol (160 mL) and stirred at room temperature for 20 h. The mixture was cooled to 0° C., made basic with 10% NaOH, and extracted with ethyl acetate (3×300 mL). The combined organic layers were washed with water (300 mL) and brine (300 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 94:6:0.5 dichloromethane/methanol/conc. NH4OH) yields 10.4 g (30% based on erythromycin) of the title compound as a colorless solid. MS 686 (M+H)+.
[0167] Step F
[0168] EDCI (3.92 g, 20.45 mmol) was added to a solution of the compound from step E (2.00 g, 2.92 mmol) and dimethyl sulfoxide (3.70 mL, 52.14 mmol) in dichloromethane (10 ml) at 0° C. A solution of pyridinium trifluoroacetate (3.94 g, 20.40 mmol) in dichloromethane (10 mL) was added over 10 min and the resulting solution was stirred at 0° C. for 2 h before being quenched with water (2 mL). After 5 min, the mixture was diluted with dichloromethane (50 mL), washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. The material was used in the next step without further purification. If desired, pure material could be obtained by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH). MS 684 (M+H)+.
[0169] Step G
[0170] The crude product from step F was allowed to stand in methanol (20 mL) for 24 h and then concentrated. Purification by chromatography (SiO2, 94:6:0.2 dichloromethane/methanol/conc. NH4OH) yields 1.39 g (74%) of the title compound as a colorless solid. MS 642 (M+H)+.
Compound 2 (Formula 1a: R5 is H, R6 is H)
[0171] A solution Compound IX (1.00 g, 1.56 mmol), 2,5-dimethoxytetrahydrofuran (0.40 mL, 3.09 mmol), and trifluoroacetic acid (0.60 mL, 7.79 mmol) in CH3CN (10 mL) was stirred at room temperature for 24 h. Water (5 mL) was added and the solution was stirred for 20 h. The reaction mixture was diluted with ethyl acetate (75 mL), washed with sat. aq. NaHCO3 (50 mL) and brine (50 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 550 mg (51%) of the title compound. MS 692 (M+H)+.
Compound 3 (Formula 1a: R5 is C(O)H, R6 is H)
[0172] A solution of Compound IX (500 mg, 0.78 mmol), 2,5-dimethoxy-3-tetrahydrofurancarboxaldehyde (625 mg, 3.90 mmol), and trifluoroacetic acid (0.60 mL, 7.79 mmol) in CH3CN (5 mL) was stirred at room temperature for 18 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with sat. aq. NaHCO3 (25 mL) and brine (25 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) yielded 255 mg (45%) of the title compound. MS 720 (M+H)+.
Compound 4 (Formula 1a: R5 is CN, R6 is H)
[0173] A solution of Compound IX (5.00 g, 7.79 mmol), 2-formyl-4,4-dimethoxybutanenitrile, (5.40 g, 34.36 mmol, prepared as described in Reference Example 68), and trifluoroacetic acid (6.0 mL, 77.88 mmol) in CH3CN (40 mL) was heated to 60° C. for 24 h. The reaction mixture was diluted with ethyl acetate (250 mL), washed with sat. aq. NaHCO3 (250 mL), water (250 mL), and brine (250 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) yielded 3.00 g (54%) of the title compound. MS 717 (M+H)+.
Compound 5 (Formula 1b: R12 is H, R13 is H, R14 is H)
[0174] Method A
[0175] Hydrazine (105 μL, 3.34 mmol) was added to a solution of Compound 4 (475 mg, 0.66 mmol) in CH3CN (5 mL) and the resulting solution was stirred for 30 min. Concentration and purification by chromatography (SiO2, 94:6:0.2 dichloromethane/methanol/conc. NH4OH) yielded 346 mg (80%) of the title compound. MS 657 (M+H)+.
[0176] Method B
[0177] Hydrazine (110 μL, 3.50 mmol) was added to a solution of Compound 3 (500 mg, 0.69 mmol) in DMSO (2.5 mL) and the resulting solution was stirred at rt for 24 h. Additional hydrazine (110 μL, 3.50 mmol) was added and stirring at rt was continued for 4 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×20 mL). The combied organic layers were washed with water (2×30 mL) and brine (30 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 94:6:0.5 dichloromethane/methanol/conc. NH4OH) yielded 136 mg (30%) of the title compound. MS 657 (M+H)+.
Compound 6 (Formula 1d: R9 is (2E)-3-phenyl-2-propenyl)
[0178] Compound 4 (25 mg, 0.035 mmol) was added to a mixture of cinnamyl alcohol (26 mg, 0.19 mmol) and DBU (26 μL, 0.17 mmol) in CH3CN (0.25 mL) and the resulting solution was stirred for 90 min at rt. The solution was diluted with ethyl acetate (10 mL), washed with 10% aq. NH4Cl, sat. aq. NaHCO3, and brine (10 ml each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 11 mg (42%) of the title compound. MS 759 (M+H)+.
Compound 7 (Formula 1d: R9 is (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl)
[0179] DBU (420 μL, 2.81 mmol) was added to a solution of (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol (600 mg, 2.83 mmol, prepared as described in Reference Example 65) in THF (4.5 mL) and DMSO (0.5 mL), the mixture was stirred at rt for 5 min, and then cooled to 0° C. Compound 4 (500 mg, 0.70 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (50 mL), washed with 10% aq. NH4Cl (50 mL—discarded), and extracted with 1.2 N HCl (3×10 mL). The combined acidic extracts were cooled to 0° C., made basic with 10% aq. NaOH, and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine (50 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 243 mg (42%) of the title compound. MS 837 (M+H)+.
Compounds 8-285
[0180] Following the procedure of Example 7, except substituting the reagent of formula R9OH for the (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Example 7, Compounds 8-48 shown in the table below of formula 1d, wherein R9 is as described in the table, can be prepared.
2|
|
Compound
No.R9MS [(M+H)+]
|
|
8phenylmethyl733
92-phenylethyl747
103-phenyl-2-propynyl757
113-phenylpropyl761
124-phenylbutyl775
13(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl837
14(2E)-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl837
15(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl837
16(2E)-3-[4-(2-pyridinyl)phenyl]-2-propenyl836
17(2E)-3-[4-(3-pyridinyl)phenyl]-2-propenyl836
18(2E)-3-[4-(4-pyridinyl)phenyl]-2-propenyl836
19(2E)-3-(4-pyrazinylphenyl)-2-propenyl837
20(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl837
21(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl825
22(2E)-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl826
23(2E)-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propenyl826
24(2E)-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propenyl826
25(2E)-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl825
26(2E)-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propenyl839
27(2E)-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propenyl839
28(2E)-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl855
29(2E)-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl843
30(2E)-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl843
31(2E)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-843
propenyl
32(2E)-3-[6-(1H-pyrazol-1-yl)-3-pyridinyl]-2-propenyl826
33(2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl825
34(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl827
35(2E)-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propenyl827
36(2E)-3-(2-quinolinyl)-2-propenyl810
37(2E)-3-(3-quinolinyl)-2-propenyl810
38(2E)-3-(4-quinolinyl)-2-propenyl810
39(2E)-3-(5-quinolinyl)-2-propenyl810
40(2E)-3-(6-quinolinyl)-2-propenyl810
41(2E)-3-(7-quinolinyl)-2-propenyl810
42(2E)-3-(8-quinolinyl)-2-propenyl810
43(2E)-3-(2-quinoxalinyl)-2-propenyl811
44(2E)-3-(6-quinoxalinyl)-2-propenyl811
45(2E)-3-(4-isoquinolinyl)-2-propenyl810
46(2E)-3-(6-bromo-3-pyridinyl)-2-propenyl838, 840
47(2E)-3-[4-(2-oxazolyl)phenyl]-2-propenyl826
48(2E)-3-[4-(5-oxazolyl)phenyl]-2-propenyl826
49(2E)-3-[4-(2-thiazolyl)phenyl]-2-propenyl842
50(2E)-3-[4-(2-thienyl)phenyl]-2-propenyl841
51(2E)-3-[4-(3-isoxazolyl)phenyl]-2-propenyl826
52(2E)-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl827
53(2E)-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propenyl827
54(2E)-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl827
55(2E)-3-(1-methyl-1H-benzimidazol-2-yl)-2-propenyl813
56(2E)-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propenyl915, 917
57(2E)-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propenyl855
58(2E)-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propenyl865
59(2E)-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propenyl851
60(2E)-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propenyl867
61(2E)-3-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propenyl851
62(2E)-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propenyl867
63(2E)-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl842
64(2E)-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl843
65(2E)-3-(5-pyrazinyl-2-thienyl)-2-propenyl843
66(2E)-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl842
67(2E)-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl843
68(2E)-3-(4-pyrazinyl-2-thienyl)-2-propenyl843
69(2E)-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl842
70(2E)-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl843
71(2E)-3-(5-pyrazinyl-3-thienyl)-2-propenyl843
72(2E)-3-(2-phenyl-5-pyrimidinyl)-2-propenyl837
73(2E)-3-[2,2′-bithiophen]-5-yl-2-propenyl847
74(2E)-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl853
75(2E)-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propenyl855
76(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-butenyl851
77[4-(2-pyrimidinyl)phenyl]methyl811
78[4-(3-pyridazinyl)phenyl]methyl811
79(4-pyrazinylphenyl)methyl811
803-[4-(2-pyrimidinyl)phenyl]-2-propynyl835
813-[4-(4-pyrimidinyl)phenyl]-2-propynyl835
823-[4-(5-pyrimidinyl)phenyl]-2-propynyl835
833-[4-(2-pyridinyl)phenyl]-2-propynyl834
843-[4-(3-pyridinyl)phenyl]-2-propynyl834
853-[4-(4-pyridinyl)phenyl]-2-propynyl834
863-(4-pyrazinylphenyl)-2-propynyl835
873-[4-(3-pyridazinyl)phenyl]-2-propynyl835
883-[4-(1H-pyrazol-1-yl)phenyl]-2-propynyl823
893-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propynyl824
903-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propynyl824
913-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propynyl824
923-[4-(1H-imidazol-1-yl)phenyl]-2-propynyl823
933-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propynyl837
943-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propynyl837
953-(1-phenyl-1H-pyrazol-4-yl)-2-propynyl823
963-(2-quinolinyl)-2-propynyl808
973-(3-quinolinyl)-2-propynyl808
983-(4-quinolinyl)-2-propynyl808
993-(5-quinolinyl)-2-propynyl808
1003-(6-quinolinyl)-2-propynyl808
1013-(7-quinolinyl)-2-propynyl808
1023-(8-quinolinyl)-2-propynyl808
1033-(2-quinoxalinyl)-2-propynyl809
1043-(6-quinoxalinyl)-2-propynyl809
1053-(4-isoquinolinyl)-2-propynyl808
1063-[4-(2-oxazolyl)phenyl]-2-propynyl824
1073-[4-(5-oxazolyl)phenyl]-2-propynyl824
1083-[4-(2-thiazolyl)phenyl]-2-propynyl840
1093-[4-(2-thienyl)phenyl]-2-propynyl839
1103-[4-(3-isoxazolyl)phenyl]-2-propynyl824
1113-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propynyl825
1123-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propynyl825
1133-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propynyl825
1143-(1-methyl-1H-benzimidazol-2-yl)-2-propynyl811
1153-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propynyl913, 915
1163-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propynyl853
1173-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propynyl863
1183-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propynyl849
1193-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propynyl865
1203-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propynyl849
1213-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propynyl865
1223-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl825
1233-[5-(2-pyridinyl)-2-thienyl]-2-propynyl840
1243-[5-(3-pyridinyl)-2-thienyl]-2-propynyl840
1253-[5-(4-pyridinyl)-2-thienyl]-2-propynyl840
1263-[5-(2-pyrimidinyl)-2-thienyl]-2-propynyl841
1273-(5-pyrazinyl-2-thienyl)-2-propynyl841
1283-[4-(2-pyridinyl)-2-thienyl]-2-propynyl840
1293-[4-(3-pyridinyl)-2-thienyl]-2-propynyl840
1303-[4-(4-pyridinyl)-2-thienyl]-2-propynyl840
1313-[4-(2-pyrimidinyl)-2-thienyl]-2-propynyl841
1323-[5-(2-pyridinyl)-3-thienyl]-2-propynyl840
1333-[5-(3-pyridinyl)-3-thienyl]-2-propynyl840
1343-(2-phenyl-5-pyrimidinyl)-2-propynyl835
1353-[2,2′-bithiophen]-5-yl-2-propynyl845
1363-[4-(2-pyrimidinyloxy)phenyl]-2-propynyl851
1374-[4-(2-pyrimidinyl)phenyl]-3-butynyl849
1385-[4-(2-pyrimidinyl)phenyl]-4-pentynyl863
1393-[4-(2-pyrimidinyl)phenyl]propyl839
1403-(4-pyrazinylphenyl)propyl839
1413-[4-(3-pyridazinyl)phenyl]propyl839
1423-[4-(2-pyridinyl)phenyl]propyl838
1433-[4-(1H-pyrazol-1-yl)phenyl]propyl827
1443-[4-(1H-1,2,4-triazol-1-yl)phenyl]propyl828
1453-[4-(1H-1,2,3-triazol-1-yl)phenyl]propyl828
1463-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]propyl841
1473-(2-quinolinyl)propyl812
1483-(3-quinolinyl)propyl812
1493-(4-quinolinyl)propyl812
1503-(5-quinolinyl)propyl812
1513-(6-quinolinyl)propyl812
1523-(7-quinolinyl)propyl812
1533-(8-quinolinyl)propyl812
1543-(2-quinoxalinyl)propyl813
1553-(6-quinoxalinyl)propyl813
1563-[4-(2-oxazolyl)phenyl]propyl828
1573-[5-(2-pyridinyl)-2-thienyl]propyl844
1583-[5-(2-pyrimidinyl)-2-thienyl]propyl845
1593-(1H-benzimidazol-1-yl)propyl801
160(2Z)-2-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl855
161(2Z)-2-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl855
162(2Z)-2-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl855
163(2Z)-2-fluoro-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl855
164(2Z)-2-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl854
165(2Z)-2-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl854
166(2Z)-2-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl854
167(2Z)-2-fluoro-3-(4-pyrazinylphenyl)-2-propenyl855
168(2Z)-2-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl855
169(2Z)-2-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl843
170(2Z)-2-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-844
propenyl
171(2Z)-2-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-844
propenyl
172(2Z)-2-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-844
propenyl
173(2Z)-2-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl843
174(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-857
propenyl
175(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-857
propenyl
176(2Z)-2-fluoro-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-873
propenyl
177(2Z)-2-fluoro-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-861
propenyl
178(2Z)-2-fluoro-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-861
propenyl
179(2Z)-2-fluoro-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-862
2-propenyl
180(2Z)-2-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl843
181(2Z)-2-fluoro-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-845
propenyl
182(2Z)-2-fluoro-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propenyl845
183(2Z)-2-fluoro-3-(2-quinolinyl)-2-propenyl828
184(2Z)-2-fluoro-3-(3-quinolinyl)-2-propenyl828
185(2Z)-2-fluoro-3-(4-quinolinyl)-2-propenyl828
186(2Z)-2-fluoro-3-(5-quinolinyl)-2-propenyl828
187(2Z)-2-fluoro-3-(6-quinolinyl)-2-propenyl828
188(2Z)-2-fluoro-3-(7-quinolinyl)-2-propenyl828
189(2Z)-2-fluoro-3-(8-quinolinyl)-2-propenyl828
190(2Z)-2-fluoro-3-(2-quinoxalinyl)-2-propenyl829
191(2Z)-2-fluoro-3-(6-quinoxalinyl)-2-propenyl829
192(2Z)-2-fluoro-3-(4-isoquinolinyl)-2-propenyl828
193(2Z)-2-fluoro-3-(6-bromo-3-pyridinyl)-2-propenyl856, 858
194(2Z)-2-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propenyl844
195(2Z)-2-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propenyl844
196(2Z)-2-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl860
197(2Z)-2-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl859
198(2Z)-2-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl844
199(2Z)-2-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-845
propenyl
200(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-845
propenyl
201(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-845
propenyl
202(2Z)-2-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-831
propenyl
203(2Z)-2-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-873
propenyl
204(2Z)-2-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-869
propenyl
205(2Z)-2-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-885
propenyl
206(2Z)-2-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-869
propenyl
207(2Z)-2-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl860
208(2Z)-2-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl860
209(2Z)-2-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl860
210(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
211(2Z)-2-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propenyl861
212(2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl860
213(2Z)-2-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl860
214(2Z)-2-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl860
215(2Z)-2-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
216(2Z)-2-fluoro-3-(4-pyrazinyl-2-thienyl)-2-propenyl861
217(2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl860
218(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl861
219(2Z)-2-fluoro-3-(5-pyrazinyl-3-thienyl)-2-propenyl861
220(2Z)-2-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propenyl855
221(2Z)-2-fluoro-3-[2,2′-bithiophen]-5-yl-2-propenyl865
222(2Z)-2-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl871
223(2Z)-2-fluoro-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-873
propenyl
224(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl855
225(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl855
226(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl855
227(2Z)-3-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl854
228(2Z)-3-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl854
229(2Z)-3-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl854
230(2Z)-3-fluoro-3-(4-pyrazinylphenyl)-2-propenyl855
231(2Z)-3-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl855
232(2Z)-3-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl843
233(2Z)-3-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-844
propenyl
234(2Z)-3-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-844
propenyl
235(2Z)-3-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-844
propenyl
236(2Z)-3-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl843
237(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-857
propenyl
238(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-857
propenyl
239(2Z)-3-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl843
240(2Z)-3-fluoro-3-(2-quinolinyl)-2-propenyl828
241(2Z)-3-fluoro-3-(3-quinolinyl)-2-propenyl828
242(2Z)-3-fluoro-3-(4-quinolinyl)-2-propenyl828
243(2Z)-3-fluoro-3-(5-quinolinyl)-2-propenyl828
244(2Z)-3-fluoro-3-(6-quinolinyl)-2-propenyl828
245(2Z)-3-fluoro-3-(7-quinolinyl)-2-propenyl828
246(2Z)-3-fluoro-3-(8-quinolinyl)-2-propenyl828
247(2Z)-3-fluoro-3-(2-quinoxalinyl)-2-propenyl829
248(2Z)-3-fluoro-3-(6-quinoxalinyl)-2-propenyl829
249(2Z)-3-fluoro-3-(4-isoquinolinyl)-2-propenyl828
250(2Z)-3-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propenyl844
251(2Z)-3-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propenyl844
252(2Z)-3-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl860
253(2Z)-3-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl859
254(2Z)-3-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl844
255(2Z)-3-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-845
propenyl
256(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-845
propenyl
257(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-845
propenyl
258(2Z)-3-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-831
propenyl
259(2Z)-3-fluoro-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-933, 935
propenyl
260(2Z)-3-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-873
propenyl
261(2Z)-3-fluoro-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-883
propenyl
262(2Z)-3-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-869
propenyl
263(2Z)-3-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-885
propenyl
264(2Z)-3-fluoro-3-[4-(6-methyl-3-pyridazinyl)phenyl]-2-869
propenyl
265(2Z)-3-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-885
propenyl
266(2Z)-3-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl860
267(2Z)-3-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl860
268(2Z)-3-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl860
269(2Z)-3-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
270(2Z)-3-fluoro-3-[5-(4-pyrimidinyl)-2-thienyl]-2-propenyl861
271(2Z)-3-fluoro-3-[5-(5-pyrimidinyl)-2-thienyl]-2-propenyl861
272(2Z)-3-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propenyl861
273(2Z)-3-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl860
274(2Z)-3-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl860
275(2Z)-3-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl860
276(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
277(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)-2-thienyl]-2-propenyl861
278(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)-2-thienyl]-2-propenyl861
279(2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl860
280(2Z)-2-fluoro-3-[5-(3-pyridinyl)-3-thienyl]-2-propenyl860
281(2Z)-3-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propenyl855
282(2Z)-3-fluoro-3-[2,2′-bithiophen]-5-yl-2-propenyl865
283(2Z)-3-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl871
284(2Z)-2-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl845
285(2Z)-3-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl845
|
Compound 286 (Formula 1d: R9 is 4-[4-(2-pyrimidinyl)phenyl]butyl)
[0181] A mixture of Compound 137 (63 mg, 0.074 mmol), 10% Pd/C (30 mg), and ammonium formate (47 mg, 0.074 mmol) in methanol (1 mL) was stirred for 20 min at room temperature. Solids were removed by filtration through Celite, the filter pad was rinsed with additional methanol, and the filtrate was concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 43 mg (68%) of the title compound. MS 853 (M+H)+.
Compound 287 (Formula 1d: R9 is 5-[4-(2-pyrimidinyl)phenyl]pentyl)
[0182] The title compound is prepared by a procedure analogous to Example 286 by substituting Compound 138 for the Compound 137 of Example 286. MS 867 (M+H)+.
Compound 288 (Formula 1y: W′ is OR9, and R9 is (2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-propenyl)
[0183] Step A:
[0184] A mixture of the Compound 7 (100 mg, 0.12 mmol), triethylamine (35 μL, 0.25 mmol), and acetic anhydride (23 μL, 0.24 mmol) in dichloromethane (1 mL) was stirred for 18 h at room temperature. The reaction mixture was diluted with dichloromethane (15 mL) washed with sat. aq. NaHCO3 (10 mL), dried (Na2SO4), and concentrated. MS 879 (M+H)+.
[0185] Step B:
[0186] Sodium hexamethyldisilazide (1.0M in THF, 180 μL, 0.18 mmol) was added dropwise to a solution of the product from step A (0.12 mmol) in DMF (1.5 mL) at −60° C. The mixture was stirred for 30 min at −60° C. and then SELECTFLUOR™ (51 mg, 0.14 mmol) was added. The resulting mixture was stirred for 10 min at −60° C. and then diluted with ethyl acetate (15 mL) and 10% aq. NH4Cl (10 mL). The organic layer was washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL), dried (Na2SO4), and concentrated. MS 897 (M+H)+.
[0187] Step C:
[0188] The material from Step B was allowed to stand in methanol for 18 h and then concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 66 mg (65%) of the title compound. MS 855(M+H)+.
Compounds 289-569
[0189] By a procedure analogous to that of Example 288, Compounds 289-569 shown in the table below of formula 1y, wherein W′ is OR9, and R9 is as described in the table, can be prepared.
3|
|
Compound
No.R9MS [(M+H)+]
|
|
289phenylmethyl751
2902-phenylethyl765
2913-phenyl-2-propynyl775
2923-phenylpropyl779
2934-phenylbutyl793
294(2E)-3-phenyl-2-propenyl777
295(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl855
296(2E)-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl855
297(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl855
298(2E)-3-[4-(2-pyridinyl)phenyl]-2-propenyl854
299(2E)-3-[4-(3-pyridinyl)phenyl]-2-propenyl854
300(2E)-3-[4-(4-pyridinyl)phenyl]-2-propenyl854
301(2E)-3-(4-pyrazinylphenyl)-2-propenyl855
302(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl855
303(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl843
304(2E)-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl844
305(2E)-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propenyl844
306(2E)-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propenyl844
307(2E)-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl843
308(2E)-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propenyl857
309(2E)-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propenyl857
310(2E)-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-873
propenyl
311(2E)-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl861
312(2E)-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl861
313(2E)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-861
propenyl
314(2E)-3-[6-(1H-pyrazol-1-yl)-3-pyridinyl]-2-propenyl844
315(2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl843
316(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl845
317(2E)-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propenyl845
318(2E)-3-(2-quinolinyl)-2-propenyl828
319(2E)-3-(3-quinolinyl)-2-propenyl828
320(2E)-3-(4-quinolinyl)-2-propenyl828
321(2E)-3-(5-quinolinyl)-2-propenyl828
322(2E)-3-(6-quinolinyl)-2-propenyl828
323(2E)-3-(7-quinolinyl)-2-propenyl828
324(2E)-3-(8-quinolinyl)-2-propenyl828
325(2E)-3-(2-quinoxalinyl)-2-propenyl829
326(2E)-3-(6-quinoxalinyl)-2-propenyl829
327(2E)-3-(4-isoquinolinyl)-2-propenyl828
328(2E)-3-(6-bromo-3-pyridinyl)-2-propenyl856, 858
329(2E)-3-[4-(2-oxazolyl)phenyl]-2-propenyl844
330(2E)-3-[4-(5-oxazolyl)phenyl]-2-propenyl844
331(2E)-3-[4-(2-thiazolyl)phenyl]-2-propenyl860
332(2E)-3-[4-(2-thienyl)phenyl]-2-propenyl859
333(2E)-3-[4-(3-isoxazolyl)phenyl]-2-propenyl844
334(2E)-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl845
335(2E)-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propenyl845
336(2E)-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl845
337(2E)-3-(1-methyl-1H-benzimidazol-2-yl)-2-propenyl831
338(2E)-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propenyl933, 835
339(2E)-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propenyl873
340(2E)-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propenyl883
341(2E)-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propenyl869
342(2E)-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propenyl885
343(2E)-3-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propenyl869
344(2E)-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propenyl885
345(2E)-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl860
346(2E)-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
347(2E)-3-(5-pyrazinyl-2-thienyl)-2-propenyl861
348(2E)-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl860
349(2E)-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl861
350(2E)-3-(4-pyrazinyl-2-thienyl)-2-propenyl861
351(2E)-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl860
352(2E)-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl861
353(2E)-3-(5-pyrazinyl-3-thienyl)-2-propenyl861
354(2E)-3-(2-phenyl-5-pyrimidinyl)-2-propenyl855
355(2E)-3-[2,2′-bithiophen]-5-yl-2-propenyl865
356(2E)-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl871
357(2E)-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propenyl873
358(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-butenyl869
359[4-(2-pyrimidinyl)phenyl]methyl829
360[4-(3-pyridazinyl)phenyl]methyl829
361(4-pyrazinylphenyl)methyl829
3623-[4-(2-pyrimidinyl)phenyl]-2-propynyl853
3633-[4-(4-pyrimidinyl)phenyl]-2-propynyl853
3643-[4-(5-pyrimidinyl)phenyl]-2-propynyl853
3653-[4-(2-pyridinyl)phenyl]-2-propynyl852
3663-[4-(3-pyridinyl)phenyl]-2-propynyl852
3673-[4-(4-pyridinyl)phenyl]-2-propynyl852
3683-(4-pyrazinylphenyl)-2-propynyl853
3693-[4-(3-pyridazinyl)phenyl]-2-propynyl853
3703-[4-(1H-pyrazol-1-yl)phenyl]-2-propynyl841
3713-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propynyl842
3723-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propynyl842
3733-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propynyl842
3743-[4-(1H-imidazol-1-yl)phenyl]-2-propynyl841
3753-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propynyl855
3763-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propynyl855
3773-(1-phenyl-1H-pyrazol-4-yl)-2-propynyl841
3783-(2-quinolinyl)-2-propynyl826
3793-(3-quinolinyl)-2-propynyl826
3803-(4-quinolinyl)-2-propynyl826
3813-(5-quinolinyl)-2-propynyl826
3823-(6-quinolinyl)-2-propynyl826
3833-(7-quinolinyl)-2-propynyl826
3843-(8-quinolinyl)-2-propynyl826
3853-(2-quinoxalinyl)-2-propynyl827
3863-(6-quinoxalinyl)-2-propynyl827
3873-(4-isoquinolinyl)-2-propynyl826
3883-[4-(2-oxazolyl)phenyl]-2-propynyl842
3893-[4-(5-oxazolyl)phenyl]-2-propynyl842
3903-[4-(2-thiazolyl)phenyl]-2-propynyl858
3913-[4-(2-thienyl)phenyl]-2-propynyl857
3923-[4-(3-isoxazolyl)phenyl]-2-propynyl842
3933-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propynyl843
3943-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propynyl843
3953-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propynyl843
3963-(1-methyl-1H-benzimidazol-2-yl)-2-propynyl829
3973-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propynyl931, 933
3983-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propynyl871
3993-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propynyl881
4003-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propynyl867
4013-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propynyl883
4023-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propynyl867
4033-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propynyl883
4043-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl843
4053-[5-(2-pyridinyl)-2-thienyl]-2-propynyl858
4063-[5-(3-pyridinyl)-2-thienyl]-2-propynyl858
4073-[5-(4-pyridinyl)-2-thienyl]-2-propynyl858
4083-[5-(2-pyrimidinyl)-2-thienyl]-2-propynyl859
4093-(5-pyrazinyl-2-thienyl)-2-propynyl859
4103-[4-(2-pyridinyl)-2-thienyl]-2-propynyl858
4113-[4-(3-pyridinyl)-2-thienyl]-2-propynyl858
4123-[4-(4-pyridinyl)-2-thienyl]-2-propynyl858
4133-[4-(2-pyrimidinyl)-2-thienyl]-2-propynyl859
4143-[5-(2-pyridinyl)-3-thienyl]-2-propynyl858
4153-[5-(3-pyridinyl)-3-thienyl]-2-propynyl858
4163-(2-phenyl-5-pyrimidinyl)-2-propynyl853
4173-[2,2′-bithiophen]-5-yl-2-propynyl863
4183-[4-(2-pyrimidinyloxy)phenyl]-2-propynyl869
4194-[4-(2-pyrimidinyl)phenyl]-3-butynyl867
4205-[4-(2-pyrimidinyl)phenyl]-4-pentynyl881
4213-[4-(2-pyrimidinyl)phenyl]propyl857
4223-(4-pyrazinylphenyl)propyl857
4233-[4-(3-pyridazinyl)phenyl]propyl857
4243-[4-(2-pyridinyl)phenyl]propyl856
4253-[4-(1H-pyrazol-1-yl)phenyl]propyl845
4263-[4-(1H-1,2,4-triazol-1-yl)phenyl]propyl846
4273-[4-(1H-1,2,3-triazol-1-yl)phenyl]propyl846
4283-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]propyl859
4293-(2-quinolinyl)propyl830
4303-(3-quinolinyl)propyl830
4313-(4-quinolinyl)propyl830
4323-(5-quinolinyl)propyl830
4333-(6-quinolinyl)propyl830
4343-(7-quinolinyl)propyl830
4353-(8-quinolinyl)propyl830
4363-(2-quinoxalinyl)propyl831
4373-(6-quinoxalinyl)propyl831
4383-[4-(2-oxazolyl)phenyl]propyl846
4393-[5-(2-pyridinyl)-2-thienyl]propyl862
4403-[5-(2-pyrimidinyl)-2-thienyl]propyl863
4413-(1H-benzimidazol-1-yl)propyl819
442(2Z)-2-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl873
443(2Z)-2-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl873
444(2Z)-2-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl873
445(2Z)-2-fluoro-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl873
446(2Z)-2-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl872
447(2Z)-2-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl872
448(2Z)-2-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl872
449(2Z)-2-fluoro-3-(4-pyrazinylphenyl)-2-propenyl873
450(2Z)-2-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl873
451(2Z)-2-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl861
452(2Z)-2-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-862
propenyl
453(2Z)-2-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-862
propenyl
454(2Z)-2-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-862
propenyl
455(2Z)-2-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl861
456(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-875
propenyl
457(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-875
propenyl
458(2Z)-2-fluoro-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-891
2-propenyl
459(2Z)-2-fluoro-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-879
propenyl
460(2Z)-2-fluoro-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-879
propenyl
461(2Z)-2-fluoro-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-880
2-propenyl
462(2Z)-2-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl861
463(2Z)-2-fluoro-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-863
propenyl
464(2Z)-2-fluoro-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-863
propenyl
465(2Z)-2-fluoro-3-(2-quinolinyl)-2-propenyl846
466(2Z)-2-fluoro-3-(3-quinolinyl)-2-propenyl846
467(2Z)-2-fluoro-3-(4-quinolinyl)-2-propenyl846
468(2Z)-2-fluoro-3-(5-quinolinyl)-2-propenyl846
469(2Z)-2-fluoro-3-(6-quinolinyl)-2-propenyl846
470(2Z)-2-fluoro-3-(7-quinolinyl)-2-propenyl846
471(2Z)-2-fluoro-3-(8-quinolinyl)-2-propenyl846
472(2Z)-2-fluoro-3-(2-quinoxalinyl)-2-propenyl847
473(2Z)-2-fluoro-3-(6-quinoxalinyl)-2-propenyl847
474(2Z)-2-fluoro-3-(4-isoquinolinyl)-2-propenyl846
475(2Z)-2-fluoro-3-(6-bromo-3-pyridinyl)-2-propenyl874, 876
476(2Z)-2-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propenyl862
477(2Z)-2-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propenyl862
478(2Z)-2-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl878
479(2Z)-2-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl877
480(2Z)-2-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl862
481(2Z)-2-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-863
propenyl
482(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-863
propenyl
483(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-863
propenyl
484(2Z)-2-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-849
propenyl
485(2Z)-2-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-891
propenyl
486(2Z)-2-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-887
propenyl
487(2Z)-2-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-903
propenyl
488(2Z)-2-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-887
propenyl
489(2Z)-2-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl878
490(2Z)-2-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl878
491(2Z)-2-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl878
492(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl879
493(2Z)-2-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propenyl879
494(2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl878
495(2Z)-2-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl878
496(2Z)-2-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl878
497(2Z)-2-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl879
498(2Z)-2-fluoro-3-(4-pyrazinyl-2-thienyl)-2-propenyl879
499(2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl878
500(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl879
501(2Z)-2-fluoro-3-(5-pyrazinyl-3-thienyl)-2-propenyl879
502(2Z)-2-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propenyl873
503(2Z)-2-fluoro-3-[2,2′-bithiophen]-5-yl-2-propenyl883
504(2Z)-2-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl889
505(2Z)-2-fluoro-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-891
propenyl
506(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl873
507(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl873
508(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl873
509(2Z)-3-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl872
510(2Z)-3-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl872
511(2Z)-3-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl872
512(2Z)-3-fluoro-3-(4-pyrazinylphenyl)-2-propenyl873
513(2Z)-3-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl873
514(2Z)-3-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl861
515(2Z)-3-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-862
propenyl
516(2Z)-3-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-862
propenyl
517(2Z)-3-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-862
propenyl
518(2Z)-3-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl861
519(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-875
propenyl
520(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-875
propenyl
521(2Z)-3-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl861
522(2Z)-3-fluoro-3-(2-quinolinyl)-2-propenyl846
523(2Z)-3-fluoro-3-(3-quinolinyl)-2-propenyl846
524(2Z)-3-fluoro-3-(4-quinolinyl)-2-propenyl846
525(2Z)-3-fluoro-3-(5-quinolinyl)-2-propenyl846
526(2Z)-3-fluoro-3-(6-quinolinyl)-2-propenyl846
527(2Z)-3-fluoro-3-(7-quinolinyl)-2-propenyl846
528(2Z)-3-fluoro-3-(8-quinolinyl)-2-propenyl846
529(2Z)-3-fluoro-3-(2-quinoxalinyl)-2-propenyl847
530(2Z)-3-fluoro-3-(6-quinoxalinyl)-2-propenyl847
531(2Z)-3-fluoro-3-(4-isoquinolinyl)-2-propenyl846
532(2Z)-3-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propenyl862
533(2Z)-3-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propenyl862
534(2Z)-3-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl878
535(2Z)-3-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl877
536(2Z)-3-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl862
537(2Z)-3-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-863
propenyl
538(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-863
propenyl
539(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-863
propenyl
540(2Z)-3-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-849
propenyl
541(2Z)-3-fluoro-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-951, 953
propenyl
542(2Z)-3-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-891
propenyl
543(2Z)-3-fluoro-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-901
propenyl
544(2Z)-3-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-887
propenyl
545(2Z)-3-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-903
propenyl
546(2Z)-3-fluoro-3-[4-(6-methyl-3-pyridazinyl)phenyl]-2-887
propenyl
547(2Z)-3-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-903
propenyl
548(2Z)-3-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl878
549(2Z)-3-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl878
550(2Z)-3-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl878
551(2Z)-3-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl879
552(2Z)-3-fluoro-3-[5-(4-pyrimidinyl)-2-thienyl]-2-propenyl879
553(2Z)-3-fluoro-3-[5-(5-pyrimidinyl)-2-thienyl]-2-propenyl879
554(2Z)-3-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propenyl879
555(2Z)-3-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl878
556(2Z)-3-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl878
557(2Z)-3-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl878
558(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl879
559(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)-2-thienyl]-2-propenyl879
560(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)-2-thienyl]-2-propenyl879
561(2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl878
562(2Z)-2-fluoro-3-[5-(3-pyridinyl)-3-thienyl]-2-propenyl878
563(2Z)-3-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propenyl873
564(2Z)-3-fluoro-3-[2,2′-bithiophen]-5-yl-2-propenyl883
565(2Z)-3-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propenyl889
5664-[4-(2-pyrimidinyl)phenyl]butyl871
5675-[4-(2-pyrimidinyl)phenyl]pentyl885
568(2Z)-2-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl863
569(2Z)-3-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl863
|
Compound 570 (Formula 1c: R10 is H, R11 is phenylmethyl)
[0190] A mixture of O-benzylhydroxylamine (22 mg, 0.18 mmol) and Compoujd 4 (25 mg, 0.070 mmol) in DMSO (0.25 mL) was heated to 60° C. for 18 h. The solution was diluted with ethyl acetate (15 mL), washed with water (2×10 mL) and brine (10 ml), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 8.3 mg (32%) of the title compound. MS 748 (M+H)+.
Compounds 571-619
[0191] Following the procedure of Example 570, except substituting the reagent of formula R11ONH2 for the O-benzylhydroxylamine of Example 570, the compounds 571-619 shown in the table below of formula 1c wherein R10 is H and R11 is as described in the table, can be prepared.
4|
|
CompoundMS
No.R11[(M+H)+]
|
5712-[4-(2-pyrimidinyl)phenyl]ethyl840
5722-[4-(4-pyrimidinyl)phenyl]ethyl840
5732-[4-(5-pyrimidinyl)phenyl]ethyl840
5742-[3-(2-pyrimidinyl)phenyl]ethyl840
5752-[4-(2-pyridinyl)phenyl]ethyl839
5762-[4-(3-pyridinyl)phenyl]ethyl839
5772-[4-(4-pyridinyl)phenyl]ethyl839
5782-(4-pyrazinylphenyl)ethyl840
5792-[4-(3-pyridazinyl)phenyl]ethyl840
5802-[4-(1H-pyrazol-1-yl)phenyl]ethyl828
5812-[4-(1H-1,2,4-triazol-1-yl)phenyl]ethyl829
5822-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl829
5832-[4-(1H-imidazol-1-yl)phenyl]ethyl828
5842-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]ethyl842
5852-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]ethyl842
5862-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]ethyl846
5872-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]ethyl846
5882-(1-phenyl-1H-pyrazol-4-yl)ethyl828
5892-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]ethyl830
5902-(2-quinolinyl)ethyl813
5912-(3-quinolinyl)ethyl813
5922-(4-quinolinyl)ethyl813
5932-(5-quinolinyl)ethyl813
5942-(6-quinolinyl)ethyl813
5952-(7-quinolinyl)ethyl813
5962-(8-quinolinyl)ethyl813
5972-(2-quinoxalinyl)ethyl814
5982-(6-quinoxalinyl)ethyl814
599[4-(2-pyrimidinyl)phenyl]methyl826
600[4-(3-pyridazinyl)phenyl]methyl826
601(4-pyrazinylphenyl)methyl826
6023-[4-(2-pyrimidinyl)phenyl]-2-propynyl850
6033-(4-pyrazinylphenyl)-2-propynyl850
6043-[4-(3-pyridazinyl)phenyl]-2-propynyl850
605(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl852
606(2E)-3-(4-pyrazinylphenyl)-2-propenyl852
607(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl852
6083-[4-(2-pyrimidinyl)phenyl]propyl854
6093-(4-pyrazinylphenyl)propyl854
6103-[4-(3-pyridazinyl)phenyl]propyl854
6112-phenylethyl762
6123-phenylpropyl776
613(2E)-3-phenyl-2-propenyl774
6143-phenyl-2-propynyl772
615(2E)-3-(3-pyridinyl)-2-propenyl775
616(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl852
617(2E)-3-[4-(2-pyridinyl)phenyl]-2-propenyl851
6183-(3-quinolinyl)-2-propynyl823
619(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl840
|
Compound 620 (Formula 1o′: Ar is 3-quinolinyl
[0192] Step A
[0193] Following the procedure of Example 570, except substituting the reagent of O-allylhydroxylamine hydrochloride for the O-benzylhydroxylamine of Example 570, the compound of formula 1c wherein R10 is H and R11 is 2-propenyl can be prepared.
[0194] Step B
[0195] The compound from step A (90 mg, 0.13 mmol), tri-o-tolylphosphine (4 mg, 0.013 mmol) and triethylamine (53 mg, 0.52 mmol) in 3 mL DMF was degassed with nitrogen for 5 minutes. Palladium acetate (2 mg, 0.0065 mmol) and 3-bromoquinoline (81 mg, 0.39 mmol) were added. The reaction mixture was heated at 100° C. for 24 hrs. Water (10 mL) was added and the mixture was extracted with ethyl acetate (3×15 mL). The organic layer was collected, dried and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 18 mg (17%) of the title compound. MS 825 (M+H)+.
Compound 621 (Formula 1c: R10 is CH3, R11 is 2-[4-(2-pyrimidinyl)phenyl]ethyl)
[0196] Compound 571 (100 mg, 0.12 mmol) and parafomaldehyde (36 mg, 1.2 mmol) were dissolved in 1 mL acetonitrile. To this reaction mixture was added TFA (120 μL, 1.2 mmol) followed by triethylsilane (240 μL, 1.2 mmol). The reaction mixture was heated at 60° C. for 24 h. Saturated NaHCO3 was added and the mixture was extracted with ethyl acetate. The organic layer was dried and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 6 mg (6%) of the title compound. MS 855 (M+H)+.
Compound 622 (Formula 1y: W′ is NR10OR11, R10 is H, and R11 is (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propenyl
[0197] Step A
[0198] Compound 605 (30 mg, 0.034 mmol) was converted to its 2′-acetate derivative by a procedure analogous to Example 1, step D.
[0199] Step B
[0200] Sodium hexamethyldisilazide (1.0 M in THF, 51 μL, 0.051 mmol) was added dropwise to a solution of the product from Step A (0.034 mmol) in DMF (1 mL) at −60° C. The mixture was stirred for 20 min at this temperature and then SELECTFLUOR™ (15 mg, 0.041 mmol) was added. The resulting mixture was stirred for one hour at −60° C., diluted with ethyl acetate, washed with water and brine, dried and concentrated. This material was allowed to stand in methanol for 24 h and then concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 18 mg (62%) of the title compound. MS 870 (M+H)+.
Compound 623 (Formula 1y: W′ is NR10OR11, R10 is H, and R11 is 3-(3-quinolinyl)-2-propynyl
[0201] The title compound was prepared by procedures analogous to Example 622 by substituting the compound of Example 618 for the compound of Example 605. MS 841 (M+H)+.
Compound 624 (Formula 1b: R12 is H, R13 is phenyl, R14 is H)
[0202] Phenylhydrazine (70 μL, 0.71 mmol) was added to a solution of Compound 4 (50 mg, 0.070 mmol) in DMSO (0.5 mL) and the resulting solution was stirred for 5 days. The solution was diluted with ethyl acetate (10 mL), washed with water and brine (5 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 15 mg (29%) of the title compound. MS 733 (M+H)+.
Compound 625 (Formula 1b: R12 is H, R13 is phenylmethyl, R14 is H)
[0203] A mixture of Compound 5 (50 mg, 0.076 mmol), benzaldehyde (9 μL, 0.089 mmol), and acetic acid (18 μL, 0.31 mmol) in methanol (0.5 mL) was stirred at rt for 1 h. Sodium cyanoborohydride (19 mg, 0.30 mmol) was added, followed by a small amount of bromocresol green, and then acetic acid dropwise until the color of the solution remained yellow. After 18 h at rt, the solution was diluted with ethyl acetate (15 mL), washed with 1 N NaOH, water, and brine (10 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 40 mg (70%) of the title compound. MS 747 (M+H)+.
Compound 626 (Formula 1b: R12 is H, R13 is 2-[4-(2-pyrimidinyl)phenyl]ethyl, R14 is H)
[0204] A mixture of Compound 5 (200 mg, 0.30 mmol), 4-(2-pyrimidinyl)benzeneacetaldehyde (72 mg, 0.36 mmol, prepared as described in Reference Example 64), and acetic acid (75 μL, 1.31 mmol) in methanol (2 mL) was stirred at rt for 1 h. Sodium cyanoborohydride (80 mg, 1.27 mmol) was added, followed by a small amount of bromocresol green, and then acetic acid dropwise until the color of the solution remained yellow. After 18 h at rt, the solution was diluted with ethyl acetate (30 mL), washed with 1 N NaOH and brine (15 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 186 mg (72%) of the title compound. MS 839 (M+H)+.
Compounds 627-743
[0205] Following the procedure of Example 625, except substituting the reagent below for the benzaldehyde of Example 625, the compounds 627-743 shown in the table below of formula 1b wherein R12 is H, R14 is H, and R13 is as described in the table, can be prepared.
5|
|
Compound
No.ReagentR13MS [(M+H)+]
|
|
6274-(4-2-[4-(4-pyrimidinyl)phenyl]ethyl839
pyrimidinyl)benzeneacetaldehyde
6284-(5-2-[4-(5-pyrimidinyl)phenyl]ethyl839
pyrimidinyl)benzeneacetaldehyde
6293-(2-2-[3-(2-pyrimidinyl)phenyl]ethyl839
pyrimidinyl)benzeneacetaldehyde
6304-(2-pyridinyl)benzeneacetaldehyde2-[4-(2-pyridinyl)phenyl]ethyl838
6314-(3-pyridinyl)benzeneacetaldehyde2-[4-(3-pyridinyl)phenyl]ethyl838
6324-(4-pyridinyl)benzeneacetaldehyde2-[4-(4-pyridinyl)phenyl]ethyl838
6334-pyrazinylbenzeneacetaldehyde2-(4-pyrazinylphenyl)ethyl839
6344-(3-2-[4-(3-pyridazinyl)phenyl]ethyl839
pyridazinyl)benzeneacetaldehyde
6354-(1H-pyrazol-1-2-[4-(1H-pyrazol-1-yl)phenyl]ethyl827
yl)benzeneacetaldehyde
6364-(1H-1,2,4-triazol-1-yl)2-[4-(1H-1,2,4-triazol-1-yl)phenyl]ethyl828
benzeneacetaldehyde
6374-(1H-1,2,3-triazol-1-yl)2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl828
benzeneacetaldehyde
6384-(1H-imidazol-1-yl)2-[4-(1H-imidazol-1-yl)phenyl]ethyl827
benzeneacetaldehyde
6394-(1-methyl-1H-pyrazol-3-2-[4-(1-methyl-1H-pyrazol-3-841
yl)benzeneacetaldehydeyl)phenyl]ethyl
6404-(1-methyl-1H-pyrazol-5-2-[4-(1-methyl-1H-pyrazol-5-841
yl)benzeneacetaldehydeyl)phenyl]ethyl
6413-fluoro-4-(1H-pyrazol-1-2-[3-fluoro-4-(1H-pyrazol-1-845
yl)benzeneacetaldehydeyl)phenyl]ethyl
6422-fluoro-4-(1H-pyrazol-1-2-[2-fluoro-4-(1H-pyrazol-1-845
yl)benzeneacetaldehydeyl)phenyl]ethyl
6432-(1-phenyl-1H-pyrazol-4-2-(1-phenyl-1H-pyrazol-4-yl)ethyl827
yl)acetaldehyde
6442-[1-(2-pyrimidinyl)-1H-imidazol-4-2-[1-(2-pyrimidinyl)-1H-imidazol-4-829
yl]acetaldehydeyl]ethyl
6452-(2-quinolinyl)acetaldehyde2-(2-quinolinyl)ethyl812
6462-(3-quinolinyl)acetaldehyde2-(3-quinolinyl)ethyl812
6472-(4-quinolinyl)acetaldehyde2-(4-quinolinyl)ethyl812
6482-(5-quinolinyl)acetaldehyde2-(5-quinolinyl)ethyl812
6492-(6-quinolinyl)acetaldehyde2-(6-quinolinyl)ethyl812
6502-(7-quinolinyl)acetaldehyde2-(7-quinolinyl)ethyl812
6512-(8-quinolinyl)acetaldehyde2-(8-quinolinyl)ethyl812
6522-(2-quinoxalinyl)acetaldehyde2-(2-quinoxalinyl)ethyl813
6532-(6-quinoxalinyl)acetaldehyde2-(6-quinoxalinyl)ethyl813
6543-[4-(2-pyrimidinyl)phenyl]-2-3-[4-(2-pyrimidinyl)phenyl]-2-propynyl849
propynal
6553-[4-(3-pyridazinyl)phenyl]-2-3-[4-(3-pyridazinyl)phenyl]-2-propynyl849
propynal
6563-(4-pyrazinylphenyl)-2-propynal3-(4-pyrazinylphenyl)-2-propynyl849
6574-(2-pyrimidinyl)benzenepropanal3-[4-(2-pyrimidinyl)phenyl]propyl853
6584-(3-pyridazinyl)benzenepropanal3-[4-(3-pyridazinyl)phenyl]propyl853
6594-pyrazinylbenzenepropanal3-(4-pyrazinylphenyl)propyl853
6604-phenylbutanal4-phenylbutyl789
6616-quinolinecarboxaldehyde6-quinolinylmethyl798
6623-(1H-pyrazol-1-yl)benzaldehyde[3-(1H-pyrazol-1-yl)phenyl]methyl813
6634-(4-methyl-1H-pyrazol-1-[4-(4-methyl-1H-pyrazol-1-827
yl)benzaldehydeyl)phenyl]methyl
6643-methoxy-4-(1H-pyrazol-1-[3-methoxy-4-(1H-pyrazol-1-843
yl)benzaldehydeyl)phenyl]methyl
6653-fluoro-4-(1H-pyrazol-1-[3-fluoro-4-(1H-pyrazol-1-831
yl)benzaldehydeyl)phenyl]methyl
6663-fluoro-4-(1H-1,2,4-triazol-1-[3-fluoro-4-(1H-1,2,4-triazol-1-832
yl)benzaldehydeyl)phenyl]methyl
6672-fluoro-4-(1H-pyrazol-1-[2-fluoro-4-(1H-pyrazol-1-831
yl)benzaldehydeyl)phenyl]methyl
6684-(2-pyrimidinyloxy)benzaldehyde[4-(2-pyrimidinyloxy)phenyl]methyl841
6691-(2-pyrimidinyl)-1H-imidazole-4-[1-(2-pyrimidinyl)-1H-imidazol-4-815
carboxaldehydeyl]methyl
6703-(2-pyridinyl)benzaldehyde[3-(2-pyridinyl)phenyl]methyl824
6713-(2-pyrimidinyl)benzaldehyde[3-(2-pyrimidinyl)phenyl]methyl825
6724-(4-methoxy-2-[4-(4-methoxy-2-855
pyrimidinyl)benzaldehydepyrimidinyl)phenyl]methyl
6734-(4-methyl-2-[4-(4-methyl-2-839
pyrimidinyl)benzaldehydepyrimidinyl)phenyl]methyl
6742-fluoro-4-(2-[2-fluoro-4-(2-843
pyrimidinyl)benzaldehydepyrimidinyl)phenyl]methyl
6754-(3-pyridazinyl)benzaldehyde[4-(3-pyridazinyl)phenyl]methyl825
6764-(2-pyrimidinyl)benzaldehyde[4-(2-pyrimidinyl)phenyl]methyl825
6774-pyrazinylbenzaldehyde[4-pyrazinylphenyl]methyl825
6784-(4-pyrimidinyl)benzaldehyde[4-(4-pyrimidinyl)phenyl]methyl825
6794-(5-nitro-2-pyridinyl)benzaldehyde[4-(5-nitro-2-pyridinyl)phenyl]methyl869
6803-[4-(1H-pyrazol-1-yl)phenyl]-2-3-[4-(1H-pyrazol-1-yl)phenyl]-2-837
propynalpropynyl
6813-(3-quinolinyl)-2-propynal3-(3-quinolinyl)-2-propynyl847
682(2E)-3-[6-(1H-pyrazol-1-yl)-3-(2E)-3-[6-(1H-pyrazol-1-yl)-3-pyridinyl]-840
pyridinyl]-2-propenal2-propenyl
683(2E)-3-(6-bromo-3-pyridinyl)-2-(2E)-3-(6-bromo-3-pyridinyl)-2-852, 854
propenalpropenyl
684(2E)-3-[4-(3-pyridinyl)phenyl]-2-(2E)-3-[4-(3-pyridinyl)phenyl]-2-850
propenalpropenyl
685(2E)-3-[2-fluoro-4-(1H-pyrazol-1-(2E)-3-[2-fluoro-4-(1H-pyrazol-1-857
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
686(2E)-3-[3-methoxy-4-(1H-pyrazol-1-(2E)-3-[3-methoxy-4-(1H-pyrazol-1-869
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
687(2E)-3-(6-quinoxalinyl)-2-propenal(2E)-3-(6-quinoxalinyl)-2-propenyl825
688(2E)-3-(6-quinolinyl)-2-propenal(2E)-3-(6-quinolinyl)-2-propenyl824
689(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-839
propenalpropenyl
690(2E)-3-[6-(1H-1,2,4-triazol-1-yl)-2-(2E)-3-[6-(1H-1,2,4-triazol-1-yl)-2-841
pyridinyl]-2-propenalpyridinyl]-2-propenyl
691(2E,4E)-5-[6-(1H-1,2,4-triazol-1-yl)-(2E,4E)-5-[6-(1H-1,2,4-triazol-1-yl)-2-867
2-pyridinyl]-2,4-pentadienalpyridinyl]-2,4-pentadienyl
692(2E)-3-[4-(2-pyridinyl)phenyl]-2-(2E)-3-[4-(2-pyridinyl)phenyl]-2-850
propenalpropenyl
693(2E)-3-[4-(4-pyridinyl)phenyl]-2-(2E)-3-[4-(4-pyridinyl)phenyl]-2-850
propenalpropenyl
694(2E)-3-[4-(5-pyrimidinyl)phenyl]-2-(2E)-3-[4-(5-pyrimidinyl)phenyl]-2-851
propenalpropenyl
695(2E)-3-[4-(1H-1,2,4-triazol-1-(2E)-3-[4-(1H-1,2,4-triazol-1-840
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
696(2E)-3-[4-(1H-1,2,3-triazol-1-(2E)-3-[4-(1H-1,2,3-triazol-1-840
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
697(2E)-3-[4-(1H-imidazol-1-yl)phenyl]-(2E)-3-[4-(1H-imidazol-1-yl)phenyl]-2-839
2-propenalpropenyl
698(2E)-3-(4-quinolinyl)-2-propenal(2E)-3-(4-quinolinyl)-2-propenyl824
699(2E)-3-[3-(2-pyridinyl)phenyl]-2-(2E)-3-[3-(2-pyridinyl)phenyl]-2-850
propenalpropenyl
700(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-851
propenalpropenyl
701(2E)-3-[4-(4-methyl-2-(2E)-3-[4-(4-methyl-2-865
pyrimidinyl)phenyl]-2-propenalpyrimidinyl)phenyl]-2-propenyl
702(2E)-3-[3-(1H-pyrazol-1-yl)phenyl]-2-(2E)-3-[3-(1H-pyrazol-1-yl)phenyl]-2-839
propenalpropenyl
703(2E)-3-[4-(1-methyl-1H-pyrazol-3-(2E)-3-[4-(1-methyl-1H-pyrazol-3-853
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
704(2E)-3-[4-(1-methyl-1H-pyrazol-5-(2E)-3-[4-(1-methyl-1H-pyrazol-5-853
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
705(2E)-3-[4-(5-nitro-2-pyridinyl)phenyl]-(2E)-3-[4-(5-nitro-2-pyridinyl)phenyl]-2-895
2-propenalpropenyl
706(2E)-3-(8-quinolinyl)-2-propenal(2E)-3-(8-quinolinyl)-2-propenyl824
707(2E)-3-(7-quinolinyl)-2-propenal(2E)-3-(7-quinolinyl)-2-propenyl824
708(2E)-3-[6-(1H-pyrazol-1-yl)-2-(2E)-3-[6-(1H-pyrazol-1-yl)-2-pyridinyl]-840
pyridinyl]-2-propenal2-propenyl
709(2E)-3-(4-isoquinolinyl)-2-propenal(2E)-3-(4-isoquinolinyl)-2-propenyl824
710(2E)-3-[3-fluoro-4-(1H-pyrazol-1-(2E)-3-[3-fluoro-4-(1H-pyrazol-1-857
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
711(2E)-3-[3-fluoro-4-(1H-1,2,4-triazol-(2E)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-858
1-yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
712(2E)-3-[5-(2-pyridinyl)-2-thienyl]-2-(2E)-3-[5-(2-pyridinyl)-2-thienyl]-2-856
propenalpropenyl
713(2E,4E)-5-[4-(1H-pyrazol-1-(2E,4E)-5-[4-(1H-pyrazol-1-yl)phenyl]-865
yl)phenyl]-2,4-pentadienal2,4-pentadienyl
714(2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-(2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-839
propenalpropenyl
715(2E)-3-[4-(4-methyl-1H-pyrazol-1-(2E)-3-[4-(4-methyl-1H-pyrazol-1-853
yl)phenyl]-2-propenalyl)phenyl]-2-propenyl
716(2E)-3-[4-(4-methoxy-2-(2E)-3-[4-(4-methoxy-2-881
pyrimidinyl)phenyl]-2-propenalpyrimidinyl)phenyl]-2-propenyl
717(2E)-3-(4-pyrazinylphenyl)-2-(2E)-3-(4-pyrazinylphenyl)-2-propenyl851
propenal
718(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-851
propenalpropenyl
719(2E)-3-[4-(2-pyrimidinyloxy)phenyl]-(2E)-3-[4-(2-pyrimidinyloxy)phenyl]-2-865
2-propenalpropenyl
720(2E)-3-[2-fluoro-4-(2-(2E)-3-[2-fluoro-4-(2-869
pyrimidinyl)phenyl]-2-propenalpyrimidinyl)phenyl]-2-propenyl
721(2E)-3-[4-(3-pyridazinyl)phenyl]-2-(2E)-3-[4-(3-pyridazinyl)phenyl]-2-851
propenalpropenyl
722(2E)-3-[1-(2-pyrimidinyl)-1H-(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-841
imidazol-4-yl]-2-propenal4-yl]-2-propenyl
723[[4-(2-[[4-(2-pyrimidinyl)phenyl]methoxy]ethyl869
pyrimidinyl)phenyl]methoxy]acetalde
hyde
724(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-851
propenalpropenyl
7254-(1H-pyrazol-1-yl)benzaldehyde[4-(1H-pyrazol-1-yl)phenyl]methyl813
7264-(2-pyridinyl)benzaldehyde[4-(2-pyridinyl)phenyl]methyl824
7274-(1H-1.2,4-triazol-1-[4-(1H-1,2,4-triazol-1-yl)phenyl]methyl814
yl)benzaldehyde
7283-[4-(2-pyridinyl)phenyl]-2-propynal3-[4-(2-pyridinyl)phenyl]-2-propynyl848
7292-fluoro-4-(2-2-[2-fluoro-4-(2-857
pyrimidinyl)benzeneacetaldehydepyrimidinyl)phenyl]ethyl
7304-(2-thiazolyl)benzeneacetaldehyde2-[4-(2-thiazolyl)phenyl]ethyl844
7314-(2-oxazolyl)benzeneacetaldehyde2-[4-(2-oxazolyl)phenyl]ethyl828
7324-(4-2-[4-(4-morpholinyl)phenyl]ethyl846
morpholinyl)benzeneacetaldehyde
7332-Phenyl-5-pyrimidineacetaldehyde2-(2-phenyl-5-pyrimidinyl)ethyl839
7344-methyl-2-phenyl-5-2-(4-methyl-2-phenyl-5-853
pyrimidineacetaldehydepyrimidinyl)ethyl-
7354-(5-ethyl-2-pyrimidinyl)-2-[4-(5-ethyl-2-pyrimidinyl)phenyl]ethyl867
benzeneacetaldehyde
7365-methyl-3-phenyl-4-2-(5-methyl-3-phenyl-4-isoxazolyi)ethyl842
isoxazoleacetaldehyde
7374-(5-fluoro-2-pyrimidinyl)-2-[4-(5-fluoro-2-857
benzeneacetaldehydepyrimidinyl)phenyl]ethyl
7385-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-thienyl]methyl831
thiophenecarboxaldehyde
7395-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-thienyl]ethyl845
thiopheneacetaldehyde
7405-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-furanyl]methyl815
furancarboxaldehyde
7415-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-furanyl]ethyl829
furanacetaldehyde
7421-(2-pyrimidinyl)-1H-imidazole-4-2-[1-(2-pyrimidinyl)-1H-imidazol-4-815
carboxaldehydeyl]methyl
7431-(2-pyrimidinyl)-1H-imidazole-4-2-[1-(2-pyrimidinyl)-1H-imidazol-4-829
acetaldehydeyl]ethyl
|
Compound 744 (Formula 1b: R12 is H, R13 is (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl, R14 is CH3)
[0206] A mixture of Compound 5 (50 mg, 0.076 mmol), (2E)-3-[4-(2-pyrimidinyl)phenyl)phenyl]-2-propenal (17 mg, 0.081 mmol, prepared as described in Reference Example 29), and acetic acid (18 μL, 0.31 mmol) in methanol (0.5 mL) was stirred at rt for 1 h. Sodium cyanoborohydride (20 mg, 0.32 mmol) was added, followed by a small amount of bromocresol green, and then acetic acid dropwise until the color of the solution remained yellow. After 18 h at rt, formaldehyde (37 wt. % solution, 12 μL, 0.16 mmol) and sodium cyanoborohydride (10 mg, 0.16 mmol) were added, followed by a small amount of bromocresol green, and then acetic acid dropwise until the color of the solution remained yellow. After 2 h, the solution was diluted with ethyl acetate (15 mL), washed with 1N NaOH, water, and brine (10 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 25 mg of material that was further purified by HPLC (C18 column, 10-90% CH3CN/H2O+0.1% TFA). The lyophilized fractions were taken up in dichloromethane, washed with sat. aq. NaHCO3, dried (Na2SO4), and concentrated to provide 8.3 mg (13%) of the title compound. MS 865 (M+H)+.
Compounds 745-802
[0207] Following the procedure of Example 744, except substituting the reagent below for the (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal of Example 744, the compounds 745-802 shown in the table below of formula 1b wherein R12, is H, R14 is CH3, and R13 is as described in the table, can be prepared.
6|
|
Compound
No.ReagentR13MS [(M + H)+]
|
7454-(4-2-[4-(4-pyrimidinyl)phenyl]ethyl853
pyrimidinyl)benzeneacetaldehyde
7464-(5-2-[4-(5-pyrimidinyl)phenyl]ethyl853
pyrimidinyl)benzeneacetaldehyde
7473-(2-2-[3-(2-pyrimidinyl)phenyl]ethyl853
pyrimidinyl)benzeneacetaldehyde
7484-(2-2-[4-(2-pyridinyl)phenyl]ethyl852
pyridinyl)benzeneacetaldehyde
7494-(3-2-[4-(3-pyridinyl)phenyl]ethyl852
pyridinyl)benzeneacetaldehyde
7504-(4-2-[4-(4-pyridinyl)phenyl]ethyl852
pyridinyl)benzeneacetaldehyde
7514-pyrazinylbenzeneacetaldehyde2-(4-pyrazinylphenyl)ethyl853
7524-(3-2-[4-(3-pyridazinyl)phenyl]ethyl853
pyridazinyl)benzeneacetaldehyde
7534-(1H-pyrazol-1-2-[4-(1H-pyrazol-1-yl)phenyl]ethyl841
yl)benzeneacetaldehyde
7544-(1H-1,2,4-triazol-1-yl)2-[4-(1H-1,2,4-triazol-1-,842
benzeneacetaldehydeyl)phenyl]ethyl
7554-(1H-1,2,3-triazol-1-yl)2-[4-(1H-1,2,3-triazol-1-842
benzeneacetaldehydeyl)phenyl]ethyl
7564-(1H-imidazol-1-yl)2-[4-(1H-imidazol-1-841
benzeneacetaldehydeyl)phenyl]ethyl
7574-(1-methyl-1H-pyrazol-3-2-[4-(1-methyl-1H-pyrazol-3-855
yl)benzeneacetaldehydeyl)phenyl]ethyl
7584-(1-methyl-1H-pyrazol-5-2-[4-(1-methyl-1H-pyrazol-5-855
yl)benzeneacetaldehydeyl)phenyl]ethyl
7593-fluoro-4-(1H-pyrazol-1-2-[3-fluoro-4-(1H-pyrazol-1-859
yl)benzeneacetaldehydeyl)phenyl]ethyl
7602-fluoro-4-(1H-pyrazol-1-2-[2-fluoro-4-(1H-pyrazol-1-859
yl)benzeneacetaldehydeyl)phenyl]ethyl
7612-(1-phenyl-1H-pyrazol-4-2-(1-phenyl-1H-pyrazol-4-yl)ethyl841
yl)acetaldehyde
7622-[1-(2-pyrimidinyl)-1H-imidazol-4-2-[1-(2-pyrimidinyl)-1H-imidazol-843
yl]acetaldehyde4-yl]ethyl
7632-(2-quinolinyl)acetaldehyde2-(2-quinolinyl)ethyl826
7642-(3-quinolinyl)acetaldehyde2-(3-quinolinyl)ethyl826
7652-(4-quinolinyl)acetaldehyde2-(4-quinolinyl)ethyl826
7662-(5-quinolinyl)acetaldehyde2-(5-quinolinyl)ethyl826
7672-(6-quinolinyl)acetaldehyde2-(6-quinolinyl)ethyl826
7682-(7-quinolinyl)acetaldehyde2-(7-quinolinyl)ethyl826
7692-(8-quinolinyl)acetaldehyde2-(8-quinolinyl)ethyl826
7702-(2-quinoxalinyl)acetaldehyde2-(2-quinoxalinyl)ethyl827
7712-(6-quinoxalinyl)acetaldehyde2-(6-quinoxalinyl)ethyl827
772(2E)-3-(4-pyrazinylphenyl)-2-(2E)-3-(4-pyrazinylphenyl)-2-865
propenalpropenyl
773(2E)-3-[4-(3-pyridazinyl)phenyl]-2-(2E)-3-[4-(3-pyridazinyl)phenyl]-865
propenal2-propenyl
7744-(2-pyrimidinyl)benzaldehyde[4-(2-pyrimidinyl)phenyl]methyl839
7754-(3-pyridazinyl)benzaldehyde[4-(3-pyridazinyl)phenyl]methyl839
7764-pyrazinylbenzaldehyde(4-pyrazinylphenyl)methyl839
7773-[4-(2-pyrimidinyl)phenyl]-2-3-[4-(2-pyrimidinyl)phenyl]-2-863
propynalpropynyl
7783-[4-(3-pyridazinyl)phenyl]-2-3-[4-(3-pyridazinyl)phenyl]-2-863
propynalpropynyl
7793-(4-pyrazinylphenyl)-2-propynal3-(4-pyrazinylphenyl)-2-propynyl863
7804-(2-pyrimidinyl)benzenepropanal•3-[4-(2-pyrimidinyl)phenyl]propyl867
7814-(3-pyridazinyl)benzenepropanal3-[4-(3-pyridazinyl)phenyl]propyl867
7824-pyrazinylbenzenepropanal3-(4-pyrazinylphenyl)propyl867
7834-(1H-1,2,4-triazol-1-[4-(1H-1,2,4-triazol-1-828
yl)benzaldehydeyl)phenyl]methyl
7844-(1-methyl-1H-pyrazol-3-[4-(1-methyl-1H-pyrazol-3-827
yl)benzaldehydeyl)phenyl]methyl
7854-(1H-pyrazol-1-yl)benzaldehyde[4-(1H-pyrazol-1-yl)phenyl]methyl827
7864-(2-pyridinyl)benzaldehyde[4-(2-pyridinyl)phenyl]methyl838
7873-[4-(2-pyridinyl)phenyl]-2-3-[4-(2-pyridinyl)phenyl]-2-862
propynalpropynyl
7882-fluoro-4-(2-2-[2-fluoro-4-(2-871
pyrimidinyl)benzeneacetaldehydepyrimidinyl)phenyl]ethyl
7894-(2-2-[4-(2-thiazolyl)phenyl]ethyl858
thiazolyl)benzeneacetaldehyde
7904-(2-oxazolyl)benzeneacetaldehyde2-[4-(2-oxazolyl)phenyl]ethyl842
7914-(4-2-[4-(4-morpholinyl)phenyl]ethyl860
morpholinyl)benzeneacetaldehyde
7922-Phenyl-5-2-(2-phenyl-5-pyrimidinyl)ethyl853
pyrimidineacetaldehyde
7934-methyl-2-phenyl-5-2-(4-methyl-2-phenyl-5-867
pyrimidineacetaldehydepyrimidinyl)ethyl
7944-(5-ethyl-2-pyrimidinyl)-2-[4-(5-ethyl-2-881
benzeneacetaldehydepyrimidinyl)phenyl]ethyl
7955-methyl-3-phenyl-4-2-(5-methyl-3-phenyl-4-856
isoxazoleacetaldehydeisoxazolyl)ethyl
7964-(5-fluoro-2-pyrimidinyl)-2-[4-(5-fluoro-2-871
benzeneacetaldehydepyrimidinyl)phenyl]ethyl
7975-(2-pyrimidinyl)-2-[5-(2-pyrmidinyl)-2-thienyl]methyl845
thiophenecarboxaldehyde
7985-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-thienyl]ethyl859
thiopheneacetaldehyde
7995-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-829
furancarboxaldehydefuranyl]methyl
8005-(2-pyrimidinyl)-2-[5-(2-pyrimidinyl)-2-furanyl]ethyl843
furanacetaldehyde
8011-(2-pyrimidinyl)-1H-imidazole-4-2-[1-(2-pyrimidinyl)-1H-imidazol-829
carboxaldehyde4-yl]methyl
8021-(2-pyrimidinyl)-1H-imidazole-4-2-[1-(2-pyrimidinyl)-1H-imidazol-843
acetaldehyde4-yl]ethyl
|
Compound 803 (Formula 1b: R12 is H, R13 is 2-[4-(2-pyrimidinyl)phenyl]ethyl, R14 is CH3)
[0208] Sodium cyanoborohydride (19 mg, 0.30 mmol) was added to a mixture of Compound 626 (50 mg, 0.060 mmol), formaldehyde (37 wt. % solution, 12 μL, 0.16 mmol), and acetic acid (15 μL, 0.26 mmol) in methanol (0.5 mL) and the resulting solution was stirred at rt for 3 h. The solution was diluted with ethyl acetate (15 mL), washed with 1 N NaOH, water, and brine (10 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 38 mg (75%) of the title compound. MS 853 (M+H)+.
Compound 804 (Formula 1b: R12 is H, R13 is 2-[4-(2-pyrimidinyl)phenyl]ethyl, R14 is CH2CH3)
[0209] Sodium cyanoborohydride (19 mg, 0.30 mmol) was added to a mixture of Compound 626 (50 mg, 0.060 mmol), acetaldehyde (10 μL, 0.18 mmol), and acetic acid (15 μL, 0.26 mmol) in methanol (0.5 mL) and the resulting solution was stirred at rt for 3 h. The solution was diluted with ethyl acetate (15 mL), washed with 1 N NaOH, water, and brine (10 mL each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 41 mg (79%) of the title compound. MS 867 (M+H)+.
EXAMPLE 805
[0210] Compound 805 (Formula 1b: R12 is H, R13 is (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl, R14 is H) and Compound 806 (Formula 1b: R12 is H, R13 is (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl, R14 is (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl)
[0211] A mixture of Compound 5 (100 mg, 0.15 mmol), (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal (37 mg, 0.18 mmol, prepared as described in Reference Example 29), and acetic acid (35 μL, 0.61 mmol) in methanol (1 mL) was stirred at rt for 1 h. Sodium cyanoborohydride (1.0 M in THF, 0.61 mL, 0.61 mmol) was added followed by a small amount of bromocresol green, and then acetic acid dropwise until the color of the solution remained yellow. After 18 h, solid sodium cyanoborohydride (20 mg, 0.32 mmol) was added and the mixture was stirred for 96 h. The solution was diluted with ethyl acetate (15 mL), washed with 1N NaOH, water, and brine (10 ml each), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 47 mg (70%) of a mixture of compounds. This mixture was further purified by HPLC (C18 column, 10-90% CH3CN/H2O+0.1% TFA). The lyophilized fractions were taken up in dichloromethane, washed with sat. aq. NaHCO3, dried (Na2SO4), and concentrated to provide Compound 235 (14 mg, MS 851 (M+H)+) and Compound 236 (10 mg, MS 1045 (M+H)+).
Compounds 807 and 808
[0212]
36
[0213] A mixture of Compound 5 (50 mg, 0.076 mmol), 2-butoxy-3,4-dihydro-4-phenyl-2H-pyran (90 mg, 0.39 mmol, prepared as described in Reference Example 67), triethylsilane (125 μL, 0.78 mmol), and trifluoroacetic acid (60 μL, 0.78 mmol) in acetonitrile (0.5 mL) was stirred at rt for 1 h. The reaction mixture was diluted with ethyl acetate (15 mL), washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) yielded 15 mg (25%) of compound 807 (MS 801 (M+H)+) and 15 mg (25%) of compound 808 (MS 796 (M+H)+). Compound 807 was further purified by chromatography (SiO2, 98.5:1.5 acetonitrile/conc. NH4OH) to yield 8 mg (13%).
Compound 809 [Formula 1n: R11 is H, R20 is 4-methylphenyl]
[0214] To a solution of Compound 5 (150 mg, 0.23 mmol) in dichloromethane (2 mL) at room temperature was added p-toluenesulfonyl chloride (48 mg, 0.25 mmol). The reaction mixture was stirred overnight, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 123 mg (66%) of the title compound. MS 811 (M+H)+.
Compound 810 [Formula 1m′: R10 is H, R20 is 4-methylphenyl, R21′ is acetyl]
[0215] Step A:
[0216] Acetic anhydride (0.1 mL) was added to a solution of compound 809 (54 mg, 0.07 mmol) in pyridine (0.3 mL), and the reaction mixture was stirred at room temperature for 1 h. Excess pyridine and acetic anhydride were removed in vacuo, the residue dissolved in dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 50 mg (83%) of product. MS 895 (M+H)+.
[0217] Step B:
[0218] The product from step A (20 mg, 0.02 mmol) was stirred in MeOH (1 mL) at rt for 18 h. Solvent was evaporated in vacuo, and the crude product was purified by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) to give 15 mg (79%) of the title compound. MS 853 (M+H)+.
[Formula 1n: R13 is H, R20 is 4-(1H-pyrazol-1-yl)-phenyl]
[0219] To a solution of Compound 5 (100 mg, 0.15 mmol) in dichloromethane (1.2 mL) at room temperature was added 4-(1H-pyrazol-1-yl)-benzenesulfonyl chloride (51 mg, 0.21 mmol). The reaction mixture was stirred overnight, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 45 mg (35%) of the title compound. MS 863 (M+H)+.
Compound 812 (Formula 1k: R13 is H, R16 is methyl)
[0220] Method A:
[0221] Acetic anhydride (32 μL, 0.33 mmol) was added dropwise to a solution of Compound 5 (200 mg, 0.30 mmol) in dichloromethane (3 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 h, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 186 mg (88%) of the title compound. MS 699 (M+H)+.
[0222] Method B:
[0223] Acetyl chloride (3 μL, 45 μmol) was added dropwise to a solution of Compound 5 (25 mg, 38 μmol) in dichloromethane (0.3 mL) at rt. The reaction mixture was stirred at rt for 1 h, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 17 mg (63%) of the title compound. MS 699 (M+H)+.
[0224] Method C:
[0225] Acetic anhydride (0.1 mL, 1.06 mmol) was added to a solution of Compound 5 (50 mg, 0.08 mmol) in pyridine (0.3 mL) at rt. The reaction mixture was stirred at rt for 4 h, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. The resulting product was stirred in methanol (1 mL) overnight, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 23 mg (66%) of the title compound. MS 699 (M+H)+.
Compound 813 (Formula 1k: R13 is H, R16 is Phenyl)
[0226] Benzoic anhydride (135 mg, 0.60 mmol) was added to a solution of Compound 5 (100 mg, 0.15 mmol) in dichloromethane (0.8 mL) and pyridine (0.8 mL) at rt. The reaction mixture was stirred at rt for 18 h, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. The resulting product was refluxed in methanol (3 mL) for 7 h, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 52 mg (45%) of the title compound. MS 761 (M+H)+.
Compound 814 (Formula 1l: R13 is H, R17 is benzyl)
[0227] Benzyl chloroformate (16 μL, 114 μmol) was added to a solution of Compound 5 (50 mg, 76 μmol) in dichloromethane (0.7 mL) at rt. The reaction mixture was stirred overnight, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 31 mg (52%) of the title compound. MS 791 (M+H)+.
Compound 815 (Formula 1m: R13 is H, R18 is Me, R19 is Phenyl)
[0228] N-Methyl-N-phenyl carbamoyl chloride (34 mg, 0.19 mmol) was added to a solution of Compound 5 (100 mg, 0.15 mmol) in dichloromethane (2 mL) at room temperature. The reaction mixture was stirred at room temperature for 4 days, diluted with dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 56 mg (47%) of the title compound. MS 790 (M+H)+.
Compound 816 (Formula 1h: R13a,R14a is —(CH2)3—)
[0229] To a solution of Compound 5 (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added glutaraldehyde (50 wt % in water, 84 mg), and acetic acid (0.1 mL). The reaction mixture was stirred at room temperature for 1 h, sodium cyanoborohydride (100 mg, 1.61 mmol) was added followed by a small amount of bromocresol green, and then acetic acid was added dropwise until the color of the solution remained yellow. The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 55 mg (50%) of the title compound. MS 725 (M+H)+.
Compound 817 [Formula 1b: R12 is Me, R13 is (4-pyrazinylphenyl)methyl, R14 is H] and Compound 776 [Formula 1b: R12 is H, R13 is (4-pyrazinylphenyl)methyl, R14 is Me]
[0230] Step A: Compound of formula 1b, wherein R12 is H, R13 is H, R14 is Me and compound of formula 1b, wherein R12 is Me, R13 is H, R14 is H)
[0231] To a solution of Compound 4 (800 mg, 1.11 mmol) in dichloromethane at 0° C. was added dropwise a solution of methylhydrazine (0.30 mL, 5.55 mmol). The reaction mixture was stirred at 0° C. for an additional 15 min, at room temperature for 1 h, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 550 mg (67%) of a 1:1 mixture of the title compounds. MS 671 (M+H)+.
[0232] Step B: Compound 817 and Compound 776
[0233] To a solution of a 1:1 mixture of compounds from step A (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added 4-pyrazinylbenzaldehyde (27 mg, 0.15 mmol, prepared as described in Reference Example 17) and acetic acid (0.1 mL). The reaction mixture was stirred at room temperature for 30 min, sodium cyanoborohydride (50 mg, 0.80 mmol) was added followed by a small amount of bromocresol green, and then acetic acid was added dropwise until the color of the solution remained yellow. The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 46 mg (44%) of a 1:1 mixture of the title compounds [MS 839 (M+H)+]. This mixture was separated by reverse phase HPLC (C18 column, 30-70% CH3CN/H2O+0.1% TFA). The lyophilized fractions were taken up in dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo to provide 10 mg of Compound 817 and 10 mg of Compound 776.
EXAMPLE 816
[0234] Compound 818 {Formula 1b: R12 is Me, R13 is [4-(2-pyridinyl)phenyl]methyl, R14 is H} and Compound 786 {Formula 1b: R12 is H, R13 is [4-(2-pyridinyl)phenyl]methyl, R14 is Me}
[0235] The title compounds were prepared by a procedure analogous to Example 815, by substituting 4-(2-pyridinyl)benzaldehyde for 4-pyrazinylbenzaldehyde. MS 838 (M+H)+.
Compound 819 [Formula 1b: R12 is Me, R13 is (4-pyrazinylphenyl)methyl, R14 is Me] and Compound 776 [Formula 1b: R12 is H, R13 is (4-pyrazinylphenyl)methyl, R14 is Me]
[0236] To a solution of a 1:1 mixture of compounds from step A of Example 815 (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added 4-pyrazinylbenzaldehyde (50 mg, 0.30 mmol, prepared as described in Reference Example 17)) and acetic acid (0.1 mL). The reaction mixture was stirred at room temperature for 30 min, sodium cyanoborohydride (50 mg, 0.80 mmol) was added followed by a small amount of bromocresol green, and then acetic acid was added dropwise until the color of the solution remained yellow. The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. To a solution of this crude reaction mixture in methanol (1 mL) was added formaldehyde (37 wt % in H2O, 0.1 mL) and acetic acid (0.1 mL). The reaction mixture was stirred at room temperarture for 15 min, sodium cyanoborohydride (50 mg, 0.80 mmol) was added followed by a small amount of bromocresol green, and then acetic acid was added dropwise until the color of the solution remained yellow. The reaction mixture was stirred at room temperature for 30 min, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 76 mg of a 1:1 mixture of the title compounds. This mixture was separated by reverse phase HPLC (C18 column, 30-70% CH3CN/H2O+0.1% TFA). The lyophilized fractions were taken up in dichloromethane, washed with sat. aq. NaHCO3, dried with Na2SO4, concentrated in vacuo to provide 15 mg of compound 776 [(M+H)+839] and 15 mg of compound 819 [(M+H)+853].
Compound 820 [Formula 1b: R12 is Me, R13 is 2-(4-pyrazinylphenyl)ethyl, R14 is H] and Compound 751 [Formula 1b: R12 is H, R13 is 2-(4-pyrazinylphenyl)ethyl, R14 is Me]
[0237] The title compounds were prepared by a procedure analogous to Example 815 by substituting 4-pyrazinylbenzeneacetaldehyde (prepared as described in Reference Example 420) for 4-pyrazinylbenzaldehyde. MS 853 (M+H)+.
Compound 821 [Formula 1b: R12 is Me, R13 is 2-(4-pyrazinylphenyl)ethyl, R14 is Me] and Compound 751 [Formula 1b: R12 is H, R13 is 2-(4-pyrazinylphenyl)ethyl, R14 is Me]
[0238] The title compounds were prepared by a procedure analogous to Example 817 by substituting 4-pyrazinylbenzeneacetaldehyde (prepared as described in Reference Example 420) for 4-pyrazinylbenzaldehyde. Compound 821, MS 867 (M+H)+; and Compound 751, MS 853 (M+H)+.
Compound 822 [Formula 1j′: R13a is 2-(4-pyrazinylphenyl)methyl, n is 3]
[0239] To compound 751 (120 mg, 0.14 mmol) in methanol (1 mL) at room temperature was added glutaraldehyde (50 wt % in water, 50 μL) and acetic acid (0.1 mL). The reaction mixture was stirred at room temperature for 1 h, sodium cyanoborohydride (50 mg, 0.81 mmol) was added followed by a small amount of bromocresol green, and then acetic acid was added dropwise until the color of the solution remained yellow. The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, the organic layer dried with Na2SO4, and concentrated in vacuo to give 120 mg (91%) of the title compound. MS 925 (M+H)+.
Compound 823 [Formula 1k′: R13a is 2-(4-pyrazinylphenyl)methyl, n is 3]
[0240] To Compound 822 (100 mg, 0.11 mmol) in dichloromethane (1.4 mL) at room temperature was added p-toluenesulfonyl chloride (27 mg, 0.14 mmol) and triethylamine (39 μL, 0.28 mmol). The reaction mixture was stirred at room temperature for four days, quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4 and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 60 mg (61%) of the title compound. MS 907 (M+H)+.
Compound 824 {Formula 1b: R12 is H, and R13,R14 together with the nitrogen to which they are attached is 3-[4-(2-pyrimidinyl)phenyl]pyrrole}
[0241] Trifluoroacetic acid (61 μL, 0.80 mmol) was added to a solution of Compound 5 (39 mg, 0.06 mmol) and 2-[4-(tetrahydro-2,5-dimethoxy-3-furanyl)phenyl]pyrimidine (24 mg, 0.08 mmol, prepared as described in Reference Example 441) in acetonitrile (1 mL) at room temperature. The reaction mixture was stirred at 55° C. for 3 h, cooled to room temperature, quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 22 mg (70%) of the title compound. MS 861 (M+H)+.
Compound 825 [Formula 1f: R13a is 4-(2-pyrimidinyl)phenyl]
[0242] To a solution of Compound 5 (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added 4-(2-pyrimidinyl)benzaldehyde (34 mg, 0.18 mmol, prepared as described in WO 9828264), and acetic acid (50 μL). The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 43 mg (34%) of the title compound. MS 823 (M+H)+.
Compound 826 {Formula 1f: R13a is [4-(2-pyrimidinyl)phenyl]methyl}
[0243] To a solution of Compound 5 (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added 4-(2-pyrimidinyl)benzeneacetaldehyde (40 mg, 0.20 mmol, prepared as described in Example 64), and acetic acid (50 μL). The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 48 mg (38%) of the title compound. MS 837 (M+H)+.
Compound 827 {Formula 1f: R13a is 2-[4-(2-pyrimidinyl)phenyl]ethenyl}
[0244] To a solution of Compound 5 (100 mg, 0.15 mmol) in methanol (1 mL) at room temperature was added (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal (32 mg, 0.15 mmol, prepared as described in Reference Example 29), and acetic acid (50 μL). The reaction mixture was stirred at room temperature for 1 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 41 mg (32%) of the title compound. MS 849 (M+H)+.
Compound 828 {Formula 1t′: W′ is 1-methyl-1-[2-(4-pyrazinylphenyl)ethyl]hydrazinyl}
[0245] Step A:
[0246] To Compound 751 (106 mg, 0.12 mmol) in dichloromethane (1 mL) at room temperature was added acetic anhydride (113 μL, 1.20 mmol) and triethylamine (333 μL, 2.40 mmol). The reaction was stirred at room temperature for 1 h, diluted with dichloromethane, washed with sat. aq. NH4Cl, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) gave 82 mg (74%) of product. MS 895 (M+H)+.
[0247] Step B:
[0248] Product from step A (82 mg, 0.09 mmol) in DMF (1 mL) under nitrogen was cooled to −60° C. and NaHMDS (420 μL, 0.42 mmol, 1M solution in THF) was added dropwise. The reaction was stirred for 30 min at −60° C., SELECTFLUOR™ was added, the mixture stirred for an additional 20 min, quenched with sat. aq. NH4Cl, dried with Na2SO4, and concentrated in vacuo. The crude reaction mixture was stirred in methanol at room temperature for 18 h, concentrated in vacuo, and purified by medium pressure liquid chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) to give 29 mg (36%) of title product. MS 871 (M+H)+.
Compound 829 {Formula 1t′: W′ is 1-methyl-1-[2-(4-pyridazinylphenyl)ethyl]hydrazinyl}
[0249] The title compound was prepared by following the procedure used for Example 826, except substituting Compound 752 for Compound 751. MS 871 (M+H)+.
Compound 830 (Formula 1e′: R9 is (2E)-3-phenyl-2-propenyl)
[0250] DBU (64 mg, 0.42 mmol) was added to a solution of (2E)-3-phenyl-2-propene-1-thiol (63 mg, 0.42 mmol, prepared as described in Reference Example 473) in THF (1 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (100 mg, 0.14 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 13 mg (12%) of the title compound. MS 775 (M+H)+.
Compound 831 (Formula 1e′: R9 is phenylmethyl)
[0251] DBU (78 mg, 0.51 mmol) was added to a solution of benzyl mercaptan (63 mg, 0.51 mmol) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (120 mg, 0.17 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 26 mg (20%) of the title compound. MS 749 (M+H)+.
Compound 832 (Formula 1e′: R9 is 2-propenyl)
[0252] DBU (320 mg, 2.1 mmol) was added to a solution of allyl mercaptan (156 mg, 2.1 mmol) in THF (2.5 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (500 mg, 0.7 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (60 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 133 mg (27%) of the title compound. MS 699 (M+H)+.
Compound 833 (Formula 1e′: R9 is (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propenyl)
[0253] DBU (110 μL, 0.75 mmol) was added to a solution of (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propene-1-thiol (170 mg, 0.75 mmol, prepared as described in Reference Example 472) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (180 mg, 0.25 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer Was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 96:4:0.2 dichloromethane/methanol/conc. NH4OH) yielded 96 mg (45%) of the title compound. MS 854 (M+H)+.
Compound 834 (Formula 1e′: R9 is [4-(2-pyrimidinyl)phenyl]methyl)
[0254] DBU (75 μL, 0.5 mmol) was added to a solution of 4-(2-pyrimidinyl)benzenemethanethiol (100 mg, 0.5 mmol, prepared as described in Reference Example 464) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (180 mg, 0.25 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 26 mg (13%) of the title compound. MS 828 (M+H)+.
EXAMPLE 833
[0255] Compound 835 (Formula 1e′: R9 is 2-[4-(2-pyrimidinyl)phenyl]ethyl) DBU (55 μL, 0.37 mmol) was added to a solution of 4-(2-pyrimidinyl)benzeneethanethiol (80 mg, 0.37 mmol, prepared as described in Reference Example 465) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (132 mg, 0.18 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 10 mg (7%) of the title compound. MS 842 (M+H)+.
Compound 836 (Formula 1e′: R9 is [4-(1H-1,2,4-triazol-1-yl)phenyl]ethyl)
[0256] DBU (40 μL, 0.27 mmol) was added to a solution of 4-(1H-1,2,4-triazol-1-yl)benzeneethanethiol (55 mg, 0.27 mmol, prepared as described in Reference Example 466) in THF (1 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4(100 mg, 0.14 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 7 mg (6%) of the title compound. MS 831 (M+H)+.
Compound 837 (Formula 1e′: R9 is (2E)-3-(3-quinolinyl)-2-propenyl)
[0257] DBU (40 μL, 0.27 mmol) was added to a solution of (2E)-3-(3-quinolinyl)-2-propene-1-thiol (54 mg, 0.27 mmol, prepared as described in Reference Example 467) in THF (1 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (100 mg, 0.14 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) yielded 6 mg (6%) of the title compound. MS 827 (M+H)+.
Compound 838 (Formula 1e′: R9 is 3-quinolinylmethyl)
[0258] DBU (94 μL, 0.63 mmol) was added to a solution of 3-quinolinemethanethiol (110 mg, 0.63 mmol, prepared as described in Reference Example 468) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (225 mg, 0.32 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 27 mg (11%) of the title compound. MS 800 (M+H)+.
Compound 839 (Formula 1e′: R9 is [5-(2-pyridinyl)-2-thienyl]methyl)
[0259] DBU (140 μL, 0.92 mmol) was added to a solution of 5-(2-pyridinyl)-2-thiophenemethanethiol (190 mg, 0.92 mmol, prepared as described in Reference Example 469) in THF (2 mL), the mixture was stirred at rt for 5 min, and then cooled to 0° C. The compound from Example 4 (220 mg, 0.31 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 23 mg (9%) of the title compound. MS 833 (M+H)+.
Compound 840 (Formula 1e′: R9 is [4-(1H-1,2,4-triazol-1-yl)phenyl]methyl)
[0260] DBU (120 μL, 0.84 mmol) was added to a solution of 4-(1H-1,2,4-triazol-1-yl)benzenemethanethiol (160 mg, 0.84 mmol, prepared as described in Reference Example 470) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (200 mg, 0.28 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 20 mg (9%) of the title compound. MS 816 (M+H)+.
Compound 841 (Formula 1e′: R9 is [1-(2-pyrimidinyl)-1H-imidazol-4-yl]methyl)
[0261] DBU (120 μL, 0.84 mmol) was added to a solution of 1-(2-pyrimidinyl)-1H-imidazole-4-methanethiol (160 mg, 0.84 mmol, prepared as described in Reference Example 471) in THF (2 mL), the mixture was stirred at room temperature for 5 min, and then cooled to 0° C. Compound 4 (200 mg, 0.28 mmol) was added and the resulting solution was stirred for 3 h at 0° C. The solution was diluted with ethyl acetate (20 mL), washed with 10% aq. NH4Cl, sat. NaHCO3 and brine. The organic layer was dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 95:5:0.2 dichloromethane/methanol/conc. NH4OH) followed by HPLC separation yielded 32 mg (14%) of the title compound. MS 817 (M+H)+.
Compound 842 (Formula 1f′: R22 and R23 are H)
[0262] 1,1,3,3-Tetramethoxypropane (0.49 mL, 2.94 mmol), trifluoroacetic acid (0.45 mL, 6.1 mmol), and 4 A molecular sieves (2.0 g) were added to a solution of Compound 5 (1.280 g, 1.96 mmol) in dichloromethane (8 mL). This mixture was heated at 60° C. in a sealed culture tube for 30 min. The reaction mixture was cooled to room temperature, diluted with dichloromethane, and the molecular sieves removed by filtration. The filtrate was washed with sat. aq. NaHCO3, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) gave 854 mg (63%) of the title compound. MS 693 (M+H)+.
Compound 843 (Formula 1g′: R10 is phenyl, R11 is H)
[0263] To a solution of Compound 842 (100 mg, 0.15 mmol) in THF (0.5 mL) under nitrogen at room temperature was added dropwise a solution of benzylmagnesium chloride (2.0 M in THF, 0.22 mL, 0.45 mmol). The reaction mixture was stirred at rt for 5 min and carefully quenched with sat. aq. NH4Cl, extracted three times with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) gave 46 mg (45%) of the title compound. MS 717 (M+H)+.
Compound 844 (Formula 1g′: R10 is 3-phenylethyl, R11 is H)
[0264] To a suspension of magnesium powder (240 mg, 10 mmol) in THF (5 mL) was added 1-bromo-3-phenylpropane (1.68 mL, 11 mmol) dropwise. One drop of dibromoethane was added and the reaction mixture stirred at rt until all the magnesium powder dissolved (30 min). In a separate flask, to a solution of Compound 842 (80 mg, 0.12 mmol) in THF (1 mL) at room temperature was added the above prepared Grignard solution (1 mL, 2 mmol) dropwise. This mixture was stirred at room temperature for 15 min, carefully quenched with sat. aq. NH4Cl, extracted three times with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) gave 20 mg (23%) of the title compound. MS 745 (M+H)+.
Compound 845 (Formula 1i′: R5 is H, R10 is phenyl, R11 is H)
[0265] To a solution of Compound 4 (195 mg, 0.27 mmol) in THF (2.0 mL) under nitrogen at room temperature was added dropwise a solution of benzylmagnesium chloride (2.0 M in THF, 0.54 mL, 1.08 mmol). The reaction mixture was stirred at room temperature for 5 min and carefully quenched with sat. aq. NH4Cl, extracted three times with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) gave 46 mg (33% based on recovered starting material) of the title compound. MS 809 (M+H)+.
Compound 846 (Formula 1i′: R5 is H, R10 is 2-phenylethyl, R11 is H)
[0266] To a suspension of magnesium powder (240 mg, 10 mmol) in THF (5 mL) was added 1-bromo-3-phenylpropane (1.68 mL, 11 mmol) dropwise. One drop of dibromoethane was added and the reaction mixture stirred at room temperature until all the magnesium powder dissolved (30 min). In a separate flask, to a solution of Compound 4 (165 mg, 0.23 mmol) in THF (1 mL) at room temperature was added the above prepared Grignard solution (2 mL, 4 mmol) dropwise. This mixture was stirred at room temperature for 4 h, carefully quenched with sat. aq. NH4Cl, extracted three times with dichloromethane, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 95:5:0.5 dichloromethane/methanol/conc. NH4OH) gave 51 mg (43% based on recovered starting material) of the title compound. MS 837 (M+H)+.
4-Phenylbutanal
[0267] 4-Phenylbutanol (700 mg, 4.66 mmol) was added to a solution of the Dess-Martin reagent (2.40 g, 5.66 mol) in dichloromethane (35 mL). After 30 min at RT, the solution was quenched with 10% aq. Na2S2O3, washed with sat. aq. NaHCO3 and brine, dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 9:1 hexane/ethyl acetate) yielded the title compound. MS 149 (M+H)+.
4-Pyridinepropanal
[0268] 4-Pyridinepropanol (0.60 mL, 4.65 mmol) was added to a solution of the Dess-Martin reagent (2.37 g, 5.58 mol) in dichloromethane (30 mL). After 60 min at RT, the solution was quenched with 10% aq. Na2S2O3, washed with sat. aq. NaHCO3 and brine, dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) yielded the title compound. MS 136 (M+H)+.
3-(1H-Pyrazol-1-yl)benzaldehyde
[0269] A mixture of 3-formylphenylboronic acid (2.00 g, 13.34 mmol), pyrazole (0.46 g, 6.67 mmol), copper(II) acetate (1.82 g, 10.01 mmol), pyridine (1.10 mL, 13.34 mmol), and powdered 4A molecular sieves (2.5 g) in dichloromethane (20 mL) was stirred under an air atmosphere for 24 h. The mixture was then filtered through Celite, the filtered solids were washed with methanol, and the combined filtrate was concentrated. Purification by chromatography (SiO2, 3:1 hexane/ethyl acetate) yielded the title compound. MS 173 (M+H)+.
4-(4-Methyl-1H-pyrazol-1-yl)benzaldehyde
[0270] A solution of 4-methylpyrazole (1.98 g, 24.11 mmol) in DMF (8 mL) was added to sodium hydride (60% in oil, 0.97 g, 24.25 mmol) in DMF (6 mL) and the resulting mixture was stirred 2 h at RT. 4-Fluorobenzaldehyde (1.26 g, 7.45 mmol) was added dropwise and the resulting mixture heated to 80° C. for 3 h. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) followed by recrystallization from hexane yielded the title compound. MS 187 (M+H)+.
3-Methoxy-4-(1H-pyrazol-1-yl)benzaldehyde
[0271] A mixture of 4-fluoro-3-methoxybenzaldehyde (2.00 g, 12.98 mmol), pyrazole (1.32 g, 19.39 mmol), and powdered K2CO3 (2.68 g, 19.39 mmol) in DMF (20 mL) was heated to 120° C. for 20 h. The cooled reaction mixture was diluted with ethyl acetate (200 mL), washed with water (3×200 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) yielded 1.52 g (58%) of the title compound as a yellow oil. MS 203 (M+H)+.
3-Fluoro-4-(1H-pyrazol-1-yl)benzaldehyde
[0272] The title compound was prepared by a procedure analogous to Reference Example 5 by substituting 3,4-difluorobenzaldehyde for the 4-fluoro-3-methoxybenzaldehyde of Reference Example 5. MS 191 (M+H)+.
3-Fluoro-4-(1H-1,2,4-triazol-1-yl)benzaldehyde
[0273] The title compound was prepared by a procedure analogous to Reference Example 5 by substituting 3,4-difluorobenzaldehyde and 1,2,4-triazole, respectively, for the 4-fluoro-3-methoxybenzaldehyde and pyrazole of Reference Example 5. MS 192 (M+H)+.
2-Fluoro-4-(1H-pyrazol-1-yl)benzaldehyde
[0274] Step A: 2-Fluoro-4-(1H-pyrazol-1-yl)benzonitrile
[0275] A mixture of 2-fluoro-4-hydrazinobenzonitrile (3.03 g, 20.05 mmol, prepared as described in U.S. Pat. No. 5,006,148), malonaldehyde bis(diethyl)acetal (4.80 mL, 20.02 mmol), and conc. HCl (1 mL) in ethanol (20 mL) was heated to reflux for 1 h. Upon cooling to RT, the reaction mixture solidified. Water (40 mL) was added and the mixture was cooled to 0° C. and made basic with 10% NaOH. The solids were removed by filtration, washed with water, and dried in vacuo to yield 3.59 g (96%) of the title compound as a light brown solid.
[0276] Step B: 2-Fluoro-4-(1H-pyrazol-1-yl)benzaldehyde
[0277] Diisobutylaluminum hydride (1.0 M in toluene, 11.00 mL, 11.00 mol) was added dropwise over 10 min to a vigorously stirred suspension of the compound from step A (1.88 g, 10.04 mmol) in toluene (100 mL) at −78° C. After 1 h at −78° C., methanol (1 mL) was added, the mixture was stirred for 5 min, and then poured into a stirred, cold (0° C.) mixture of 1.2 N HCl (100 mL) and ethyl acetate (100 mL). After stirring for 30 min at RT, the layers were separated and the aqueous layer was extracted with additional ethyl acetate (100 mL). The combined organic layers were washed with sat. aq. NaHCO3 (100 mL) and brine (100 mL), dried (MgSO4), and concentrated. Recrystallization from IPA followed by chromatography (SiO2, dichloromethane) provided 1.25 g (65%) of the title compound as a colorless solid. MS 191 (M+H)+.
4-(2-Pyrimidinyloxy)benzaldehyde
[0278] Sodium hydride (60% in oil, 1.44 g, 36.00 mmol) was added to a 0° C. solution of 4-hydroxybenzaldehyde (4.40 g, 36.03 mmol) in DMF (16 mL). After stirring for 20 min at 0° C., the mixture was allowed to warm to RT and a solution of 2-chloropyrimidine (4.12 g, 35.97 mmol) in DMF (8 mL) was added. The resulting mixture was heated to 100° C. for 18 h. The solvent was evaporated, the residue was dissolved in ethyl acetate, washed with water and brine, dried (MgSO4), and concentrated to provide 6.20 g (86%) of the title compound. MS 201 (M+H)+.
1-(2-Pyrimidinyl)-1H-imidazole-4-carboxaldehyde
[0279] The title compound was prepared by a procedure analogous to Reference Example 9 by substituting 1H-imidazole-4-carboxaldehyde for the 4-hydroxybenzaldehyde of Reference Example 9. MS 175 (M+H)+.
3-(2-pyridinyl)benzaldehyde
[0280] 2M aq. Na2CO3 (5 mL) and a solution of 3-formylphenylboronic acid (1.14 g, 7.60 mmol) in methanol (5 mL) were added to a solution of 2-bromopyridine (1.00 g, 6.33 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.22 g, 0.19 mmol) in toluene (10 mL) and the mixture was heated to reflux for 18 h. The cooled reaction mixture was diluted with dichloromethane, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) yielded 1.03 g (89%) of the title compound. MS 184 (M+H)+.
3-(2-Pyrimidinyl)benzaldehyde
[0281] A mixture of Na2CO3 (4.74 g, 44.72 mmol) and 3-formylphenylboronic acid (3.40 g, 22.67 mmol) in water (15 mL) were added to a solution of 2-bromopyrimidine (3.00 g, 18.87 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.72 g, 0.62 mmol) in DME (30 mL) and the mixture was heated to reflux for 24 h. The cooled reaction mixture was diluted with dichloromethane, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) yielded 2.20 g (63%) of the title compound. MS 185 (M+H)+.
4-(4-Methoxy-2-pyrimidinyl)benzaldehyde
[0282] 1M aq. Na2CO3 (20 mL) and ethanol (10 mL) were added to a solution of 2-chloro-4-methoxypyrimidine (2.90 g, 20.06 mmol, prepared as described in Tetrahedron 1997, 53, 11595), 4-formylphenylboronic acid (3.90 g, 26.01 mmol) and [1,4-bis(diphenylphosphino)butane]palladium(II) dichloride (0.60 g, 0.99 mmol) in toluene (40 mL) and the mixture was heated to reflux for 18 h. The cooled reaction mixture was diluted with ethyl acetate, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) yielded 1.80 g (42%) of the title compound. MS 215 (M+H)+.
4-(4-Methyl-2-pyrimidinyl)benzaldehyde
[0283] The title compound was prepared by a procedure analogous to Reference Example 12 by substituting 4-formylphenylboronic acid and 2-bromo-4-methylpyrimidine (prepared as described in Helv. Chim. Acta 1992, 75, 1621) for the 3-formylphenylboronic acid and 2-bromopyridine, respectively, of Reference Example 12. MS 199 (M+H)+.
2-Fluoro-4-(2-pyrimidinyl)benzaldehyde
[0284] Step A:
[0285] Dimethyl sulfoxide (70 mL) and 4-bromo-2-fluorobenzaldehyde (2.44 g, 12.02 mmol) were added to a mixture of potassium acetate (3.54 g, 36.07 mmol), bis(pinacolato)diboron (3.36 g, 13.23 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (294 mg, 0.36 mmol). The mixture was heated to 80° C. for 18 h. The cooled reaction mixture was diluted with benzene, washed with water, dried (MgSO4), and concentrated. The material was used in the next step without further purification.
[0286] Step B:
[0287] The title compound was prepared by a procedure analogous to Reference Example 12 by substituting the product of step A for the 3-formylphenylboronic acid of Reference Example 12. MS 203 (M+H)+.
4-(3-Pyridazinyl)benzaldehyde
[0288] The title compound was prepared by a procedure analogous to Reference Example 13 by substituting 3-chloropyridazine (prepared as described in WO 9724124) for the 2-chloro-4-methoxypyrimidine of Reference Example 13. MS 185 (M+H)+.
4-Pyrazinylbenzaldehyde
[0289] The title compound was prepared by a procedure analogous to Reference Example 13 by substituting chloropyrazine for the 2-chloro-4-methoxypyrimidine of Reference Example 13. MS 185 (M+H)+.
4-(4-Pyrimidinyl)benzaldehyde
[0290] The title compound was prepared by a procedure analogous to Reference Example 13 by substituting 4-chloropyrimidine hydrochloride (prepared as described in WO 9821188) for the 2-chloro-4-methoxypyrimidine of Reference Example 13. MS 185 (M+H)+.
4-(5-Nitro-2-pyridinyl)benzaldehyde
[0291] The title compound was prepared by a procedure analogous to Reference Example 11 by substituting 4-formylphenylboronic acid and 2-bromo-5-nitropyridine for the 3-formylphenylboronic acid and 2-bromopyridine, respectively, of Reference Example 11. MS 229 (M+H)+.
3-[4-(1H-Pyrazol-1-yl)phenyl]-2-propynal
[0292] Step A: 3-[4-(1H-pyrazol-1-yl)phenyl]-2-propyn-1-ol
[0293] A mixture of 1-(4-bromophenyl)-1H-pyrazole (prepared as described in Bull. Soc. Chim. Fr. 1966, 2832) (2.24 g, 10.04 mmol), Pd(Ph3P)2Cl2 (180 mg, 0.26 mmol), and copper(I) iodide (95 mg, 0.50 mmol) in TEA (20 mL) was stirred for 5 min, propargyl alcohol (0.70 mL, 12.02 mmol) was added, and the mixture was heated to 80° C. for 48 h. The volatiles were evaporated, ethyl acetate (50 mL) and water (50 mL) were added to the residue, and the mixture was filtered through a pad of Celite. The organic layer from the filtrate was washed with brine (50 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 3:2 hexane/ethyl acetate) yielded 0.73 g (37%) of the title compound as a brown solid. MS 199 (M+H)+.
[0294] Step B: 3-[4-(1H-pyrazol-1-yl)phenyl]-2-propynal
[0295] A mixture of the compound from step A (0.71 g, 3.58 mmol) and MnO2 (3.10 g, 35.66 mmol) in acetone (40 mL) was heated to reflux for 3 h. The cooled reaction mixture was filtered through Celite and the filtrate was concentrated. Purification by chromatography (SiO2, 6:1 hexane/ethyl acetate) yielded 0.19 g (27%) of the title compound as an off-white solid. MS 197 (M+H)+.
3-(3-Quinolinyl)-2-propynal
[0296] A mixture of 3-(3-quinolinyl)-2-propyn-1-ol (prepared as described in J. Med Chem. 1996, 39, 3179) (360 mg, 1.96 mmol) and the Dess-Martin reagent (1.00 g, 2.36 mmol) in dichloromethane (10 mL) was stirred at RT for 1.5 h. The solution was washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:4 hexane/ethyl acetate) yielded 258 mg (72%) of the title compound. MS 182 (M+H)+.
(2E)-3-[6-(1H-Pyrazol-1-yl)-3-pyridinyl]-2-propenal
[0297] Step A: 5-Bromo-2-(1H-pyrazol-1-yl)pyridine
[0298] Pyrazole (2.05 g, 30.11 mol) was added in portions to sodium hydride (60% in oil, 1.20 g, 30.00 mmol) in DMF (40 mL) and the resulting mixture was stirred for 1 h at RT. 2,5-Dibromopyridine (4.75 g, 20.05 mmol) was added and the mixture was heated to 100° C. for 2 h. Ice-water (100 mL) was added to the cooled reaction mixture and the precipitated solids were removed by filtration and allowed to air-dry. Recrystallization from hexane provided 3.31 g (74%) of the title compound as a tan solid. MS 224 (M+H)+.
[0299] Step B: Methyl (2E)-3-([6-(1H-pyrazol-1-yl)pyridin-3-yl]-2-propenoate
[0300] A solution of the compound from step A (450 mg, 2.01 mmol) and tri(o-tolyl)phosphine (123 mg, 0.40 mmol) in DMF (8 mL) was cooled to 0° C. and purged with nitrogen for 15 min. TEA (0.56 mL, 4.02 mmol) and methyl acrylate (0.36 mL, 4.00 mmol) were added and purging was continued for 5 min. Palladium acetate (45 mg, 0.20 mmol) was added and the flask was stoppered and heated to 120° C. for 24 h. The cooled reaction mixture was diluted with ether (50 mL) and washed with water (2×25 mL) and brine (25 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 4:1 hexane/ethyl acetate) yielded 356 mg (77%) of the title compound. MS 230 (M+H)+.
[0301] Step C: (2E)-3-[6-(1H-pyrazol-1-yl)-3-pyridinyl]-2-propen-1-ol
[0302] DIBAL (1.0 M solution in toluene, 3.10 mL, 3.10 mmol) was added dropwise to a suspension of the compound from step B (350 mg, 1.53 mmol) in toluene (10 mL) and dichloromethane (4 mL) at −78° C. and the mixture was stirred for 2 h at that temperature. Methanol (1 mL) was added and the mixture was poured into a stirring mixture of ethyl acetate (20 mL) and 10% aq. potassium sodium tartrate (20 mL) and stirred for 1 h at RT. The organic layer was washed with brine (20 mL), dried (Na2SO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) yielded 185 mg (59%) of the title compound. MS 202 (M+H)+.
[0303] Step D: (2E)-3-[6-(1H-pyrazol-1-yl)-3-pyridinyl]-2-propenal
[0304] A mixture of the compound from step C (185 mg, 0.92 mmol) and MnO2 (1.60 g, 18.40 mmol) in acetone (15 mL) was heated to reflux for 1 h. The cooled reaction mixture was filtered through Celite and the filtrate was concentrated. Purification by chromatography (SiO2, 2:1 hexane/ethyl acetate) yielded 78 mg (43%) of the title compound. MS 200 (M+H)+.
(2E)-3-(6-Bromo-3-pyridinyl)-2-propenal
[0305] 2-Propylmagnesium chloride (2.0 M in THF, 5.00 mL 10.00 mmol) was added to a solution of 2,5-dibromopyridine (2.37 g, 10.00 mmol) in THF (5.0 mL) at RT. The resulting brown suspension was stirred for 1 h and then cooled to 0° C. 3-Dimethylaminoacrolein (95%, 1.30 mL, 12.36 mmol) was added and the mixture was warmed to RT and stirred for 2 h. 2 N HCl was added and after 5 min the mixture was cooled to 0° C. The precipitated solids were removed by filtration and partitioned between ethyl acetate (75 mL) and 10% NaOH (25 mL). The ethyl acetate layer was washed with brine (25 mL), dried (MgSO4), and concentrated. Recrystallization from ethyl acetate provided 550 mg (26%) of the title compound as shiny brown flakes. MS 211 (M+H)+.
(2E)-3-[4-(3-Pyridinyl)phenyl]-2-propenal
[0306] 2M aq. Na2CO3 (1 mL) and a solution of 3-pyridinylboronic acid (148 mg, 1.20 mmol) in methanol (1 mL) were added to a solution of 4-bromocinnamaldehyde (211 mg, 1.00 mmol, prepared as described in Tetrahedron 1998, 54, 10761) and tetrakis(triphenylphosphine)palladium(0) (35 mg, 0.030 mmol) in toluene (2 mL) and the mixture was heated to reflux for 36 h. The cooled reaction mixture was diluted with dichloromethane, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) yielded the title compound. MS 210 (M+H)+.
(2E)-3-[2-Fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenal
[0307] A mixture of 2-fluoro-4-(1H-pyrazol-1-yl)benzaldehyde (1.06 g, 5.57 mmol, prepared as described in Reference Example 8), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (3.60 g, 8.39 mmol), and TDA-1 (1.80 mL, 5.63 mmol) in dichloromethane (30 mL) and sat. aq. K2CO3 (30 mL) was heated to reflux for 20 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×15 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried (Na2SO4), and concentrated. THF (15 mL) and 10% HCl (15 mL) were added and the mixture was stirred for 1 h at rt. The mixture was cooled to 0° C., the precipitated solids were removed by filtration, washed with water and dried in vacuo. Recrystallization from IPA provided 0.84 g (70%) of the title compound as tan needles. MS 217 (M+H)+.
(2E)-3-[3-Methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propenal
[0308] A mixture of 3-methoxy-4-(1H-pyrazol-1-yl)benzaldehyde (1.52 g, 7.52 mmol, prepared as described in Reference Example 5), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (4.85 g, 11.30 mmol), and TDA-1 (2.40 mL, 7.50 mmol) in dichloromethane (35 mL) and sat. aq. K2CO3 (35 mL) was heated to reflux for 18 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×20 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. THF (20 mL) and 10% HCl (20 mL) were added and the mixture was stirred for 1 h at rt. The reaction mixture was cooled to 0° C., made basic with 10% NaOH, and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 2:1 hexane/ethyl acetate) provided 1.47 g (86%) of the title compound as a yellow solid. MS 229 (M+H)+.
(2E)-3-(6-Quinoxalinyl)-2-propenal
[0309] A mixture of 6-quinoxalinecarboxaldehyde (0.62 g, 3.92 mmol, prepared as described in Photochem. Photobiol. 1991, 54, 7), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (2.50 g, 5.82 mmol), and TDA-1 (1.20 mL, 3.75 mmol) in dichloromethane (20 mL) and sat. aq. K2CO3 (20 mL) was heated to reflux for 4 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×20 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (Na2SO4), and concentrated. THF (10 mL) and 10% HCl (10 mL) were added and the mixture was stirred for 1 h at rt. The mixture was cooled to 0° C., the precipitated solids were removed by filtration, washed with water and dried in vacuo to give 0.47 g (65%) of the title compound as a tan solid. MS 185 (M+H)+.
(2E)-3-(6-Quinolinyl)-2-propenal
[0310] A mixture of 6-quinolinecarboxaldehyde (1.58 g, 10.05 mmol, prepared as described in U.S. Pat. No. 5,559,256), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (6.45 g, 15.02 mmol), and TDA-1 (3.20 mL, 10.00 mmol) in dichloromethane (50 mL) and sat. aq. K2CO3 (50 mL) was heated to reflux for 5 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. THF (25 mL) and 10% HCl (25 mL) were added and the mixture was stirred for 1 h at rt. The reaction mixture was cooled to 0° C., made basic with 10% NaOH, and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. Chromatography (SiO2, 1:1 hexane/ethyl acetate+0.2% triethylamine) provided a yellow solid that was partioned between ethyl acetate (20 mL) and 10% HCl (15 mL). The aqueous layer was washed with ethyl acetate (2×20 mL) and then made basic with 10% NaOH. The precipitated solids were collected by filtration, washed with water, and dried in vacuo to give 1.20 g (65%) of the title compound as a light yellow solid. MS 184 (M+H)+.
(2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-propenal
[0311] A mixture of 4-(2-pyrimidinyl)-benzaldehyde (1.83 g, 9.94 mmol, prepared as described in WO 9828264), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (6.45 g, 15.02 mmol), and TDA-1 (3.20 mL, 10.00 mmol) in dichloromethane (50 mL) and sat. aq. K2CO3 (50 mL) was heated to reflux for 20 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. THF (25 mL) and 10% HCl (25 mL) were added and the mixture was stirred for 1 h at rt. The mixture was cooled to 0° C., the precipitated solids were removed by filtration, washed with water and air-dried. Recrystallization from 2-propanol provided 1.20 g (57%) of the title compound as a light yellow solid. MS 211 (M+H)+.
(2E)-3-[4-(1H-Pyrazol-1-yl)phenyl]-2-propenal
[0312] A mixture of 4-(1H-pyrazol-1-yl)-benzaldehyde (prepared as described in J. Med Chem. 1998, 41, 2390) (1.65 g, 9.58 mmol), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (6.45 g, 15.02 mmol), and TDA-1 (3.20 mL, 10.00 mmol) in dichloromethane (50 mL) and sat. aq. K2CO3 (50 mL) was heated to reflux for 20 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. THF (25 mL) and 10% HCl (25 mL) were added and the mixture was stirred for 1 h at rt. The reaction mixture was cooled to 0° C., made basic with 10% NaOH, and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 3:1 hexane/ethyl acetate) provided 1.69 g (89%) of the title compound as a yellow solid. MS 199 (M+H)+.
(2E)-3-[6-(1H-1,2,4-Triazol-1-yl)-2-pyridinyl]-2-propenal and (2E,4E)-5-[6-(1H-1,2,4-triazol-1-yl)-2-pyridinyl]-2,4-pentadienal
[0313] Step A:
[0314] A solution of 1,2,4-triazole (1.55 g, 22.35 mmol) in DMF (7 mL) was added to sodium hydride (60% in oil, 0.90 g, 22.50 mmol) in DMF (7 mL) and the resulting mixture was stirred 2 h at RT. 2-(1,3-Dioxolan-2-yl)-6-fluoropyridine (1.26 g, 7.45 mmol, prepared as described in J. Med. Chem. 1998, 41, 5070) was added dropwise and the resulting mixture heated to 80° C. for 3 h. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried (MgSO4), and concentrated. The residue obtained was dissolved in a mixture of formic acid (12 mL) and water (3 mL), CuSO45H2O (0.19 g, 0.76 mmol) was added, and the mixture was heated to 65° C. for 5 h. The reaction mixture was concentrated, diluted with 10% aq. NaOH to pH>10, and extracted with ethyl acetate. The combined organic extracts were washed with dilute aq. ammonium hydroxide and brine, dried (MgSO4), and concentrated. The material was used in the next step without further purification.
[0315] Step B:
[0316] A mixture of the product from step A (0.80 g, 4.59 mmol), (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide (3.00 g, 6.99 mmol), and TDA-1 (2.00 mL, 6.25 mmol) in dichloromethane (?0 mL) and sat. aq. K2CO3 (20 mL) was heated to reflux for 20 h. The layers were separated and the aqueous layer was extracted with dichloromethane (2×20 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried (Na2SO4), and concentrated. THF (10 mL) and 10% HCl (10 mL) were added and the mixture was stirred for 1 h at rt. The reaction mixture was cooled to 0° C., made basic with 10% NaOH, and extracted with ethyl acetate (3×15 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 2:1 hexane/ethyl acetate) provided 0.40 g (43%) of an inseparable mixture of 3-[6-(1H-1,2,4-triazol-1-yl)-2-pyridinyl]-2-propenal [MS 201 (M+H)+] and 5-[6-(1H-1,2,4-triazol-1-yl)-2-pyridinyl]-2,4-pentadienal [MS 227 (M+H)+].
(2E)-3-[4-(2-Pyridinyl)phenyl]-2-propenal
[0317] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(2-pyridinyl)-benzaldehyde for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 210 (M+H)+.
(2E)-3-[4-(4-Pyridinyl)phenyl]-2-propenal
[0318] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4-pyridinyl)-benzaldehyde (prepared as described in WO 9828264) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 210 (M+H)+.
(2E)-3-[4-(5-Pyrimidinyl)phenyl]-2-propenal
[0319] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(5-pyrimidinyl)-benzaldehyde (prepared as described in WO 9828264) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 211 (M+H)+.
(2E)-3-[4-(1H-1,2,4-Triazol-1-yl)phenyl]-2-propenal
[0320] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1H-1,2,4-triazol-1-yl)-benzaldehyde (prepared as described in J. Med Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-[4-(1H-1,2,3-Triazol-1-yl)phenyl]-2-propenal
[0321] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1H-1,2,3-triazol-1-yl)-benzaldehyde (prepared as described in J. Med Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-[4-(1H-Imidazol-1-yl)phenyl]-2-propenal
[0322] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1H-imidazol-1-yl)-benzaldehyde (prepared as described in J. Med Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 199 (M+H)+.
(2E)-3-(4-Quinolinyl)-2-propenal
[0323] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-quinolinecarboxaldehyde for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 184 (M+H)+.
(2E)-3-[3-(2-Pyridinyl)phenyl]-2-propenal
[0324] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-(2-pyridinyl)benzaldehyde (prepared as described in Reference Example 11) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 210 (M+H)+.
(2E)-3-[3-(2-Pyrimidinyl)phenyl]-2-propenal
[0325] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-(2-pyrimidinyl)benzaldehyde (prepared as described in Reference Example 12) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 211 (M+H)+.
(2E)-3-[4-(4-Methyl-2-pyrimidinyl)phenyl]-2-propenal
[0326] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4-methyl-2-pyrimidinyl)benzaldehyde (prepared as described in Reference Example 14) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 225 (M+H)+.
(2E)-3-[3-(1H-Pyrazol-1-yl)phenyl]-2-propenal
[0327] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-(1H-pyrazol-1-yl)-benzaldehyde (prepared as described in Reference Example 3) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 199 (M+H)+.
(2E)-3-[4-(1-Methyl-1H-pyrazol-3-yl)phenyl]-2-propenal
[0328] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1-methyl-1H-pyrazol-3-yl)benzaldehyde (prepared as described in J. Med. Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 213 (M+H)+.
(2E)-3-[4-(1-Methyl-1H-pyrazol-5-yl)phenyl]-2-propenal
[0329] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1-methyl-1H-pyrazol-5-yl)benzaldehyde (prepared as described in J. Med. Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 213 (M+H)+.
(2E)-3-[4-(5-Nitro-2-pyridinyl)phenyl]-2-propenal
[0330] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(5-nitro-2-pyridinyl)benzaldehyde (prepared as described in Reference Example 19) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 255 (M+H)+.
(2E)-3-(8-Quinolinyl)-2-propenal
[0331] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 8-quinolinecarboxaldehyde (prepared as described in J. Am. Chem. Soc. 1997, 119, 8891) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 184 (M+H)+.
(2E)-3-(7-Quinolinyl)-2-propenal
[0332] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 7-quinolinecarboxaldehyde (prepared as described in J. Med. Chem. 1993, 36, 3308) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 184 (M+H)+.
(2E)-3-[6-(1H-Pyrazol-1-yl)-2-pyridinyl]-2-propenal
[0333] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 6-(1H-pyrazol-1-yl)-2-pyridinecarboxaldehyde (prepared as described in J. Med. Chem. 1998, 41, 5070) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-(4-Isoquinolinyl)-2-propenal
[0334] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-isoquinolinecarboxaldehyde for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 184 (M+H)+.
(2E)-3-[3-Fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenal
[0335] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-fluoro-4-(1H-pyrazol-1-yl)benzaldehyde (prepared as described in Reference Example 6) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-[3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenal
[0336] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-fluoro-4-(1H-1,2,4-triazol-1-yl)benzaldehyde (prepared as described in Reference Example 7) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 218 (M+H)+.
(2E)-3-[5-(2-Pyridinyl)-2-thienyl]-2-propenal
[0337] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 5-(2-pyridinyl)-2-thiophenecarboxaldehyde (prepared as described in J. Chem Soc., Perkin Trans. 2 1998, 437) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 216 (M+H)+.
(2E,4E)-5-[4-(1H-Pyrazol-1-yl)phenyl]-2,4-pentadienal
[0338] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenal (prepared as described in Reference Example 30) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 225 (M+H)+.
(2E)-3-(1-Phenyl-1H-pyrazol-4-yl)-2-propenal
[0339] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 1-phenyl-1H-pyrazol-4-ylcarboxaldehyde (prepared as described in Synth. Commun. 1998, 28, 1299) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 199 (M+H)+.
(2E)-3-[4-(4-Methyl-1H-pyrazol-1-yl)phenyl]-2-propenal
[0340] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4-methyl-1H-pyrazol-1-yl)-benzaldehyde (prepared as described in Reference Example 4) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 213 (M+H)+.
(2E)-3-[4-(4-Methoxy-2-pyrimidinyl)phenyl]-2-propenal
[0341] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4-methoxy-2-pyrimidinyl)benzaldehyde (prepared as described in Reference Example 13) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 241 (M+H)+.
(2E)-3-(4-Pyrazinylphenyl)-2-propenal
[0342] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-pyrazinylbenzaldehyde (prepared as described in Reference Example 17) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 211 (M+H)+.
(2E)-3-[4-(4-Pyrimidinyl)phenyl]-2-propenal
[0343] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4-pyrimidinyl)benzaldehyde (prepared as described in Reference Example 18) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 211 (M+H)+.
(2E)-3-[4-(2-Pyrimidinyloxy)phenyl]-2-propenal
[0344] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(2-pyrimidinyloxy)benzaldehyde (prepared as described in Reference Example 9) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 227 (M+H)+.
(2E)-3-[2-Fluoro-4-(2-pyrimidinyl)phenyl]-2-propenal
[0345] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 2-fluoro-4-(2-pyrimidinyl)benzaldehyde (prepared as described in Reference Example 15) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 229 (M+H)+.
(2E)-3-[4-(3-Pyridazinyl)phenyl]-2-propenal
[0346] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(3-pyridazinyl)benzaldehyde (prepared as described in Reference Example 16) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 211 (M+H)+.
(2E)-3-[1-(2-Pyrimidinyl)-1H-imidazol-4-yl]-2-propenal
[0347] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 1-(2-pyrimidinyl)-1H-imidazole-4-carboxaldehyde (prepared as described in Reference Example 10) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 201 (M+H)+.
[[4-(2-Pyrimidinyl)phenyl]methoxy]acetaldehyde
[0348] Step A: 4-(2-pyrimidinyl)benzenemethanol
[0349] The title compound was prepared by a procedure analogous to Reference Example 12 by substituting 4-(hydroxymethyl)phenylboronic acid for the 3-formylphenylboronic acid of Reference Example 12. MS 187 (M+H)+.
[0350] Step B: [[4-(2-pyrimidinyl)phenyl]methoxy]acetaldehyde
[0351] A solution of the product from step A (559 mg, 3.00 mmol) in DMF (4 mL) was added dropwise to a suspension of sodium hydride (60% in mineral oil, 144 mg, 3.60 mmol) at 0° C. The solution was stirred for 30 min at 0° C., bromoacetaldehyde diethyl acetal (0.55 mL, 3.66 mmol) and tetrabutylammonium iodide (111 mg, 0.30 mmol) were added, and the resulting mixture was stirred at 70° C. for 12 h. Additional sodium hydride (60% in mineral oil, 70 mg, 1.75 mmol) and bromoacetaldehyde diethyl acetal (0.55 mL, 3.66 mmol) were added and heating at 70° C. was continued for 12 h. The reaction mixture was concentrated, the residue was diluted with water and extracted with ethyl acetate, the combined organic layers were dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) gave material which was taken up in ethanol (2 mL) and 10% aq. HCl (10 mL) and stirred for 12 h. The reaction mixture was made basic with aq. NaOH, extracted with ethyl acetate, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) provided 80 mg (12%) of the title compound. MS 229 (M+H)+.
4-(2-Pyrimidinyl)benzeneacetaldehyde
[0352] Sodium hexamethyldisilazide (1.0M in THF, 2.65 mL, 2.65 mmol) was added to a suspension of methoxymethyltriphenylphosphonium chloride (0.93 g, 2.71 mmol) in THF (13 mL) at 0° C., and the red-orange mixture was stirred for 15 min at 0° C. A solution of 4-(2-pyrimidinyl)benzaldehyde (250 mg, 1.36 mmol, prepared as described in WO 9828264) in THF (5 mL) was added, and stirring was continued at 0° C. for 1 h. 10% aq. HCl (13 mL) was added and the mixture was heated to 50° C. for 1 h. The reaction mixture was then cooled to 0° C. and solid Na2CO3 was added cautiously until the solution was basic. The mixture was extracted with ethyl acetate (2×25 mL) and the combined organic extracts were washed with brine (2×25 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 2:1 hexane/ethyl acetate) yielded 141 mg (52%) of the title compound. MS 199 (M+H)+.
(2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-propen-1-ol
[0353] DIBAL (1.0 M in THF, 18.0 mL) was added over 10 min to a −78° C. suspension of (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal (2.50 g, 11.89 mmol, prepared as described in Reference Example 29) in dichloromethane (100 mL). The resulting suspension was stirred for 30 min at −78° C., methanol (2 mL) was added cautiously, and stirring was continued for 5 min at −78° C. The mixture was poured into a mixture of 10% aq. citric acid (300 mL) and dichloromethane (200 mL) and allowed to stir for 1 h. The organic layer was separated, washed with sat. aq. NaHCO3 (200 mL) and brine (200 mL), dried (MgSO4), filtered through Celite, and concentrated. The resulting material was triturated with ether and dried in vacuo to provide 2.08 g (82%) of the title compound. MS 213 (M+H)+.
(2E)-3-[4-(3-Pyridazinyl)phenyl]-2-propen-1-ol
[0354] Sodium borohydride (90 mg, 2.38 mmol) was added to a suspension of (2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenal (400 mg, 1.90 mmol, prepared as described in Reference Example 61) in ethanol (5 mL) maintained in a room temperature water bath. After 20 min, the reaction was quenched with water (10 mL), allowed to stir for 10 min, and then concentrated to remove the ethanol. The solids were removed by filtration, washed with water, and dried in vacuo to provide 360 mg (89%) of the title compound. MS 213 (M+H)+.
2-Butoxy-3,4-dihydro-4-phenyl-2H-pyran
[0355] A neat mixture of cinnamaldehyde (0.66 g, 4.99 mmol), butyl vinyl ether (1.30 mL, 10.05 mmol), and Yb(fod)3 (265 mg, 0.25 mmol) was stirred at rt for 72 h and then heated to 50° C. for 18 h. Purification by chromatography (SiO2, 95:5 hexane/ethyl acetate) yielded 0.89 g (77%) of the title compound. MS 233 (M+H)+.
2-Formyl-4,4-dimethoxybutanenitrile
[0356] Lithium diisopropylamide mono(tetrahydrofuran) (1.5 M in cyclohexane, 22.0 mL, 33.00 mmol) was added to THF (100 mL) at −30° C. and the resulting solution was stirred for 10 min before 3-cyanopropionaldehyde dimethyl acetal (3.90 mL, 29.90 mmol) was added dropwise over 5 min. After 15 min, methyl formate (2.80 mmol, 45.42 mmol) was added and the resulting solution was stirred at −20° C. to −15° C. for 2 h. The reaction mixture was quenched with water (100 mL) and washed with ether (2×50 mL, discarded). The aqueous layer was acidified with 10% HCl and extracted with ether (3×50 mL). The combined ether extracts were washed with brine (3×50 mL), dried (MgSO4), and concentrated. The residue was dissolved in dichloromethane and concentrated to remove traces of THF and provide 2.28 g (49%) of the title compound as a pale yellow oil.
4-(5-Fluoro-2-pyrimidinyl)benzaldehyde
[0357] A suspension of 2M aq. Na2CO3 (7 mL) and 4-formylphenylboronic acid (1.35 g, 9.0 mmol) in ethanol (4 mL) was added to a solution of 2-chloro-5-fluoropyrimidine (922 mg, 7.0 mmol, prepared as described in Org. Prep. Proc. Int. 1995, 27, 600), and [1,4-bis(diphenylphosphino)butane]palladium(II) dichloride (0.209 g, 0.35 mmol) in toluene (15 mL). The reaction mixture was heated to reflux for 6 h, cooled to room temperature, diluted with ethyl acetate, washed with sat. aq. NaHCO3 and brine, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 20:1 hexanes/ethyl acetate) gave 732 mg (52%) of the title compound. MS 203 (M+H)+.
4-(5-Ethyl-2-pyrimidinyl)benzaldehyde
[0358] A suspension of saturated aq. Na2CO3 (10 mL) and 4-formylphenylboronic acid (1.80 g, 12.0 mmol) in ethanol (5 mL) was added to a solution of 2-chloro-5-ethylpyrimidine (1.20 mL, 10.0 mmol) and [1,4-bis(diphenylphosphino)butane]palladium(II) dichloride (0.300 g, 0.5 mmol) in toluene (20 mL). The reaction mixture was heated to reflux for 5 h, cooled to room temperature, diluted with ethyl acetate, washed with sat. aq. NaHCO3 and brine, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 3:1 hexanes/ethyl acetate) gave 1.62 g (76%) of the title compound. MS 213 (M+H)+.
2-Phenyl-5-pyrimidinecarboxyaldehyde
[0359] To a solution of 5-bromo-2-phenylpyrimidine (850 mg, 3.65 mmol, prepared as described in Org. Lett. 2002, 4, 513) in THF (15 mL) at −100° C. was added dropwise n-BuLi (1.60 mL, 4.00 mmol, 2.5 M solution in hexanes). The reaction mixture was stirred at −100° C. for 15 min, and methyl formate (0.26 mL, 4.20 mmol) was added dropwise. The reaction mixture was stirred for an additional 15 min at −100° C., carefully quenched with a 1 M HCl solution in diethyl ether (4.50 mL, 4.50 mmol), warmed to room temperature, and concentrated in vacuo. The crude reaction mixture was partitioned between dichloromethane and sat. aq. NaHCO3, the organic layer dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 4:1 hexanes/ethyl acetate) gave 226 mg (34%) of the title compound. MS 185 (M+H)+.
4-(2-Thiazolyl)benzaldehyde
[0360] A mixture of NaHCO3 (3.83 g, 45.6 mmol) and 4-formylphenylboronic acid (2.69 g, 18.0 mmol) in water (60 mL) was added to a solution of 2-bromothiazole (2.50 g, 15.2 mmol) and tetrakis(triphenylphosphine)palladium(0) (500 mg, 0.43 mmol) in DME (60 mL). The reaction mixture was heated to reflux for 18 h, cooled to room temperature, diluted with ethyl acetate, washed with sat. aq. NaHCO3 and brine, dried with Na2SO4, and concentrated in vacuo. Two consecutive recrystallizations from hexanes/ethyl acetate yielded 998 mg (35%) of the title compound. MS 190 (M+H)+.
4-(2-Oxazolyl)benzaldehyde
[0361] Step A: 2-(4-Methylphenyl)oxazole
[0362] Polyphosphoric acid (20 g), vinylene carbonate (5.73 mL, 90.0 mmol) and p-toluamide (12.2 g, 90.0 mmol) were combined and heated at 170° C. for 2 h. The reaction mixture was allowed to cool to ˜80° C., water (˜100 mL) was carefully added, and stirred for ˜10 min. This mixture was extracted three times with ethyl acetate, combined organic extracts were dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 97:3 hexanes/acetone) gave 6.41 g (45%) of the title compound. MS 160 (M+H)+.
[0363] Step B: 4-(2-Oxazolyl)benzaldehyde
[0364] To 2-(4-methylphenyl)oxazole (6.41 g, 40.3 mmol) and N-bromosuccinimide (14.7 g, 82.6 mmol) in carbon tetrachloride (300 mL) was added 2,2′-azobisisobutyronitrile (500 mg, 3.1 mmol) and the reaction mixture was heated at 100° C. for 12 h. The reaction mixture was cooled to 0° C., filtered through a fritted funnel, and concentrated in vacuo. To this crude reaction mixture was added 95% ethanol (300 mL) and silver nitrate (15.1 g, 88.8 mmol), and the reaction mixture was refluxed for 4 h, cooled to room temperature, filtered through a fritted funnel, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 10:1 hexanes/ethyl acetate) gave 880 mg (13%, 2 steps) of the title compound. MS 174 (M+H)+.
4-(3-isoxazolyl)benzaldehyde
[0365] The title compound is prepared by a procedure analogous to Step B of Reference Example 73 by substituting 3-(4-methylphenyl)isoxazole (prepared as described in J. Organomet. Chem. 1966, 6, 598) for the 2-(4-methylphenyl)oxazole of Step B of Reference Example 73. MS 174 (M+H)+.
4-(1,2,4-Oxadiazol-3-yl)benzaldehyde
[0366] The title compound is prepared by a procedure analogous to Step B of Reference Example 73 by substituting 3-(4-methylphenyl)-1,2,4-oxadiazole (prepared as described in Bull. Chem. Soc. Jpn. 1978, 51,1484) for the 2-(4-methylphenyl)oxazole of Step B of Reference Example 73. MS 175 (M+H)+.
4-(1,2,4-Oxadiazol-5-yl)benzaldehyde
[0367] Step A: 5-(4-methylphenyl)-1,2,4-oxadiazole
[0368] To a solution of 3.54 g (0.0510 mol) of hydroxylamine hydrochloride in a mixture of 10.2 mL (0.0510 mol) of 5 N NaOH, dioxane (50 mL), and 70% aq. acetic acid (100 mL), is added 6.79 g (0.0424) of N-[(dimethylamino)methylene]-4-methylbenzamide (prepared as described in J. Chem. Soc. Perkin. Trans. 1 1989, 589). The mixture is stirred at 90° C. for 1.5 h and the product is isolated from the cooled reaction mixture. MS 161 (M+H)+.
[0369] Step B: 4-(1,2,4-Oxadiazol-5-yl)benzaldehyde
[0370] The title compound is prepared by a procedure analogous to Step B of Reference Example 73 by substituting the 5-(4-methylphenyl)-1,2,4-oxadiazole from Step A above for the 2-(4-methylphenyl)oxazole of Step B of Reference Example 73. MS 175 (M+H)+.
4-(1,3,4-Oxadiazol-2-yl)benzaldehyde
[0371] Step A: Dimethoxymethyl Benzoic Acid Hydrazide
[0372] Triethylamine (11.8 mL, 84.6 mmol) was added to a solution of 4-(dimethoxymethyl)benzoic acid (11.0 g, 56.4 mmol, prepared as described in Tetrahedron 1998, 54,15679-15690) in dichloromethane (120 mL) at room temperature. The reaction mixture was cooled to −40° C., ethyl chloroformate (6.7 mL, 70.0 mmol) was added dropwise, and stirring continued at −40° C. for 30 min. Hydrazine (8.85 mL, 282 mmol) was added and the reaction mixture was warmed to room temperature and stirred for an additional 1 h. The reaction mixture was diluted with dichloromethane, washed with water, dried with Na2SO4, and concentrated in vacuo to give 9.06 g (77%) of the title compound, which was used in the next step without further purification. MS 211 (M+H)+.
[0373] Step B: 2-[4-(Dimethoxymethyl)phenyl]-1,3,4-oxadiazole
[0374] Methyl orthoformate (20 mL) was added to the product from step A (9.06 g, 43.1 mmol), and this mixture was heated under Dean-stark conditions for 48 h. Excess methyl orthoformate was removed in vacuo, and the residue purified by medium pressure liquid chromatography (SiO2, 3:1 hexanes/ethyl acetate) to give 5.26 g (56%) of the title compound. MS 221 (M+H)+.
[0375] Step C: 4-(1,3,4-Oxadiazol-2-yl)benzaldehyde
[0376] To the product from step B (175 mg, 0.80 mmol) in a 1:1 mixture of tetrahydrofuran/water (2 mL) at room temperature was added p-toluenesulfonic acid (50 mg, 0.3 mmol). The reaction mixture was stirred at room temperature for 1 h, and partitioned between dichloromethane and sat. aq. NaHCO3. The organic layer was dried with Na2SO4, and concentrated in vacuo to give 100 mg (72%) of the title product, which was used without further purification. MS 175 (M+H)+.
(2E)-3-[4-(1,3,4-Oxadiazol-2-yl)phenyl]-2-propenal
[0377] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(1,3,4-oxadiazol-2-yl)benzaldehyde (prepared as described in Reference Example 77) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 201 (M+H)+.
(2E)-3-[4-(5-oxazolyl)phenyl]-2-propenal
[0378] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(5-oxazolyl)benzaldehyde (prepared as described in J. Med. Chem. 1998, 41, 2390) for the 4-(11H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-[4-(3-isoxazolyl)phenyl]-2-propenal
[0379] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-(3-isoxazolyl)benzaldehyde (prepared as described in Reference Example 74) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-[4-(1,2,4-Oxadiazol-3-yl)phenyl]-2-propenal
[0380] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-(1,2,4-oxadiazol-3-yl)benzaldehyde (prepared as described in Reference Example 75) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 201 (M+H)+.
(2E)-3-[4-(1,2,4-Oxadiazol-5-yl)phenyl]-2-propenal
[0381] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-(1,2,4-oxadiazol-5-yl)benzaldehyde (prepared as described in Reference Example 76) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 201 (M+H)+.
(2E)-3-[4-(2-thienyl)phenyl]-2-propenal
[0382] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(2-thienyl)benzaldehyde (prepared as described in J. Med. Chem. 1998, 41, 2390) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 215 (M+H)+.
(2E)-3-(1-methyl-1H-benzimidazol-2-yl)-2-propenal
[0383] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 1-methyl-1H-benzimidazole-2-carboxaldehyde for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 187 (M+H)+.
(2E)-3-[2,2′-bithiophen]-5-yl-2-propenal
[0384] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting [2,2′-bithiophene]-5-carboxaldehyde for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 221 (M+H)+.
5-(2-pyrimidinyl)-2-thiophenecarboxaldehyde
[0385] A mixture of Na2CO3 (3.16 g) and 5-formyl-2-thiopheneboronic acid (2.4 g, 15.1 mmol) in water (15 mL) were added to a solution of 2-bromopyrimidine (2 g, 12.58 mmol) and tetrakis(triphenylphosphine)palladium(0) (480 mg, 0.46 mmol) in DME (30 mL) and the mixture was heated to reflux for 24 hr. The cooled reaction mixture was diluted with dichloromethane, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) yielded 620 mg (26%) of the title compound. MS 191 (M+H)+.
5-pyrazinyl-2-thiophenecarboxaldehyde
[0386] The title compound was prepared by a procedure analogous to Reference Example 86 by substituting 2-chloropyrazine for the 2-bromopyrimidine of Reference Example 86. MS 191 (M+H)+.
(2E)-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenal
[0387] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 5-(2-pyrimidinyl)-2-thiophenecarboxaldehyde (prepared as described in Reference Example 86) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-(5-pyrazinyl-2-thienyl)-2-propenal
[0388] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 5-pyrazinyl-2-thiophenecarboxaldehyde (prepared as described in Reference Example 87) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
4-(2-pyrimidinyl)-2-thiophenecarboxaldehyde
[0389] A mixture of Na2CO3 (3.16 g) and 5-formyl-3-thiopheneboronic acid (2.4 g, 15.1 mmol) in water (15 mL) are added to a solution of 2-bromopyrimidine (2 g, 12.58 mmol) and tetrakis(triphenylphosphine)palladium(0) (480 mg, 0.46 mmol) in DME (30 mL) and the mixture is heated to reflux for 24 hr. The cooled reaction mixture is diluted with dichloromethane, washed with sat. aq. NaHCO3 and brine, dried (MgSO4), and concentrated. Purification by chromatography yields the title compound. MS 191 (M+H)+.
4-(2-pyridinyl)-2-thiophenecarboxaldehyde
[0390] The title compound is prepared by a procedure analogous to Reference Example 90 by substituting 2-bromopyridine for the 2-bromopyrimidine of Reference Example 90. MS 190 (M+H)+.
4-pyrazinyl-2-thiophenecarboxaldehyde
[0391] The title compound is prepared by a procedure analogous to Reference Example 90 by substituting chloropyrazine for the 2-bromopyrimidine of Reference Example 90. MS 191 (M+H)+.
5-(2-pyrimidinyl)-3-thiophenecarboxaldehyde
[0392] The title compound is prepared by a procedure analogous to Reference Example 15 by substituting 5-bromo-3-thiophenecarboxaldehyde (prepared as described in Chem. Pharm. Bull. 1999, 47,1393) for the 4-bromo-2-fluorobenzaldehyde of Reference Example 15. MS 191 (M+H)+.
5-(2-pyridinyl)-3-thiophenecarboxaldehyde
[0393] The title compound is prepared by a procedure analogous to Reference Example 15 by substituting 5-bromo-3-thiophenecarboxaldehyde (prepared as described in Chem. Pharm. Bull. 1999, 47,1393) and 2-bromopyridine, respectively, for the 4-bromo-2-fluorobenzaldehyde and 2-bromopyrimidine of Reference Example 15. MS 190 (M+H)+.
5-pyrazinyl-3-thiophenecarboxaldehyde
[0394] The title compound is prepared by a procedure analogous to Reference Example 15 by substituting 5-bromo-3-thiophenecarboxaldehyde (prepared as described in Chem. Pharm. Bull. 1999, 47,1393) and chloropyrazine, respectively, for the 4-bromo-2-fluorobenzaldehyde and 2-bromopyrimidine of Reference Example 15. MS 191 (M+H)+.
(2E)-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenal
[0395] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-(2-pyrimidinyl)-2-thiophenecarboxaldehyde (prepared as described in Reference Example 90) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-[4-(2-pyridinyl)-2-thienyl]-2-propenal
[0396] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-(2-pyridinyl)-2-thiophenecarboxaldehyde (prepared as described in Reference Example 91) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 216 (M+H)+.
(2E)-3-(4-pyrazinyl-2-thienyl)-2-propenal
[0397] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 4-pyrazinyl-2-thiophenecarboxaldehyde (prepared as described in Reference Example 92) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenal
[0398] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 5-(2-pyrimidinyl)-3-thiophenecarboxaldehyde (prepared as described in Reference Example 93) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-[5-(2-pyridinyl)-3-thienyl]-2-propenal
[0399] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 5-(2-pyridinyl)-3-thiophenecarboxaldehyde (prepared as described in Reference Example 94) or the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 216 (M+H)+.
(2E)-3-(5-pyrazinyl-3-thienyl)-2-propenal
[0400] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 5-pyrazinyl-3-thiophenecarboxaldehyde (prepared as described in Reference Example 95) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 217 (M+H)+.
(2E)-3-(2-quinoxalinyl)-2-propenal
[0401] The title compound is prepared by a procedure analogous to Reference Example 30 by substituting 2-quinoxalinecarboxaldehyde (prepared as described in J. Chem. Soc. 1956, 2052) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 185 (M+H)+.
(2E)-3-[4-(4H-1,2,4-Triazol-4-yl)phenyl]-2-propenal
[0402] The title compound was prepared by a procedure analogous to Reference Example 30 by substituting 4-(4H-1,2,4-triazol-4-yl)-benzaldehyde (prepared as described in WO 98/03476) for the 4-(1H-pyrazol-1-yl)-benzaldehyde of Reference Example 30. MS 200 (M+H)+.
(2E)-3-[4-(2-pyridinyl)phenyl]-2-propen-1-ol
[0403] (2E)-3-[4-(2-pyridinyl)phenyl]-2-propenal (500 mg, 2.4 mmol, prepared as described in Reference Example 32) was dissolved in THF (10 mL) and methanol (10 mL) at 0° C. Sodium borohydride (109 mg, 2.9 mmol) was added and the mixture was stirred at 0° C. for 30 min. The reaction mixture was concentrated. Water (10 mL) was added and the mixture was extracted with ethyl acetate (3×15 mL). The organic layer was collected, dried and concentrated. MS 212 (M+H)+.
REFERENCE EXAMPLES 105-126
[0404] The compounds of Reference Examples 105-126, listed in the table below, are prepared by the method of Reference Example 104 by substituting the appropriate aldehyde for the (2E)-3-[4-(2-pyridinyl)phenyl]-2-propenal of Reference Example 104.
7|
|
MS
Ref. Ex.Compound[(M + H)+]
|
105(2E)-3-[4-(5-oxazolyl)phenyl]-2-propen-1-ol202
106(2E)-3-[4-(2-thienyl)phenyl]-2-propen-1-ol217
107(2E)-3-(1-methyl-1H-benzimidazol-2-yl)-2-propen-1-ol189
108(2E)-3-[2,2′-bithiophen]-5-yl-2-propen-1-ol223
109(2E)-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol219
110(2E)-3-(5-pyrazinyl-2-thienyl)-2-propen-1-ol219
111(2E)-3-[5-(2-pyridinyl)-2-thienyl]-2-propen-1-ol218
112(2E)-3-[4-(2-thiazolyl)phenyl]-2-propen-1-ol218
113(2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-propen-1-ol201
114(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propen-1-ol203
115(2E)-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propen-1-ol203
116(2E)-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propen-1-ol215
117(2E)-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propen-1-ol215
118(2E)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propen-1-ol220
119(2E)-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propen-1-ol202
120(2E)-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propen-1-ol202
121(2E)-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propen-1-ol202
122(2E)-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propen-1-ol203
123(2E)-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propen-1-ol203
124(2E)-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propen-1-ol203
125(2E)-3-[4-(3-isoxazolyl)phenyl]-2-propen-1-ol202
1264-pyrazinylbenzenemethanol187
|
REFERENCE EXAMPLES 127-154
[0405] The compounds of Reference Examples 127-154, listed in the table below, are prepared by the method of Reference Example 65 by substituting the appropriate aldehyde for the (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenal of Reference Example 65.
8|
|
Ref. Ex.CompoundMS [(M + H)+]
|
127(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propen-1-ol213
128(2E)-3-[4-(5-pyrimidinyl)phenyl]-2-propen-1-ol213
129(2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propen-1-ol213
130(2E)-3-[4-(3-pyridinyl)phenyl]-2-propen-1-ol212
131(2E)-3-[4-(4-pyridinyl)phenyl]-2-propen-1-ol212
132(2E)-3-(4-pyrazinylphenyl)-2-propen-1-ol213
133(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol201
134(2E)-3-[4-(1H-imidazol-1-yl)phenyl]-2-propen-1-ol201
135(2E)-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol231
136(2E)-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol219
137(2E)-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol219
138(2E)-3-(3-quinolinyl)-2-propen-1-ol186
139(2E)-3-(4-quinolinyl)-2-propen-1-ol186
140(2E)-3-(5-quinolinyl)-2-propen-1-ol186
141(2E)-3-(6-quinolinyl)-2-propen-1-ol186
142(2E)-3-(7-quinolinyl)-2-propen-1-ol186
143(2E)-3-(2-quinoxalinyl)-2-propen-1-ol187
144(2E)-3-(6-quinoxalinyl)-2-propen-1-ol187
145(2E)-3-(4-isoquinolinyl)-2-propen-1-ol186
146(2E)-3-[4-(2-oxazolyl)phenyl]-2-propen-1-ol202
147(2E)-3-[4-(2-pyridinyl)-2-thienyl]-2-propen-1-ol218
148(2E)-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol219
149(2E)-3-(4-pyrazinyl-2-thienyl)-2-propen-1-ol219
150(2E)-3-[5-(2-pyridinyl)-3-thienyl]-2-propen-1-ol218
151(2E)-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propen-1-ol219
152(2E)-3-(5-pyrazinyl-3-thienyl)-2-propen-1-ol219
153(2E)-3-[4-(2-pyrimidinyloxy)phenyl]-2-propen-1-ol229
154(2E)-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propen-1-ol231
|
4-(2-pyrimidinyl)benzenepropanol
[0406] A mixture of (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol (300 mg, 1.41 mmol, prepared as described in Reference Example 65), ammonium formate (445 mg, 7.06 mmol), and 10% Pd/C (100 mg) in methanol (5 mL) was stirred for 1 h at room temperature. Solids were removed by filtration through Celite and washed with additional methanol (20 mL). The filtrate was concentrated and the residue was taken up in ethyl acetate (30 mL), washed with water (20 mL), dried (MgSO4) and concentrated. Purification by chromatography (SiO2, 1:1 dichloromethane/ethyl acetate) provided 240 mg (79%) of the title compound as a colorless oil. MS 215 (M+H)+.
REFERENCE EXAMPLES 156-170
[0407] The compounds of Reference Examples 156-170, listed in the table below, are prepared by the method of Reference Example 155 by substituting the appropriate alkene for the (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 155.
9|
|
MS
Ref. Ex.Compound[(M + H)+]
|
1564-pyrazinylbenzenepropanol215
1574-(3-pyridazinyl)benzenepropanol215
1584-(2-pyridinyl)benzenepropanol214
1594-(1H-pyrazol-1-yl)benzenepropanol203
1604-(1H-1,2,4-triazol-1-yl)benzenepropanol204
1614-(1H-1,2,3-triazol-1-yl)benzenepropanol204
1624-(1-methyl-1H-pyrazol-3-yl)benzenepropanol217
1633-(2-quinolinyl)propanol188
1643-(5-quinolinyl)propanol188
1653-(6-quinolinyl)propanol188
1663-(7-quinolinyl)propanol188
1673-(6-quinoxalinyl)propanol189
1684-(2-oxazolyl)benzenepropanol204
1695-(2-pyridinyl)-2-thiophenepropanol220
1705-(2-pyrimidinyl)-2-thiophenepropanol221
|
(2Z)-2-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol
[0408] Step A: (2Z)-2-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenoic Acid Ethyl Ester
[0409] Triethyl 2-fluoro-2-phosphonoacetate (1.55 mL, 7.64 mmol) was added to a suspension of MgBr2 (1.68 g, 9.12 mmol) in THF (20 mL). The resulting mixture was cooled to 0° C., triethylamine (1.20 mL, 8.61 mmol) was added, and stirring was continued for 1 h at 0° C. A solution of 4-(2-pyrimidinyl)-benzaldehyde (1.00 g, 5.43 mmol, prepared as described in WO 9828264) in THF (10 mL) was aded via cannula and an additional amount of THF (5 mL) was used to rinse the transfer flask and cannula. The resulting mixture was stirred for 3 h at 0° C., quenched with 10% aq. ammonium chloride (5 mL), and concentrated to a small volume. The concentrate was diluted with ethyl acetate (50 mL), washed with 10% aq. ammonium chloride, sat. aq. NaHCO3, and brine (50 mL each), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 3:1 hexane/ethyl acetate) provided 1.27 g of the title compound as a 3:1 mixture with its E isomer. Recrystallization from 2-propanol provided 0.76 g (51%) of the title compound containing ca. 1% of the E isomer. MS 273 (M+H)+.
[0410] Step B: (2Z)-2-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol
[0411] Diisobutylaluminum hydride (1.0 M solution in THF, 5.5 mL, 5.50 mmol) was added dropwise to a 0° C. solution of the product from step A (500 mg, 1.84 mmol) in methylene chloride (15 mL). The resulting solution was stirred for 10 min at 0° C., quenched with methanol (0.25 mL) followed by 15% aq. Rochelle salt (20 mL), and allowed to stir at room temperature for 4 h. The layers were separated and the aqueous layer was extracted with methylene chloride (20 mL). The combined organic layers were dried (MgSO4) and concentrated to provide 415 mg (98%) of the title compound as a colorless solid. MS 231 (M+H)+.
REFERENCE EXAMPLES 172-234
[0412] The compounds of Reference Examples 172-234, listed in the table below, are prepared by the method of Reference Example 171 by substituting the appropriate aldehyde for the 4-(2-pyrimidinyl)benzaldehyde of Reference Example 171.
10|
|
Ref. Ex.Compound[(M + H)+]
|
|
172(2Z)-2-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propen-1-ol231
173(2Z)-2-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propen-1-ol231
174(2Z)-2-fluoro-3-[3-(2-pyrimidinyl)phenyl]-2-propen-1-ol231
175(2Z)-2-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propen-1-ol230
176(2Z)-2-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propen-1-ol230
177(2Z)-2-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propen-1-ol230
178(2Z)-2-fluoro-3-(4-pyrazinylphenyl)-2-propen-1-ol231
179(2Z)-2-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propen-1-ol231
180(2Z)-2-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol219
181(2Z)-2-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propen-1-ol220
182(2Z)-2-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propen-1-ol220
183(2Z)-2-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propen-1-ol220
184(2Z)-2-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propen-1-ol219
185(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propen-1-ol233
186(2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propen-1-ol233
187(2Z)-2-fluoro-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol249
188(2Z)-2-fluoro-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol237
189(2Z)-2-fluoro-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol237
190(2Z)-2-fluoro-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propen-1-ol237
191(2Z)-2-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propen-1-ol219
192(2Z)-2-fluoro-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propen-1-ol221
193(2Z)-2-fluoro-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propen-1-ol221
194(2Z)-2-fluoro-3-(2-quinolinyl)-2-propen-1-ol204
195(2Z)-2-fluoro-3-(3-quinolinyl)-2-propen-1-ol204
196(2Z)-2-fluoro-3-(4-quinolinyl)-2-propen-1-ol204
197(2Z)-2-fluoro-3-(5-quinolinyl)-2-propen-1-ol204
198(2Z)-2-fluoro-3-(6-quinolinyl)-2-propen-1-ol204
199(2Z)-2-fluoro-3-(7-quinolinyl)-2-propen-1-ol204
200(2Z)-2-fluoro-3-(8-quinolinyl)-2-propen-1-ol204
201(2Z)-2-fluoro-3-(2-quinoxalinyl)-2-propen-1-ol205
202(2Z)-2-fluoro-3-(6-quinoxalinyl)-2-propen-1-ol205
203(2Z)-2-fluoro-3-(4-isoquinolinyl)-2-propen-1-ol204
204(2Z)-2-fluoro-3-(6-bromo-3-pyridinyl)-2-propen-1-ol232, 234
205(2Z)-2-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propen-1-ol220
206(2Z)-2-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propen-1-ol220
207(2Z)-2-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propen-1-ol236
208(2Z)-2-fluoro-3-[4-(2-thienyl)phenyl]-2-propen-1-ol235
209(2Z)-2-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propen-1-ol220
210(2Z)-2-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propen-1-ol221
211(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propen-1-ol221
212(2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propen-1-ol221
213(2Z)-2-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-propen-1-ol207
214(2Z)-2-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propen-1-ol249
215(2Z)-2-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propen-1-ol245
216(2Z)-2-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propen-1-ol261
217(2Z)-2-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propen-1-ol261
218(2Z)-2-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propen-1-ol236
219(2Z)-2-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propen-1-ol236
220(2Z)-2-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propen-1-ol236
221(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
222(2Z)-2-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propen-1-ol237
223(2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propen-1-ol236
224(2Z)-2-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propen-1-ol236
225(2Z)-2-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propen-1-ol236
226(2Z)-2-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
227(2Z)-2-fluoro-3-(4-pyrazinyl-2-thienyl)-2-propen-1-ol237
228(2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propen-1-ol236
229(2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propen-1-ol237
230(2Z)-2-fluoro-3-(5-pyrazinyl-3-thienyl)-2-propen-1-ol237
231(2Z)-2-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propen-1-ol231
232(2Z)-2-fluoro-3-[2,2′-bithiophen]-5-yl-2-propen-1-ol241
233(2Z)-2-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propen-1-ol247
234(2Z)-2-fluoro-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propen-1-ol249
|
[4-(3-hydroxy-1-propynyl)phenyl]boronic Acid
[0413] Pyrrolidine (100 mL) was added to a mixture of 4-iodophenylboronic acid (19.83 g, 80.01 mol) and Pd(Ph3P)4 (0.93 g, 0.80 mmol) and the mixture was stirred for 5 min to give a solution. The solution was cooled to 0° C. and propargyl alcohol (9.4 mL, 161.5 mol) was added. The resulting solution was stirred for 1 h at 0° C. and 18 h at room temperature and then concentrated in vacuo. The residue was diluted with 2 N NaOH (200 ml), washed with dichloromethane (2×100 mL), cooled to 0° C., and acidified with 10% HCl. The precipitated solids were isolated by filtration, washed with water and dried in vacuo to provided 12.76 g (91%) of the title compound as a tan solid. MS 175 (M−H)−.
[4-(4-hydroxy-1-butynyl)phenyl]boronic Acid
[0414] The title compound was prepared by a procedure analogous to Reference Example 235 by substituting 3-butyn-1-ol for the propargyl alcohol of Reference Example 235. MS 189 (M−H)−.
[4-(5-hydroxy-1-pentynyl)phenyl]boronic Acid
[0415] The title compound was prepared by a procedure analogous to Reference Example 235 by substituting 4-pentyn-1-ol for the propargyl alcohol of Reference Example 235. MS 203 (M−H)−.
[4-[(1E)-3-hydroxy-1-propenyl]phenyl]boronic Acid
[0416] Lithium aluminum hydride (1.0 M solution in THF, 19.0 mL, 19.0 mmol) was added dropwise over 10 min to a solution of [4-(3-hydroxy-1-propynyl)phenyl]boronic acid (1.06 mg, 6.02 mmol, prepared as described in Reference Example 235) in THF (50 mL) with vigorous strirring. The resulting suspension was heated to reflux for 3 h, cooled to 0° C., cautiously quenched with water (2 mL), strirred for 10 min, and concentrated to dryness in vacuo. Water (20 mL) was added to the residue, the mixture was cooled to 0° C., acidified with 20% H2SO4 (10 mL), and stirred for 10 min at 0° C. The solids were removed by filtration, washed with water, and allowed to air-dry. Recrystallization from water provided 0.70 g (69%) of the title compound as colorless crystals. MS 177 (M−H)−.
3-[4-(2-pyrimidinyl)phenyl]-2-propyn-1-ol
[0417] A mixture of 2-bromopyrimidine (1.00 g, 6.29 mmol) and Pd(Ph3P)4 (220 mg, 0.19 mmol) in ethylene glycol dimethyl ether (25 mL) was stirred for 10 min, a slurry of sodium bicarbonate (1.58 g, 18.81 mmol) and [4-(3-hydroxy-1-propynyl)phenyl]boronic acid (1.32 g, 7.50 mmol, prepared as described in Reference Example 235) in water (25 mL) was added, and the mixture was heated to reflux for 4 h. The cooled reaction mixture was diluted with methylene chloride (100 mL) and washed with water (100 mL). The aqueous layer was extracted with dichloromethane (25 mL) and the combined organic layers were dried (MgSO4) and concentrated. Purification by chromatography (SiO2, 3:2 hexane/ethyl acetate) provided 1.04 g (79%) of the title compound as a yellow solid. MS 211 (M+H)+.
4-[4-(2-pyrimidinyl)phenyl]-3-butyn-1-ol
[0418] The title compound is prepared by a procedure analogous to Reference Example 239 by substituting [4-(4-hydroxy-1-butynyl)phenyl]boronic acid (prepared as described in Reference Example 236) for the [4-(3-hydroxy-1-propynyl)phenyl]boronic acid of Reference Example 239. MS 225 (M+H)+.
5-[4-(2-pyrimidinyl)phenyl]-4-pentyn-1-ol
[0419] The title compound is prepared by a procedure analogous to Reference Example 239 by substituting [4-(5-hydroxy-1-pentynyl)phenyl]boronic acid (prepared as described in Reference Example 237) for the [4-(3-hydroxy-1-propynyl)phenyl]boronic acid of Reference Example 239. MS 239 (M+H)+.
REFERENCE EXAMPLES 242-247
[0420] The compounds of Reference Examples 242-247, listed in the table below, are prepared by the method of Reference Example 239 by substituting the appropriate brominated or iodinated heterocycle for the 2-bromopyrimidine of Reference Example 239.
11|
|
Ref.MS
Ex.Compound[(M + H)+]
|
|
2423-[4-(5-pyrimidinyl)phenyl]-2-propyn-1-ol211
2433-[4-(2-Pyridinyl)phenyl]-2-propyn-1-ol210
2443-[4-(3-Pyridinyl)phenyl]-2-propyn-1-ol210
2453-[4-(4-Pyridinyl)phenyl]-2-propyn-1-ol210
2463-[4-(4-Methyl-2-pyrimidinyl)phenyl]-2-propyn-1-ol225
2473-[4-(5-Bromo-2-pyrimidinyl)phenyl]-2-propyn-1-ol289, 291
|
3-(4-pyrazinylphenyl)-2-propvn-1-ol
[0421] Chloropyrazine (0.78 mL, 8.73 mmol), 1 M aq. Na2CO3 (10 mL), and ethanol (5 mL) were successively added to a mixture of [1,4-bis(diphenylphosphino)butane]palladium(II) dichloride (0.30 g, 0.50 mmol) and [4-(3-hydroxy-1-propynyl)phenyl]boronic acid (1.85 g, 10.51 mmol, prepared as described in Reference Example 235) in toluene (20 mL) and the resulting mixture was heated to reflux for 3 h. The cooled reaction mixture was diluted with ethyl acetate (50 mL) and the organic layer was separated, washed with brine (50 mL), dried (MgSO4) and concentrated. Purification by chromatography (SiO2, 97:3 dichloromethane/methanol) followed by a second chromatography (SiO2, 1:1 hexane/ethyl acetate) provided 1.22 g (66%) of the title compound as a colorless solid. MS 211 (M+H)+.
REFERENCE EXAMPLES 249-255
[0422] The compounds of Reference Examples 249-255, listed in the table below, are prepared by the method of Reference Example 248 by substituting the appropriate chlorinated heterocycle for the chloropyrazine of Reference Example 248.
12|
|
Ref.MS
Ex.Compound[(M + H)+]
|
2493-[4-(3-Pyridazinyl)phenyl]-2-propyn-1-ol211
2503-[4-(4-Methoxy-2-pyrimidinyl)phenyl]-2-propyn-1-241
ol
2513-[4-(5-Fluoro-2-pyrimidinyl)phenyl]-2-propyn-1-ol229
2523-[4-(5-Ethyl-2-pyrimidinyl)phenyl]-2-propyn-1-ol239
2533-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propyn-1-ol225
2543-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propyn-1-241
ol
2553-[4-(4-pyrimidinyl)phenyl]-2-propyn-1-ol211
|
REFERENCE EXAMPLES 256-293
[0423] The compounds of Reference Examples 256-293, listed in the table below, are prepared by the method of Step A of Reference Example 20 by substituting the appropriate brominated or iodinated compound for the 1-(4-bromophenyl)-1H-pyrazole of Step A of Reference Example 20.
13|
|
Ref.MS
Ex.Compound[(M + H)+]
|
2563-[4-(1H-pyrazol-1-yl)phenyl]-2-propyn-1-ol199
2573-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propyn-1-ol200
2583-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propyn-1-ol200
2593-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propyn-1-ol200
2603-[4-(1H-imidazol-1-yl)phenyl]-2-propyn-1-ol199
2613-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propyn-1-213
ol
2623-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propyn-1-213
ol
2633-(1-phenyl-1H-pyrazol-4-yl)-2-propyn-1-ol199
2643-(5-quinolinyl)-2-propyn-1-ol184
2653-(6-quinolinyl)-2-propyn-1-ol184
2663-(7-quinolinyl)-2-propyn-1-ol184
2673-(6-quinoxalinyl)-2-propyn-1-ol185
2683-[4-(2-oxazolyl)phenyl]-2-propyn-1-ol200
2693-[4-(5-oxazolyl)phenyl]-2-propyn-1-ol200
2703-[4-(2-thiazolyl)phenyl]-2-propyn-1-ol216
2713-[4-(2-thienyl)phenyl]-2-propyn-1-ol215
2723-[4-(3-isoxazolyl)phenyl]-2-propyn-1-ol200
2733-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propyn-1-ol201
2743-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propyn-1-ol201
2753-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propyn-1-ol201
2763-(1-methyl-1H-benzimidazol-2-yl)-2-propyn-1-ol187
2773-[5-(2-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2783-[5-(3-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2793-[5-(4-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2803-[5-(2-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2813-[5-(4-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2823-[5-(5-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2833-(5-pyrazinyl-2-thienyl)-2-propyn-1-ol217
2843-[4-(2-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2853-[4-(3-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2863-[4-(4-pyridinyl)-2-thienyl]-2-propyn-1-ol216
2873-[4-(2-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2883-[4-(4-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2893-[4-(5-pyrimidinyl)-2-thienyl]-2-propyn-1-ol217
2903-[5-(2-pyridinyl)-3-thienyl]-2-propyn-1-ol216
2913-[5-(3-pyridinyl)-3-thienyl]-2-propyn-1-ol216
2923-(2-phenyl-5-pyrimidinyl)-2-propyn-1-ol211
2933-[4-(2-pyrimidinyloxy)phenyl]-2-propyn-1-ol227
|
3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propyn-1-ol
[0424] A solution of 2-(5-iodo-3-isoxazolyl)pyridine (prepared as described in WO0232919, 1.38 g, 5 mmol) and dichlorobis(triphenylphosphine)palladium(II) (35 mg, 0.05 mmol) in 8 mL triethylamine was degassed with nitrogen. Propargyl alcohol (560 mg, 10 mmol) was added and the mixture was heated at 65° C. for 16 h. The reaction mixture was cooled to room temperature, concentrated to remove the solvent. The residue was diluted with ethyl acetate (100 mL), washed with saturated NaHCO3, water and brine. The organic layer was dried and concentrated. Purification by chromatography (SiO2, 1:1 hexane/ethyl acetate) yielded 220 mg (22%) of the title compound. MS 201 (M+H)+.
(2E)-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propen-1-ol
[0425] 2 M aq. Na2CO3 (2 mL) was added to a mixture of 5-bromo-2-iodopyrimidine (0.57 g, 2.00 mmol), Pd(Ph3P)4 (23 mg, 0.020 mmol), and [4-[(1E)-3-hydroxy-1-propenyl]phenyl]boronic acid (360 mg, 2.02 mmol, prepared as described in Reference Example 238) in toluene (5 mL) and the resulting mixture was heated to reflux for 24 h. The cooled reaction mixture was diluted with ethyl acetate (20 mL) and the organic layer was separated, washed with brine (10 mL), dried (MgSO4) and concentrated. Purification by chromatography (SiO2, 3:1 hexane/ethyl acetate) provided 104 mg (18%) of the title compound as a yellow solid. MS 291, 293 (M+H)+.
(2E)-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propen-1-ol
[0426] 1 M aq. Na2CO3 (2 mL), and ethanol (1 mL) were successively added to a mixture of 2-chloro-5-ethylpyrimidine (0.30 mL, 2.47 mmol), [1,4-bis(diphenylphosphino)butane]palladium(II) dichloride (61 mg, 0.10 mmol) and [4-[(1E)-3-hydroxy-1-propenyl]phenyl]boronic acid (360 mg, 2.02 mmol, prepared as described in Reference Example 238) in toluene (4 mL) and the resulting mixture was heated to reflux for 18 h. The cooled reaction mixture was diluted with ethyl acetate (10 mL) and the organic layer was separated, washed with brine (10 mL), dried (MgSO4) and concentrated. Purification by chromatography (SiO2, 3:2 hexane/ethyl acetate) provided 220 mg (45%) of the title compound as a yellow solid. MS 241 (M+H)+.
REFERENCE EXAMPLES 297-299
[0427] The compounds of Reference Examples 297-299, listed in the table below, are prepared by the method of Reference Example 296 by substituting the appropriate chlorinated heterocycle for the 2-chloro-5-ethylpyrimidine of Reference Example 296.
14|
|
Ref.MS
Ex.Compound[(M + H)+]
|
297(2E)-3-[4-(6-methyl-3-pyridazinyl)phenyl]-227
2-propen-1-ol
298(2E)-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-243
2-propen-1-ol
299(2E)-3-[4-(5-Fluoro-2-pyrimidinyl)phenyl]-231
2-propen-1-ol
|
[4-(2-pyrimidinyl)phenyl]-2-propynal
[0428] A mixture of the Dess-Martin reagent (1.59 g, 3.75 mmol) and 3-[4-(2-pyrimidinyl)phenyl]-2-propyn-1-ol (525 mg, 2.50 mmol, prepared as described in Reference Example 239) in dichloromethane (15 mL) was stirred at room temperature for 30 min. Aqueous 10% Na2S2O3 (25 mL) and aq. sat. NaHCO3 (15 mL) were added, the mixture was stirred for 5 min, the layers were separated, and the aqueous layer was extracted with dichloromethane (10 mL). The combined organic layers were dried (MgSO4) and concentrated to provide 465 mg (89%) of the title compound as a yellow solid. MS 209 (M+H)+.
REFERENCE EXAMPLES 301-356
[0429] The compounds of Reference Examples 301-356, listed in the table below, are prepared by the method of Reference Example 300 by substituting the appropriate alcohol for the [4-(2-pyrmidinyl)phenyl]-2-propyn-1-ol of Reference Example 300.
15|
|
Ref.MS
Ex.Compound[(M + H)+]
|
|
3013-[4-(4-pyrimidinyl)phenyl]-2-propynal209
3023-[4-(5-pyrimidinyl)phenyl]-2-propynal209
3033-[4-(2-pyridinyl)phenyl]-2-propynal208
3043-[4-(3-pyridinyl)phenyl]-2-propynal208
3053-[4-(4-pyridinyl)phenyl]-2-propynal208
3063-(4-pyrazinylphenyl)-2-propynal209
3073-[4-(3-pyridazinyl)phenyl]-2-propynal209
3083-[4_(1H-1,2,4-triazol-1-yl)phenyl]-2-propynal198
3093-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propynal198
3103-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propynal198
3113-[4-(1H-imidazol-1-yl)phenyl]-2-propynal197
3123-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propynal211
3133-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propynal211
3143-(1-phenyl-1H-pyrazol-4-yl)-2-propynal197
3153-(2-quinolinyl)-2-propynal182
3163-(4-quinolinyl)-2-propynal182
3173-(5-quinolinyl)-2-propynal182
3183-(6-quinolinyl)-2-propynal182
3193-(7-quinolinyl)-2-propynal182
3203-(8-quinolinyl)-2-propynal182
3213-(2-quinoxalinyl)-2-propynal183
3223-(6-quinoxalinyl)-2-propynal183
3233-(4-isoquinolinyl)-2-propynal182
3243-[4-(2-oxazolyl)phenyl]-2-propynal198
3253-[4-(5-oxazolyl)phenyl]-2-propynal198
3263-[4-(2-thiazolyl)phenyl]-2-propynal214
3273-[4-(2-thienyl)phenyl]-2-propynal213
3283-[4-(3-isoxazolyl)phenyl]-2-propynal198
3293-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propynal199
3303-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propynal199
3313-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propynal199
3323-(1-methyl-1H-benzimidazol-2-yl)-2-propynal185
3333-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propynal287, 289
3343-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propynal227
3353-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propynal237
3363-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propynal223
3373-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propynal239
3383-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propynal223
3393-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propynal239
3403-[5-(2-pyridinyl)-2-thienyl]-2-propynal214
3413-[5-(3-pyridinyl)-2-thienyl]-2-propynal214
3423-[5-(4-pyridinyl)-2-thienyl]-2-propynal214
3433-[5-(2-pyrimidinyl)-2-thienyl]-2-propynal215
3443-[5-(4-pyrimidinyl)-2-thienyl]-2-propynal215
3453-[5-(5-pyrimidinyl)-2-thienyl]-2-propynal215
3463-(5-pyrazinyl-2-thienyl)-2-propynal215
3473-[4-(2-pyridinyl)-2-thienyl]-2-propynal214
3483-[4-(3-pyridinyl)-2-thienyl]-2-propynal214
3493-[4-(4-pyridinyl)-2-thienyl]-2-propynal214
3503-[4-(2-pyrimidinyl)-2-thienyl]-2-propynal215
3513-[4-(4-pyrimidinyl)-2-thienyl]-2-propynal215
3523-[4-(5-pyrimidinyl)-2-thienyl]-2-propynal215
3533-[5-(2-pyridinyl)-3-thienyl]-2-propynal214
3543-[5-(3-pyridinyl)-3-thienyl]-2-propynal214
3553-(2-phenyl-5-pyrimidinyl)-2-propynal209
3563-[4-(2-pyrimidinyloxy)phenyl]-2-propynal225
|
(2Z)-3-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol
[0430] Step A: (2Z)-3-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenal
[0431] A mixture of 3-[4-(2-pyrimidinyl)phenyl]-2-propynal (210 mg, 1.01 mmol, prepared as described in Reference Example 300) and tetrabutylamonium dihydrogentrifluoride (50 wt % in 1,2-dichloroethane, 1.8 g, 3.0 mmol) was heated to 110° C. for 4 h. The cooled reaction mixture was diluted with ethyl acetate (30 mL), washed with aq. sat. NaHCO3 (30 mL) and brine (30 mL), and filtered through a plug of SiO2 (5 g). The SiO2 plug was rinsed with additional ethyl acetate (30 mL) and the combined filtrates were concentrated. Purification by chromatography (SiO2, 97:3 dichloromethane/ethyl acetate) provided 116 mg (51%) of the title compound as a colorless solid. MS 229 (M+H)+. Also isolated were (2Z)-3-chloro-3-[4-(2-pyrmidinyl)phenyl]-2-propenal (10 mg, 4%, MS 245, 247 (M+H)+) and recovered starting material (15 mg, 7%).
[0432] Step B: (2Z)-3-Fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1ol
[0433] Diisobutylaluminum hydride (1.0 M solution in THF, 0.7 mL, 0.70 mmol) was added dropwise to a 0° C. suspension of the product from step A (108 mg, 0.47 mmol) in methylene chloride (5 mL). The resulting solution was stirred for 10 min at 0° C., quenched with methanol (0.2 mL) followed by 15% aq. Rochelle salt (10 mL), and allowed to stir at room temperature for 2 h. The layers were separated and the aqueous layer was extracted with methylene chloride (10 mL). The combined organic layers were dried (MgSO4) and concentrated to provide 106 mg (97%) of the title compound as a colorless solid. MS 231 (M+H)+.
REFERENCE EXAMPLES 358-417
[0434] The compounds of Reference Examples 358-417, listed in the table below, are prepared by the method of Reference Example 357 by substituting the appropriate alkynal for the [4-(2-pyrmidinyl)phenyl]-2-propynal of Reference Example 357.
16|
|
MS
Ref. Ex.Compound[(M + H)+]
|
|
358(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol231
359(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propen-1-ol231
360(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propen-1-ol231
361(2Z)-3-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propen-1-ol230
362(2Z)-3-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propen-1-ol230
363(2Z)-3-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propen-1-ol230
364(2Z)-3-fluoro-3-(4-pyrazinylphenyl)-2-propen-1-ol231
365(2Z)-3-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propen-1-ol231
366(2Z)-3-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol219
367(2Z)-3-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propen-1-ol220
368(2Z)-3-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propen-1-ol220
369(2Z)-3-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propen-1-ol220
370(2Z)-3-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propen-1-ol219
371(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propen-1-233
ol
372(2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propen-1-233
ol
373(2Z)-3-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propen-1-ol219
374(2Z)-3-fluoro-3-(2-quinolinyl)-2-propen-1-ol204
375(2Z)-3-fluoro-3-(3-quinolinyl)-2-propen-1-ol204
376(2Z)-3-fluoro-3-(4-quinolinyl)-2-propen-1-ol204
377(2Z)-3-fluoro-3-(5-quinolinyl)-2-propen-1-ol204
378(2Z)-3-fluoro-3-(6-quinolinyl)-2-propen-1-ol204
379(2Z)-3-fluoro-3-(7-quinolinyl)-2-propen-1-ol204
380(2Z)-3-fluoro-3-(8-quinolinyl)-2-propen-1-ol204
381(2Z)-3-fluoro-3-(2-quinoxalinyl)-2-propen-1-ol205
382(2Z)-3-fluoro-3-(6-quinoxalinyl)-2-propen-1-ol205
383(2Z)-3-fluoro-3-(4-isoquinolinyl)-2-propen-1-ol209
384(2Z)-3-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propen-1-ol220
385(2Z)-3-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propen-1-ol220
386(2Z)-3-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propen-1-ol236
387(2Z)-3-fluoro-3-[4-(2-thienyl)phenyl]-2-propen-1-ol235
388(2Z)-3-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propen-1-ol220
389(2Z)-3-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propen-1-ol221
390(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propen-1-ol221
391(2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propen-1-ol221
392(2Z)-3-fluoro-3-(1-methyl-1H-benzimidazol-2-yl)-2-propen-1-ol207
393(2Z)-3-fluoro-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-2-propen-1-ol309, 311
394(2Z)-3-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propen-1-ol249
395(2Z)-3-fluoro-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-2-propen-1-ol259
396(2Z)-3-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propen-1-ol245
397(2Z)-3-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propen-1-261
ol
398(2Z)-3-fluoro-3-[4-(6-methyl-3-pyridazinyl)phenyl]-2-propen-1-ol245
399(2Z)-3-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propen-1-261
ol
400(2Z)-3-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propen-1-ol236
401(2Z)-3-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propen-1-ol236
402(2Z)-3-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propen-1-ol236
403(2Z)-3-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
404(2Z)-3-fluoro-3-[5-(4-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
405(2Z)-3-fluoro-3-[5-(5-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
406(2Z)-3-fluoro-3-(5-pyrazinyl-2-thienyl)-2-propen-1-ol237
407(2Z)-3-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propen-1-ol236
408(2Z)-3-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propen-1-ol236
409(2Z)-3-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propen-1-ol236
410(2Z)-3-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
411(2Z)-3-fluoro-3-[4-(4-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
412(2Z)-3-fluoro-3-[4-(5-pyrimidinyl)-2-thienyl]-2-propen-1-ol237
413(2Z)-3-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propen-1-ol236
414(2Z)-3-fluoro-3-[5-(3-pyridinyl)-3-thienyl]-2-propen-1-ol236
415(2Z)-3-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propen-1-ol231
416(2Z)-3-fluoro-3-[2,2′-bithiophen]-5-yl-2-propen-1-ol241
417(2Z)-3-fluoro-3-[4-(2-pyrimidinyloxy)phenyl]-2-propen-1-ol247
|
(2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-buten-1-ol
[0435] Step A: (2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-butenoic Acid Ethyl Ester
[0436] Dioxane (2 mL) was added to a mixture of 2-(4-bromophenyl)pyrimidine (0.59 g, 2.51 mmol, prepared as described in U.S. Pat. No. 5,780,473), tri-t-butylphosphonium tetrafluoroborate (36 mg, 0.12 mmol), and tris(dibenzylideneacetone)dipalladium(0) (57 mg, 0.062 mmol). N-Methyldicyclohexylamine (0.64 mL, 2.99 mmol) and ethyl crotonate (0.62 mL, 4.99 mmol) were added and the mixture was stirred for 18 h at room temperature. The mixture was diluted with ethyl acetate, filtered through a small plug of silica gel which was washed with additional ethyl acetate, and the combined filtrates were concentrated. Purification by chromatography (SiO2, 5:1 hexane/ethyl acetate) provided 0.47 g (70%) of the title compound as an off-white solid. MS 269 (M+H)+.
[0437] Step B: (2E)-3-[4-(2-Pyrimidinyl)phenyl]-2-buten-1-ol
[0438] Diisobutylaluminum hydride (1.0 M solution in THF, 3.4 mL, 3.40 mmol) was added dropwise to a 0° C. solution of the product from step A (300 mg, 1.12 mmol) in methylene chloride (10 mL). The resulting solution was stirred for 20 min at 0° C., quenched with methanol (0.2 mL) followed by 15% aq. Rochelle salt (20 mL) and dichloromethane (10 mL), and allowed to stir at room temperature for 18 h. The layers were separated and the aqueous layer was extracted with methylene chloride (10 mL). The combined organic layers were washed with brine (20 mL), dried (MgSO4), and concentrated. Purification by chromatography (SiO2, 3:2 hexane/ethyl acetate) provided 221 mg (87%) of the title compound as an off-white solid. MS 227 (M+H)+.
(2E)-3-(2-Phenyl-5-pyrimidinyl)-2-propen-1-ol
[0439] Step A: (2E)-3-(2-Phenyl-5-pyrimidinyl)-2-propenoic Acid Methyl Ester
[0440] Dioxane (1.3 mL) was added to a mixture of 5-bromo-2-phenylpyrimidine (310 mg, 1.32 mmol, prepared as described in Org. Lett. 2002, 4, 513), tri-t-butylphosphonium tetrafluoroborate (11 mg, 0.038 mmol), and tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.020 mmol). N-Methyldicyclohexylamine (0.31 mL, 1.45 mmol) and methyl acrylate (0.24 mL, 2.67 mmol) were added and the mixture was stirred for 72 h at room temperature. The mixture was diluted with ethyl acetate, filtered through a small plug of silica gel which was washed with additional ethyl acetate, and the combined filtrates were concentrated. The residue was triturated with 5:1 hexane/ethyl acetate and the solid was filtered and dried in vacuo to provide 178 mg (56%) of the title compound as an off-white solid. MS 241 (M+H)+.
[0441] Step B: (2E)-3-(2-Phenyl-5-pyrimidinyl)-2-propen-1-ol
[0442] Diisobutylaluminum hydride (1.0 M solution in THF, 2.1 mL, 2.10 mmol) was added dropwise to a 0° C. solution of the product from step A (165 mg, 0.69 mmol) in methylene chloride (5 mL). The resulting solution was stirred for 15 min at 0° C., quenched with methanol (0.5 mL) followed by 15% aq. Rochelle salt (15 mL) and dichloromethane (5 mL), and allowed to stir at room temperature for 18 h. The layers were separated and the aqueous layer was extracted with methylene chloride (5 mL). The combined organic layers were dried (MgSO4) and concentrated to provide 140 mg (96%) of the title compound as a colorless solid. MS 213 (M+H)+.
4-Pyrazinyl benzeneacetaldehyde
[0443] Step A: 2-[4-[(E)-2-methoxyethenyl]phenyl]-pyrazine
[0444] Sodium hexamethyldisilazide (10.80 mL, 10.80 mmol, 11.0M in THF) was added to a suspension of methoxymethyltriphenylphosphonium chloride (3.72 g, 10.80 mmol) in THF (20 mL) at −10° C., and the red-orange mixture was stirred for 15 min at −10° C. A solution of 4-pyrazinylbenzaldehyde (1.00 g, 5.43 mmol) prepared as described in reference example 17) in THF (3 mL) was added dropwise, and stirring was continued at −10° C. for 1 h. The reaction mixture was quenched with sat. aq. NH4Cl, extracted with ethyl acetate, the organic layer dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 3:1 hexane/ethyl acetate) yielded 820 mg (71%) of the title compound (E:Z=1:1). MS 213 (M+H)+.
[0445] Step B: 4-Pyrazinylbenzeneacetaldehyde
[0446] Iodotrimethylsilane (0.46 mL, 3.30 mmol) was added dropwise to a suspension of the product from step A (175 mg, 0.82 mmol) and solid NaHCO3 (100 mg, 1.18 mmol) in dichloromethane (5 mL) at rt. The reaction mixture was stirred at rt for 18 h, carefully quenched with sat. aq. NaHCO3, extracted with dichloromethane, dried with Na2SO4, and concentrated in vacuo to give 110 mg (68%) of the title compound. The product was >95% pure as judged by its 1H NMR spectrum, and was used immediately in the next step without further purification. MS 199 (M+H)+.
REFERENCE EXAMPLE 421-440
[0447] The following compounds of Reference Examples 421-440, listed in the table below, were prepared by the method of Reference Example 420 by substituting the appropriate aldehyde for the 4-pyrazinylbenzaldehyde of Reference Example 420.
17|
|
Ref.MS
Ex.Compound[(M + H)+]
|
4213-(2-pyrimidinyl)benzeneacetaldehyde199
4222-fluoro-4-(2-pyrimidinyl)benzeneacetaldehyde217
4234-(5-fluoro-2-pyrimidinyl)benzeneacetaldehyde217
4244-(5-ethyl-2-pyrimidinyl)benzeneacetaldehyde227
4252-phenyl-5-pyrimidineacetaldehyde199
4264-methyl-2-phenyl-5-pyrimidineacetaldehyde213
4274-(2-pyridinyl)benzeneacetaldehyde198
4284-(1H-pyrazol-1-yl)benzeneacetaldehyde187
4294-(1H-1,2,4-triazol-1-yl)benzeneacetaldehyde188
4304-(1-methyl-1H-pyrazol-3-yl)benzeneacetaldehyde201
4314-(1-methyl-1H-pyrazol-5-yl)benzeneacetaldehyde201
4323-quinolineacetaldehyde172
4336-quinolineacetaldehyde172
4346-quinoxalineacetaldehyde173
4354-(3-pyridazinyl)benzeneacetaldehyde199
4364-(2-oxazolyl)benzeneacetaldehyde188
4374-(2-thiazolyl)benzeneacetaldehyde204
4384-(1,3,4-oxadiazol-2-yl)benzeneacetaldehyde189
4395-methyl-3-phenyl-4-isoxazoleacetaldehyde202
4404-(4-morpholinyl)benzeneacetaldehyde206
|
2-[4-(Tetrahydro-2,5-dimethoxy-3-furanyl)phenyl]pyrimidine
[0448] Step A: 2-[4-(3-furanyl)phenyl]pyrimidine
[0449] A suspension of 3-furanboronic acid (672 mg, 6 mmol) in 2M aq. Na3CO3 (10 mL, 20 mmol) and ethanol (8 mL) was added to a solution of 2-(4-bromo-phenyl)pyrimidine (1.30 g, 5.55 mmol, prepared as described in U.S. Pat. No. 5,780,473) and tetrakis(triphenylphosphine)palladium (693 mg, 0.60 mmol) in DME (30 mL). The reaction mixture was refluxed for 18 h, cooled to rt, diluted with ethyl acetate, washed with sat. aq. NaHCO3 and brine, dried with Na2SO4, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 3:1 hexanes/ethyl acetate) gave 793 mg (65%) of the title compound. MS 223 (M+H)+.
[0450] Step B: 2-[4-(2,5-Dihydro-2,5-dimethoxy-3-furanyl)phenyl]pyrimidine
[0451] To a slurry of 3-[4-(pyrimidin-2-yl)phenyl]furan and Na2CO3 (46 mg, 0.44 mmol) in methanol (0.8 mL) and benzene (0.8 mL) at −10° C. was added bromine (22 μL, 0.41 mmol) dropwise. The reaction mixture was stirred at −10° C. for 1 h, diluted with ethyl acetate, filtered, and concentrated in vacuo. Purification by medium pressure liquid chromatography (SiO2, 2:1 hexanes/ethyl acetate) gave 95 mg (75%) of the title compound. MS 285 (M+H)+.
[0452] Step C: 2-[4-(Tetrahydro-2,5-dimethoxy-3-furanyl)phenyl] pyrimidine
[0453] A mixture of 2,5-dihydro-2,5-dimethoxy-3-[4-(pyrimidin-2-yl)phenyl]furan (70 mg, 0.25 mmol), 10% Pd/C (20 mg), and ammonium formate (46 mg, 0.75 mmol) in methanol (1 mL) was stirred overnight. The reaction mixture was filtered through a fritted funnel, and concentrated in vacuo. The crude product was partitioned between ethyl acetate and sat. aq. NaHCO3, the organic layer dried with Na2SO4, and concentrated in vacuo to give 60 mg (85%) of the title compound, which was used without further purification. MS 287 (M+H)+.
REFERENCE EXAMPLES 442-447
[0454] The compounds of Reference Examples 442-447, listed in the table below, are prepared by the method of Reference Example 104 by substituting the appropriate aldehyde for the (2E)-3-[4-(2-pyridinyl)phenyl]-2-propenal of Reference Example 104.
18|
|
MS
Ref. Ex.Compound[(M + H)+]
|
4424-(2-pyrimidinyl)benzeneethanol201
4434-pyrazinylbenzeneethanol201
4445-(2-pyridinyl)-2-thiophenemethanol192
4454-(1H-1,2,4-triazol-1-yl)benzeneethanol190
4464-(1H-1,2,4-triazol-1-yl)benzenemethanol176
4471-(2-pyrimidinyl)-1H-imidazole-4-methanol177
|
2-[4-[(1E)-3-(aminooxy)-1-propenyl]phenyl]pyrimidine
[0455] Step A:
[0456] DEAD (0.95 mL, 6 mmol) was added dropwise at 0° C. to a stirred suspension of (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propen-1-ol (1.06 g, 5 mmol, prepared as described in Reference Example 65), triphenylphosphine (1.6 g, 6 mmol) and N-hydroxyphthalimide (1.0 g, 6 mmol) in THF (50 mL). The reaction mixture was stirred at room temperature for 16 h. The precipitate was collected and directly used in the next reaction without further purification.
[0457] Step B
[0458] The crude product from Step A was dissolved in 10 mL dichloromethane and one equivalent of methyl hydrazine was added dropwise. The reaction progress was followed by TLC. After the reaction, the precipitate was filtered and the filtrate was concentrated. Purification by chromatography (SiO2, ethyl acetate/hexanes=3/1) yielded 500 mg (45%) of the title compound. MS 228 (M+H)+.
O-(2-phenylethyl)hydroxylamine
[0459] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting phenyl ethyl alcohol for (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propen-1-ol of Reference Example 448. MS 138 (M+H)+.
O-(3-phenylpropyl)-hydroxylamine
[0460] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 3-phenyl-1-propanol for (2E)-3-[(4-(2-pyrimidinyl)phenyl)]-2-propen-1-ol of Reference Example 448. MS 152 (M+H)+.
2-[4-[2-(aminooxy)ethyl]phenyl]pyrimidine
[0461] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 4-(2-pyrimidinyl)benzeneethanol (prepared as described in Reference Example 442) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 216 (M+H)+.
2-[4-[(aminooxy)methyl]phenyl]pyrimdine
[0462] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 4-(2-pyrimidinyl)benzenemethanol (prepared as described in Step A of Reference Example 63) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 202 (M+H)+.
2-[4-[2-(aminooxy)ethyl]phenyl]pyrazine
[0463] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 4-pyrazinylbenzeneethanol (prepared as described in Reference Example 443) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 216 (M+H)+.
2-[4-[(1E)-3-(aminooxy)-1-propenyl]phenyl]pyrazine
[0464] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-3-(4-pyrazinylphenyl)-2-propen-1-ol (prepared as described in Reference Example 132) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 228 (M+H)+.
3-[(1E)-3-(aminooxy)-1-propenyl]pyridine
[0465] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-(3-pyridinyl)-2-propen-1-ol (prepared as described in J. Med. Chem. 1997, 40, 1845) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 151 (M+H)+.
2-[3-[(1E)-3-(aminooxy)-1-propenyl]phenyl]pyrimidine
[0466] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propen-1-ol (prepared as described in Reference Example 129) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 228 (M+H)+.
2-[4-[(1E)-3-(aminooxy)-1-propenyl]phenyl]pyridine
[0467] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-3-[4-(2-pyridinyl)phenyl]-2-propen-1-ol (prepared as described in Reference Example 104) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 227 (M+H)+.
3-[3-(aminooxy)-1-propynyl]quinoline
[0468] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 3-(3-quinolinyl)-2-propyn-1-ol (prepared as described in J. Med Chem. 1996, 39, 3179) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 199 (M+H)+.
3-[4-[(1E)-3-(aminooxy)-1-propenyl]phenyl]pyridazine
[0469] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-3-[4-(3-pyridazinyl)phenyl]-2-propen-1-ol (prepared as described in Reference Example 66) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 228 (M+H)+.
1-[4-[(1E)-3-(aminooxy)-1-propenyl]phenyl]-1H-pyrazole
[0470] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting (2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propen-1-ol (prepared as described in Reference Example 133) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 216 (M+H)+.
2-[4-[3-(aminooxy)-1-propynyl]phenyl]pyrimidine
[0471] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 3-[4-(2-pyrimidinyl)phenyl]-2-propyn-1-ol (prepared as described in Reference Example 239) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 226 (M+H)+.
2-[4-[(aminooxy)methyl]phenyl]pyrazine
[0472] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 4-pyrazinylbenzenemethanol (prepared as described in Reference Example 126) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 202 (M+H)+.
2-[4-[3-(aminooxy)-1-propynyl]phenyl]pyrazine
[0473] The title compound was prepared by a procedure analogous to Reference Example 448 by substituting 3-(4-pyrazinylphenyl)-2-propyn-1-ol (prepared as described in Reference Example 248) for (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol of Reference Example 448. MS 226 (M+H)+.
4-(2-pyrimidinyl)benzenemethanethiol
[0474] Step A:
[0475] 4-(2-pyrimidinyl)benzenemethanol (400 mg, 2.15 mmol, prepared as described in Step A of Reference Example 63) dissolved in dichloromethane (8 mL) at 0° C. To this solution was added PBr3 (580 mg, 2.15 mmol) dropwise. The reaction mixture was stirred at room temperature for 2 h. Methanol (0.5 mL) was added and the mixture was stirred for 5 min. Solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with cold 5% aqueous NaHCO3. The organic layer was dried and concentrated. The crude product (450 mg) was directly used in the next step without further purification.
[0476] Step B:
[0477] The product from Step A (450 mg, 1.8 mmol) was dissolved in 3 mL N,N-dimethylacetamide. Potassium thioacetate (250 mg, 2.2 mmol) was added and the reaction mixture was stirred at room temperature for 4 h. Water (10 mL) was added and the mixture was extracted with dichloromethane (2×20 mL). The organic layer was combined, dried, and concentrated. Purification by chromatography (SiO2, ethyl acetate/hexanes=1/2) yielded 300 mg (68%) of the title compound. MS 245 (M+H)+.
[0478] Step C:
[0479] The product from Step B (130 mg, 0.53 mmol) was dissolved in 10 mL methanol. The solution was degassed with N2. Aqueous potassium carbonate (0.45 g in 6 mL water) was added and the mixture was stirred at room temperature fro 3 h. Evaporation of methanol followed by extraction with methylene chloride (3×10 mL) gave the product (100 mg, 93%). MS 203 (M+H)+.
4-(2-pyrimidinyl)benzeneethanethiol
[0480] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 4-(2-pyrimidinyl)benzeneethanol (prepared as described in Reference Example 442) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 217 (M+H)+.
4-(1H-1,2,4-triazol-1-yl)benzeneethanethiol
[0481] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 4-(1H-1,2,4-triazol-1-yl)benzeneethanol (prepared as described in Reference Example 445) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 206 (M+H)+.
(2E)-3-(3-guinolinyl)-2-propene-1-thiol
[0482] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting (2E)-3-(3-quinolinyl)-2-propen-1-ol (prepared as described in Reference Example 138) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 202 (M+H)+.
3-quinolinemethanethiol
[0483] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 3-quinolinemethanol (prepared as described in Tetrahedron 2000, 56, 2239) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 176 (M+H)+.
5-(2-pyridinyl)-2-thiophenemethanethiol
[0484] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 5-(2-pyridinyl)-2-thiophenemethanol (prepared as described in Reference Example 444) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 208 (M+H)+.
4-(1H-1,2,4-triazol-1-yl)benzenemethanethiol
[0485] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 4-(1H-1,2,4-triazol-1-yl)benzenemethanol (prepared as described in Reference Example 446) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 192 (M+H)+.
1-(2-pyrimidinyl)-1H-imidazole-4-methanethiol
[0486] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting 1-(2-pyrimidinyl)-1H-imidazole-4-methanol (prepared as described in Reference Example 447) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 193 (M+H)+.
(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propene-1-thiol
[0487] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propen-1-ol (prepared as described in Reference Example 65) for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 229 (M+H)+.
(2E)-3-phenyl-2-propene-1-thiol
[0488] The title compound was prepared by a procedure analogous to Reference Example 464 by substituting (2E)-3-phenyl-2-propen-1-ol for the 4-(2-pyrimidinyl)benzenemethanol of Reference Example 464. MS 151 (M+H)+.
3-(2-pyridinyl)-5-isoxazolecarboxaldehyde
[0489] The title compound is prepared by a procedure analogous to Reference Example 300 by substituting 3-(2-pyridinyl)-5-isoxazolemethanol (prepared as described in J. Org. Chem. 2000, 65, 2225) for the 3-[4-(2-pyrimidinyl)phenyl]-2-propyn-1-ol of Reference Example 300. MS 175 (M+H)+.
(2Z)-3-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propene-1-ol
[0490] The title compound is prepared by a procedure analogous to Reference Example 171 by substituting 3-(2-pyridinyl)-5-isoxazolecarboxaldehyde (prepared as described in Reference Example 474) for the 4-(2-pyrimidinyl)benzaldehyde of Reference Example 171. MS 221 (M+H)+.
3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynal
[0491] The title compound is prepared by a procedure analogous to Reference Example 300 by substituting 3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propyn-1-ol (prepared as described in Reference Example 294) for the 3-[4-(2-pyrimidinyl)phenyl]-2-propyn-1-ol of Reference Example 300. MS 199 (M+H)+.
(2Z)-2-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propene-1-ol
[0492] The title compound is prepared by a procedure analogous to Reference Example 357 by substituting 3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propyn-1-ol (prepared as described in Reference Example 294) for the 3-[4-(2-pyrimidinyl)phenyl]-2-propynal of Reference Example 357. MS 221 (M+H)+.
[0493] The invention has been described in detail with particular reference to the above embodiments thereof. The above embodiments and examples are given to illustrate the scope and spirit of the present invention. These embodiments and examples will make apparent, to those skilled in the art, other embodiments and examples. These other embodiments and examples are within the contemplation of the present invention. It will be understood that variations and modifications can be effected within the spirit and scope of the invention; therefore, the instant invention should be limited only by the appended claims.
Claims
- 1. A compound of Formula 1
- 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 3. A method of treating a subject having a condition caused by or contributed to by bacterial infection, which comprises administering to said subject a therapeutically effective amount of the compound of Formula I as defined in claim 1.
- 4. A method of preventing a subject from suffering from a condition caused by or contributed to by bacterial infection, which comprises administering to the subject a prophylactically effective amount of the compound of Formula 1 as defined in claim 1.
- 5. The method of claim 3 or 4 wherein said condition is selected from community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections.
- 6. The method of claim 3 or 4 wherein said bacterium is selected from S. aureus, S. epidermidis, S. pneumoniae, Enterococcus spp., Moraxella catarrhalis and H. influenzae.
- 7. The method of claim 3 or 4 wherein said bacterium is a Gram-positive coccus.
- 8. The method of claim 3 wherein said Gram-positive coccus is antibiotic-resistant.
- 9. The method of claim 8 wherein said Gram-positive coccus is erythromycin-resistant.
- 10. A process for preparation of a compound having the formula,
- 11. A process for preparation of a compound having the formula,
- 12. A process for the preparation of a compound having the formula
- 13. A process for preparation of a compound having the formula
- 14. A process for preparation of a compound having the formula
- 15. A process for preparation of a compound having the formula
- 16. A process for preparation of a compound having the formula
- 17. The compound of claim 1, wherein R 2 is hydrogen, Z is —(CH2)n— and n is 0.
- 18. The compound of claim 1, wherein W is selected from the group consisting of groups (1), (2), (3), and (4) as defined in claim 1.
- 19. The compound of claim 1, wherein R3 is ethyl.
- 20. The compound of claim 1, wherein R4 is hydrogen, acyl or aroyl.
- 21. The compound of claim 1, wherein R is hydrogen, Z is —(CH2)n—, n is 0, W is selected from the group consisting of groups (1), (2), (3), and (4) as definjed in claim 1, R3 is ethyl, and R4 is hydrogen.
- 22. The compound of claim 1 having Formula 1′:
- 23. The compound of claim 22, wherein R is selected from the group consisting of H and F.
- 24. The compound of claim 22, wherein R3 is ethyl.
- 25. The compound of claim 22, wherein R4 is selected from the group consisting of H and acyl.
- 26. The compound of claim 22, wherein W is selected from the group consisting of groups (1), (2), (3), (4), (10), (11) and (12) as defined in claim 1.
- 27. The compound of claim 22, wherein R1 is H and R3 is ethyl.
- 28. The compound of claim 22, wherein R1 is F and R3 is ethyl.
- 29. The compound of claim 22, wherein R1 is selected from the group consisting of H and F, R3 is ethyl and R4 is H.
- 30. The compound of claim 29, wherein W is selected from group consisting of groups (1), (2), (3), (4), (10), (11) and (12) as defined in claim 1.
- 31. The compound of claim 30, wherein W is group (2) and R9 is independently selected from the group consisting of C3-C8-alkenyl and C3-C8-alkynyl.
- 32. The compound of claim 31, wherein the C3-C8-alkenyl or C3-C8-alkynyl is substituted with aryl or heteroaryl.
- 33. The compound of claim 32, wherein the aryl or heteroaryl is substituted with heteroaryl.
- 34. The compound of claim 31, wherein R9 is C3-C8-alkenyl substituted with fluoro and a substituent selected from the group consisting of aryl or heteroaryl.
- 35. The compound of claim 34, wherein the aryl or heteroaryl is substituted with heteroaryl.
- 36. The compound of claim 1 having the formula
- 37. The compound of claim 1 having the formula
- 38. The compound of claim 1 having the formula
- 39. The compound of claim 1 having the formula
- 40. The compound of claim 1 having the formula
- 41. The compound of claim 1 having the formula
- 42. The compound of claim 1 having the formula
- 43. The compound of claim 1 having the formula
- 44. The compound of claim 1 having the formula
- 45. The compound of claim 1 having the formula
- 46. The compound of claim 1 having the formula
- 47. The compound of claim 1 having the formula
- 48. The compound of claim 1 having the formula
- 49. The compound of claim 1 having the formula
- 50. The compound of claim 1 having the formula
- 51. The compound of claim 1 having the formula
- 52. The compound of claim 1 having the formula
- 53. The compound of claim 1 having the formula
- 54. The compound of claim 1 having the formula
- 55. The compound of claim 1 having the formula
- 56. The compound of claim 1 having the formula
- 57. The compound of claim 1 having the formula
Provisional Applications (2)
|
Number |
Date |
Country |
|
60392513 |
Jun 2002 |
US |
|
60338566 |
Dec 2001 |
US |